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Background: There is little current consensus regarding the route or duration of antibiotic treatment for
acute osteomyelitis (OM) and septic arthritis (SA) in children.
Objective: To assess the overall feasibility and inform the design of a future randomised controlled trial
(RCT) to reduce the duration of intravenous (i.v.) antibiotic use in paediatric OM and SA.
Design: (1) A prospective service evaluation (cohort study) to determine the current disease spectrum and
UK clinical practice in paediatric OM/SA; (2) a prospective cohort substudy to assess the use of targeted
polymerase chain reaction (PCR) in diagnosing paediatric OM/SA; (3) a qualitative study to explore families’
views and experiences of OM/SA; and (4) the development of a core outcome set via a systematic review
of literature, Delphi clinician survey and stakeholder consensus meeting.
Setting: Forty-four UK secondary and tertiary UK centres (service evaluation).
Participants: Children with OM/SA.
Interventions: PCR diagnostics were compared with culture as standard of care. Semistructured interviews
were used in the qualitative study.
Results: Data were obtained on 313 cases of OM/SA, of which 218 (61.2%) were defined as simple
disease and 95 (26.7%) were defined as complex disease. The epidemiology of paediatric OM/SA in this
study was consistent with existing European data. Children who met oral switch criteria less than 7 days
from starting i.v. antibiotics were less likely to experience treatment failure (9.6%) than children who met
oral switch criteria after 7 days of i.v. therapy (16.1% when switch was between 1 and 2 weeks; 18.2%
when switch was > 2 weeks). In 24 out of 32 simple cases (75%) and 8 out of 12 complex cases (67%)
in which the targeted PCR was used, a pathogen was detected. The qualitative study demonstrated the
importance to parents and children of consideration of short- and long-term outcomes meaningful to
families themselves. The consensus meeting agreed on the following outcomes: rehospitalisation or
recurrence of symptoms while on oral antibiotics, recurrence of infection, disability at follow-up, symptom
free at 1 year, limb shortening or deformity, chronic OM or arthritis, amputation or fasciotomy, death,
need for paediatric intensive care, and line infection. Oral switch criteria were identified, including
resolution of fever for ≥ 48 hours, tolerating oral food and medicines, and pain improvement.
Limitations: Data were collected in a 6-month period, which might not have been representative, and
follow-up data for long-term complications are limited.
Conclusions: A future RCT would need to recruit from all tertiary and most secondary UK hospitals.
Clinicians have implemented early oral switch for selected patients with simple disease without formal
clinical trial evidence of safety. However, the current criteria by which decisions to make the oral switch are
made are not clearly established or evidence based.
Future work: A RCT in simple OM and SA comparing shorter- or longer-course i.v. therapy is feasible in
children randomised after oral switch criteria are met after 7 days of i.v. therapy, excluding children
meeting oral switch criteria in the first week of i.v. therapy. This study design meets clinician preferences
and addresses parental concerns not to randomise prior to oral switch criteria being met.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
Children’s bone and joint infections are treated first with intravenous antibiotics and then oralantibiotics. Historically, long courses of intravenous antibiotics were thought to be needed, which often
involve a long hospital stay. At present there is no consensus regarding how long to treat these infections
overall, or how long to use each of intravenous or oral antibiotics. This study used a combination of
methods to assess if a clinical trial to reduce intravenous antibiotics in children will be feasible in the UK.
Data were collected from 44 UK centres to find out the current bacterial causes of children’s bone and
joint infections and how these are treated in clinical practice. A qualitative study explored families’ views
and experiences of having had a child treated for bone or joint infection. A consensus meeting was
informed by information from the clinical data collection, web-based clinician survey and qualitative study
to establish the final set of outcomes, oral switch criteria and overall future trial feasibility.
We found that clinicians are already switching from intravenous to oral antibiotics at an early stage in
selected patients with simple disease, even though there is not yet formal clinical trial evidence of the
safety of doing so. This has important implications both for current practice and for the feasibility of
different potential trial designs. We also found that a future randomised controlled trial of shorter or
longer courses of intravenous antibiotics would be feasible by including only children who need more than
a minimum of 7 days’ intravenous antibiotic treatment before switching to oral medicine.
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Scientific summary
Background and aims
Acute bacterial osteomyelitis (OM) and septic arthritis (SA) in children cause significant morbidity and use
of health-care resources. Limited data on disease spectrum and case load are available, and there is
currently little international or UK consensus regarding the route or duration of antibiotic treatment for
acute OM/SA in children.
This study comprised four components to assess the feasibility and inform the potential design of a
randomised controlled trial (RCT) to determine the safety of early oral switch from intravenous (i.v.) to oral
antibiotic therapy. We aimed:
1. to understand the current case load, disease spectrum and clinical practice in the diagnosis and
treatment of OM/SA in secondary and tertiary UK care by conducting a service evaluation of OM/SA in
children aged 1 month (the lower limit of the clindamycin licence) to 16 years
2. to assess whether or not a new molecular test is an appropriate tool to assess the molecular
epidemiology of children’s bone and joint infections by conducting a substudy at six of the service
evaluation centres
3. to understand parents’ and children’s views and experiences of bone and joint infection, and gather
their views and perceptions of both participating in a clinical trial and potential trial outcomes by
conducting a qualitative study
4. to develop a core outcome set for use in a future RCT using a systematic literature review of previously
used clinical trial outcomes in children’s bone and joint infections, a web-based clinician survey and
results of the qualitative study to inform a stakeholder consensus meeting.
Methods
Service evaluation
Clinical data from all paediatric patients presenting at 44 UK centres with presumed OM/SA were collected
via an electronic web-based database for a 6-month period at each centre, with 3 months’ clinical follow-up.
Briefly, simple cases were defined as first presentation of OM/SA with no comorbidities. Complex cases were
defined as those involving infection with a resistant or virulent organism (retrospectively allocated), infection
of an implant or the presence of comorbidity.
Microbiology substudy
In six of the participating centres, children were recruited for a molecular microbiology substudy. After
informed consent, routinely collected blood and tissue samples were transported to the central laboratory
(Southampton Public Health England South East Regional Laboratory) for polymerase chain reaction (PCR)
analysis after being processed locally. Results were compared with clinical data collected as part of the
service evaluation.
Qualitative interviews with families and children
Semistructured interviews were employed to explore the views and experiences of children treated for
bone and joint infections within the previous year and their parents. Topics included in the interviews
covered (1) experiences of becoming ill and diagnosis, (2) understandings and perceptions about aspects of
antibiotic therapy, (3) understandings and perceptions about aspects of antibiotic therapy and (4) views
about participation in a hypothetical future RCT. Thematic analysis was used.
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Development of a core outcome set
A systematic literature review, two rounds of Delphi clinician survey and a consensus meeting informed by
the qualitative interviews with families and children were used to develop a core outcome set to use in a
future RCT of shortened duration of antibiotic therapy for paediatric bone and joint infections; to identify
the oral switch criteria for use in a future RCT; and to make an overall assessment of the feasibility of a
future RCT.
Results
Service evaluation
Data from 356 children were recorded, of whom 313 were confirmed as having OM or SA, or both OM
and SA. A total of 54% (of 313) children were male and the median age was 3.4 years [interquartile range
(IQR) 1.4–9 years]. There were 218 (61.2%) simple infections and 95 (26.7%) complex infections. The
most likely joints/limbs affected in simple disease were the hip (21.1%), the knee (24.8%) and the ankle
(13.3%). Complex cases showed similar proportions of joints/bones affected (23.2%, 20% and 17.9%,
respectively), although often with multiple rather than single joint/bone infections.
At presentation, C-reactive protein (CRP) was higher in complex disease than simple cases (simple cases:
median 32 mg/l, IQR 11.8–66.7 mg/l; complex cases: median 54 mg/l, IQR 24–141 mg/l). Total white
cell/neutrophil count and erythrocyte sedimentation rate were less often used to confirm SA or OM.
Overall, a radiological diagnosis was obtained for 51.8% of simple cases (at a median of 1 day post
presentation, IQR 0–3 days) and 52.6% of complex cases (median of 1 day post presentation, IQR 0–4 days).
Diagnostic surgery was more common in SA than in OM prior to starting i.v. antibiotics [for SA, 39/107
(36.4%) simple and 15/35 (42.9%) complex cases; for OM, 21/109 (19.3%) simple and 14/56 (25%)
complex cases]. A total of 144 out of 218 (66.1%) children with simple OM or SA, and 59 out of 95
(62.1%) with complex OM or SA, had at least one test from either blood culture or tissue diagnosis (bone,
joint aspirate or periosteal pus).
Among 103 children with simple SA, the median total duration of antibiotic treatment (i.v. and oral) was
30 days (IQR 18–41 days), and the median duration of i.v. antibiotic treatment was 7 days (IQR 4–13 days).
Among 105 children with simple OM treated with antibiotics, the median total treatment duration was
40 days (IQR 21–48 days), and the median duration of i.v. antibiotic treatment was 9 days (IQR 6–16 days).
The most commonly used i.v. antibiotics were flucloxacillin and ceftriaxone. A total of 27% of simple cases
and 42% of complex cases were discharged home on i.v. antibiotics. Overall, 40.4% of simple cases
received a higher formulary initial dose of antibiotics, compared with 29.5% of complex cases. Only 30
(13.8%) simple cases and nine (9.5%) complex cases received the higher formulary dose of antibiotic
treatment throughout. Overall, among children with simple OM and SA combined, the median length of
hospital stay was 7 days (IQR 4–12 days), with 50% of children staying for ≥ 6 days but no longer than
12 days. Of 73 initially defined simple cases in whom oral switch took place very early (after < 1 week of
treatment with i.v. antibiotics), 9.6% experienced a defined treatment failure, compared with 16.1% in
whom switch took place between 1 and 2 weeks and 18.2% in whom switch took place after 2 weeks.
Microbiology substudy
A total of 151 samples were received from 50 patients. Of these, 113 were bone, fluid and blood culture
samples that were collected from 44 patients across six geographical sites. The remaining 38 samples were
from throat and wound swabs. In five (of 50) patients only throat swab samples were obtained, and in one
patient only a skin swab sample was obtained.
Overall, excluding any data from skin or throat swabs, 32 out of 44 patients (72.7%) were PCR positive for
one or more of the target organisms included in the reverse transcription PCR panel. In 24 of 32 simple
cases (75%) and 8 of 12 complex cases (67%) in which the test was used, a pathogen was detected.
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Using PCR, Staphylococcus aureus is the most commonly detected pathogen (16 cases). Kingella kingae
(seven cases) and group A Streptococcus (four cases) were also common causes of OM/SA.
Qualitative interviews with families and children
Twenty-six families were recruited to the qualitative study and interviewed. One of the most striking issues
to emerge during the course of interviews was the length of time reported to have elapsed between
children first presenting with symptoms and a diagnosis being given/treatment starting. Participants
understood the need for the use of i.v. antibiotics and identified the positive benefits of making them/their
child better in the fastest, most effective way possible. Parents expressed enthusiasm about participation in
a theoretical trial, although the concerns of those potentially unwilling or not sure reflected anxiety about
reduced courses of treatment or that rigid trial protocols might put their own child at risk. Key or ‘pinch’
points of anxiety for parents included lead-up to diagnosis (especially in case of delays); occasions during
which their child experienced distress (e.g. during insertion of cannula); fears about their child receiving
a general anaesthetic; and some follow-up anxiety around potential for future impacts, or recurrence
of infection.
Development of a core outcome set for use in clinical trials and potential oral
switch criteria for use in a clinical trial
A systematic review identified 10 relevant papers to inform potential clinical trial outcomes. The key
outcomes were combined, and summarised and discussed with study clinical co-investigators, who also
had the opportunity to review the papers, and consensus was gained that all of the available outcomes
had been extracted. In two rounds of Delphi process 37 general paediatricians, 38 paediatric orthopaedic
specialists, 34 paediatric infection specialists, four paediatric microbiologists and 13 paediatric radiologists
took part. The results of the service evaluation and the Delphi process were presented in a consensus
meeting. The oral switch criteria and outcomes reported are a product of clinician and researcher choices
during the Delphi and consensus meeting, informed by the qualitative findings.
Outcomes reaching consensus included rehospitalisation or recurrence of symptoms while on oral
antibiotics, treatment failure/recurrence of infection, disability at follow-up, being symptom free at 1 year,
limb shortening or deformity, chronic OM or chronic arthritis, amputation or fasciotomy, death, need for
paediatric intensive care, and line infection.
Oral switch criteria considered important by consensus following the meeting voting were resolution of
fever for ≥ 48 hours, tolerating oral input (medicines and food/drink) and pain improvement (rather than
resolution). Although there was much variability in the Delphi survey and consensus meeting regarding
what the CRP criteria should be, there was agreement that CRP is an important parameter in around 60%
of respondents in both round 1 and round 2 of the Delphi survey, and by approximately 70% of those at
the consensus meeting.
Discussion
A core outcome set for future clinical trials in paediatric bone and joint infections was established by a
Delphi survey and consensus meeting. The same process established agreement on the criteria needing to
be met for oral switch from i.v. therapy in any clinical trial.
A service evaluation, qualitative study and consensus meeting discussion provided information to inform
the feasibility of a RCT, and of potential RCT designs.
1. A RCT of very early oral switch to i.v. antibiotics would be supported by the service evaluation data and
was supported by the clinicians at the consensus meeting. However, the qualitative study suggested
that parents might have considerable concerns regarding participation if asked to consent to early oral
switch before what would currently be considered standard of care. In addition, the strict oral switch
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criteria identified, together with low numbers of cases of simple OM and SA likely to meet switch
criteria in the first week of i.v. treatment, means that such a study would not be likely to be feasible in
a single country (UK) trial.
2. A RCT of reduced total therapy duration after clinician-directed oral switch (based on the criteria
determined in this study) would be feasible but was not the first-choice study of the consensus meeting
participants. It would be possible to explain the study to parents and children, and feasible to recruit in
terms of numbers of cases and clinician willingness. It is unlikely that such a study design would make
an enormous impact on the overall cost to the NHS of treating bone and joint infections in children or
on the overall antibiotic burden of children in the community.
3. A RCT in simple OM and SA comparing shorter and longer courses of i.v. therapy, with no reduction in
total (i.v. and oral course combined) duration of antibiotic therapy, would be feasible if children are
included and randomised only if oral switch criteria are met after 7 days of i.v. therapy. Children would
be excluded from the trial if they met the criteria for oral switch in the first week of i.v. therapy as the
service evaluation suggests that this group are less likely to experience treatment failure than those in
whom oral switch occurs later. This study design meets clinician preference and addresses parental
concerns about randomising children before they meet currently used oral switch criteria. It would also
provide important information on whether or not i.v. therapy can be reduced without increasing
treatment failure compared with longer-course i.v. therapy, or whether or not outcomes are worse in
those treated with more i.v. antibiotics as a result of treatment failures being caused by the treatment
modality itself.
Regardless of RCT design, the qualitative study has demonstrated remaining gaps in the understanding of
parental and family decisions to participate in clinical trials that could be explored prospectively alongside
any future trial.
Conclusion
The epidemiology of paediatric OM/SA in this study was consistent with existing European data. Species-
specific PCR provides important additional information compared with using culture-based microbiology
methods alone. Clinicians have implemented early oral switch for selected patients with simple disease
without formal clinical trial evidence of safety. However, the criteria by which decisions to make the oral
switch are made are not clearly established or evidence based.
This study established a potentially feasible design for the reduction of a course of i.v. antibiotics in a
group of children with simple OM or SA. Agreement was reached regarding a core outcome set for use in
a future RCT and for oral switch criteria for use in a clinical trial.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Sections of text from this chapter were written for the Health Technology Assessment (HTA) programmeapplication, but were published separately as Faust SN, Clark J, Pallett A, Clarke NM. Managing bone
and joint infection in children. Arch Dis Child 2012;97:545–531 and are reproduced with permission from
the British Medical Journal.
Osteomyelitis and septic arthritis in children
Osteomyelitis (OM) is inflammation of the bone accompanied by bone destruction,2 usually due to bacterial
infection. It is an acute process, but if not treated effectively the inflammation can become chronic, leading
to the development of sequestra and fistulae.3 OM and septic arthritis (SA) can both be divided into three
types according to the source of the infection: haematogenous; secondary to contiguous infection; and
secondary to direct inoculation. Haematogenous OM can present acutely or subacutely as a more indolent,
progressive process, with symptoms present for > 2 weeks.4 In children, OM most often affects the long
bones (femur 36%, tibia 33%, humerus 10%, pelvis 2.8%).5 Single-site infection is most common, but
5–20% of children have multifocal OM.6 SA is acute infection of synovial joints,7,8 usually secondary to
bacteraemia. The infection affects the synovial membrane and the joint space. In younger children, the
capsule of the joint often extends to the metaphysis, and damage to the cortex can lead to SA secondary
to OM and vice versa. The epiphyseal growth plate can also be affected, causing growth discrepancies and
long-term disability or permanent joint destruction if the acute infection is not treated promptly.3
The estimated incidence for both OM and SA arthritis in Western populations is between 5 and 12 cases
per 100,000 children per year.3 Half of children with acute haematogenous OM are aged < 5 years.3,8
Boys are 1.2–3.7 times more likely to be affected by osteoarticular infection (OAI) than girls.3 The incidence
in Southampton from 1979 to 1997 was between 1.4 and 10.5 cases per 100,000 per year,9 and in
Newcastle from 1991 to 1999 was 7 cases per 100,000 for SA and 11 cases per 100,000 for OM (J Clark,
Great North Children’s Hospital, 2011, unpublished data). Recent unpublished national data from England
show that the admission rate for OM in children aged 0–18 years has varied between 4.8 and 7.0 per
100,000 child-years (M Sharland, St George’s Hospital London, 2011, personal communication). Subacute
OM appears to be have increased in recent years,10 and is reported to be 5 per 100,000 children in
Norway.11 Neonatal infection can occur in preterm or term-born babies and is associated with a wider
range of causative organisms (see below)12 and potential complications. Neonatal vascular anatomy allows
infection within the bone to reach the growth plate or joint in 76% of neonatal osteomyelitis cases.13
The pathogens implicated in paediatric bone and joint infections commonly include meticillin-sensitive
Staphylococcus aureus (MSSA) (44–80%)8,14,15 and Kingella kingae (14–50%; higher in children aged
< 36 months)8,15–19 and more rarely meticillin-resistant S. aureus (MRSA) (rare in the UK but found in
40–50% of cases in the USA),20,21 Panton–Valentine leukocidin (PVL) MSSA,22,23 group A Streptococcus
(GAS), group B Streptococcus (GBS) (neonates),12,24 non-typeable Haemophilus spp. (incidence unknown),
Haemophilus influenzae type b (in non-immunised or immunodeficient children), Escherichia coli (neonates),12,24
Streptococcus pneumoniae25 and coagulase-negative Staphylococcus (subacute). Very rarely (mostly in
immunocompromised individuals) implicated are Pseudomonas aeruginosa (usually associated with
inoculation injuries; therefore, in children aged > 1 year), Neisseria gonorrhoeae, Neisseria meningitidis
(neonates, adolescents), Mycobacterium tuberculosis (older children as OAI develops 2 years after primary
infection), Salmonella spp. (children with sickle cell disease),26 Bartonella henselae, N. gonorrhoeae,
non-tuberculous mycobacteria (associated with defects of the interferon gamma pathway), Klebsiella spp.,
Bartonella henselae, Fusobacterium (often multifocal), Aspergillus and Candida albicans (neonates, children
with damaged bone).
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The pathogens most frequently seen according to age are:
l neonates: GBS, MSSA, E. coli and other Gram-negative bacteria, and C. albicans
l children aged < 2 years: MSSA, K. kingae, S. pneumoniae, H. influenzae type b, non-typeable
Haemophilus spp., E. coli and MSSA PVL
l children aged 2–5 years: MSSA, K. kingae, GAS, S. pneumoniae, H. influenzae type b, non-typeable
Haemophilus spp., Pseudomonas spp., coagulase-negative Staphylococcus (subacute) and MSSA PVL
l children aged > 5 years. MSSA and MSSA PVL.
Clinical features
The clinical features of OM and SA are dependent on age, site of infection and type of disease. The
diagnosis and management of OAI in children should ideally be multidisciplinary, including paediatricians
and orthopaedic surgeons with radiologists and microbiologists. The diagnosis of OM or SA is made on the
basis of clinical presentation, laboratory tests, imaging and, where available, microbiology results.1
White blood cell count, C-reactive protein and erythrocyte sedimentation rate
The white blood cell (WBC) count is an unreliable indicator of an OAI as, in many cases, it remains normal
throughout the infection.27 The inflammatory markers erythrocyte sedimentation rate (ESR) and C-reactive
protein (CRP) are more reliable, although normal values also do not exclude OM.28 CRP levels are most
sensitive (elevated in up to 98% of cases)7,8 but are not specific for bone or joint infection. Two studies
have shown that CRP increases and also decreases faster than ESR, predicting recovery with more
sensitivity than the ESR or the WBC count.28,29 Differences in the causative organism may also cause
differences in the acute-phase markers. Patients with OM caused by PVL-expressing S. aureus isolates have
been found to have significantly higher mean values for ESR at admission, and higher maximum CRP, ESR
and absolute neutrophil counts at presentation, than patients whose isolates were PVL negative.23 Other
markers remain unproven. In a small study, procalcitonin has not shown benefit over CRP.30
Imaging
Imaging is of great importance in the diagnosis of acute OM. Where available, magnetic resonance
imaging (MRI) with enhancement shows the best results regarding sensitivity and specificity of diagnosis
of both OM and SA (sensitivity 97% and specificity 92% in SA;31,32 sensitivity 97–100% in OM).7 However,
as young children often require an anaesthetic to undergo MRI, and MRI is not immediately available in all
UK centres, MRI is not widely used in the UK in the initial diagnosis.
A technetium (99mTc) radionuclide bone scan also has high sensitivity and specificity in the diagnosis of
OM,33 but, as a result of the radiation burden, is now used less often except in difficult cases, and is not
useful in discitis. In SA, a bone scan may be used to exclude underlying OM following aspiration and
commencement of empirical therapy. A bone scan is especially useful where there is a suspicion of
multifocal disease, but may give false-negative results in infancy, and sensitivity is reduced for the first
48 hours. New nuclear medicine technologies are available in some centres to combine computerised
tomography (CT) with a low-dose radioactive substance, single-photon emission CT, which may be useful
in increasing the resolution of nuclear medical images.34
Plain radiography is less helpful than other imaging techniques as osteolytic changes or periosteal elevation
occur most often 10–21 days after the onset of symptoms.2,8,35 However, once apparent, the extent of
bony change provides a good correlate to the severity of the disease. Plain radiographs also provide a
baseline for comparison of subsequent change. Radiographic changes are frequently seen in subacute OM,
but can be confused with malignancies such as Ewing’s sarcoma or osteoid osteoma.13 In SA, plain
radiographs are of limited use. In discitis, lateral radiographs of the spine 2–3 weeks into the illness often
will reveal disc space narrowing with erosion of the vertebral end plates of the contiguous vertebrae. In
vertebral OM, radiographs initially show localised rarefaction of a single vertebral body then anterior
bone destruction.
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Ultrasonography is useful in SA for identifying the presence of deep effusions and in OM for subperiosteal
collections, but cannot differentiate between purulent and non-purulent material.7,36 Ultrasonography may
also be used to distinguish infection from other causes of similar symptoms or to direct fine-needle aspiration.37
Computerised tomography is most valuable for guided procedures, such as aspiration or drainage of the
infected bone or joint.38 It effectively demonstrates air, sequestra and cortical destruction in chronic OM,36
but gives non-specific results in discitis.
Microbiological investigation
Identification of the pathogenic organism by culture should be attempted, with samples preferably taken
prior to starting antibiotic therapy, as positive identification of the causative organisms allows targeted
antibiotic therapy. Blood cultures, joint fluid (from aspiration), periosteal pus or bone biopsy can all be
used. Samples from the infected bone or joint require an invasive procedure but are more likely to be
positive (40–50% positive) than blood cultures (9–22% positive).15,27 Yield is generally not high for
identification of a bacteria in children with OM,27 as, unless therapeutic operative intervention is required,
bone biopsy is infrequently necessary for diagnostic reasons alone.
New molecular techniques including polymerase chain reaction (PCR) and broad-range 16s ribosomal
deoxyribonucleic acid PCR39,40 have established the basis for more rapid and sensitive microbiological
diagnosis,18 although these methods currently do not provide information on specific organism antibiotic
resistance profiles.
Blood cultures (a minimum 4-ml aerobic culture sample in older children, 2 ml in specific neonatal aerobic
bottle)41 should therefore be taken and, where available, samples from infected bones or joints placed in a
sterile universal container and sent for culture and sensitivity testing. Older reports suggesting an increase
in K. kingae recovery is gained from inoculating synovial fluid or bony exudates directly into blood culture
bottles have not been replicated in UK practice.17 K. kingae is detectable using new PCR techniques from
cultures where conventional direct plating of specimens on solid media has been used.18,19
Surgical management
There is little current high-quality evidence on which to base current surgical practice.
Osteomyelitis
Surgical drainage in acute OM is indicated if the patient is not responding to antibiotics after 48–72 hours
(although this may be because of resistance) or if there is radiological evidence of a substantial pus
collection.7 Best practice is to immobilise any surgically treated limb or focus of infection. Occasionally,
where a soft tissue or subperiosteal collection is clearly demonstrated by ultrasonography or MRI, needle
aspiration can be performed prior to starting intravenous (i.v.) antibiotics. When performed, the procedure
should be carried out under sterile conditions. If there is bony destruction or pus aspirated, surgical
debridement is usually required. With only early radiographic signs, conservative i.v. antibiotic therapy
may suffice.
Historically, the role of surgery is poorly defined. Cole et al.42 identified three groups of patients. In the
group of patients aged > 1 year who presented within 48 hours, antibiotic therapy alone was sufficient.
In the group aged > 1 year, 5 days after the onset of illness, patients usually required surgery and possibly
multiple procedures. In infants aged < 1 year, in whom the exact diagnosis was difficult to make, a single
operation and antibiotic therapy usually sufficed. In current practice, the relative roles of bacterial virulence
and host age and immunity are unclear. More invasive surgery appears more common when bacteria have
specific virulence genes, for example PVL.22 Although most children recover rapidly with simple medical
management, others require repeated debridement.
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Septic arthritis
In SA, prompt drainage and washout of the affected joint (either arthroscopic or open) is advocated by
some for both diagnostic and therapeutic purposes as the articular cartilage is damaged early.7 The role
of surgery in the treatment of SA is, in fact, poorly defined except in relation to the hip, where prompt
surgical drainage is absolutely necessary. Open capsulotomy to allow continuing drainage of septic
material is advocated, and, if the arthrotomy does not provide turbid material, drilling the femoral neck
may decompress a proximal femoral OM. The anterior approach is preferred as this also allows open
reduction of any displacement of the femoral head.
The indications for surgical drainage of septic joints other than the hip remain controversial. Where there
is a large effusion, drainage is usually advocated, although in some joints arthroscopic irrigation may be
appropriate, such as the knee or ankle. However, with arthroscopic treatment joint visualisation is less
complete. Overall, for joints other than the hip, aspiration, irrigation and i.v. antibiotic therapy is the
preferred first line of treatment. If the patient fails to respond, then the joint should be surgically drained,
usually by formal open arthrotomy rather than arthroscopic drainage.
Medical management and antibiotics
Current evidence for how to initiate treatment
Intravenous antibiotics are started empirically as soon as the clinical diagnosis of acute OM or SA is made,
as delaying therapy until the bacterium is identified increases the risk of complications. In SA, where
urgent surgery is indicated, a widespread pragmatic approach has been to start antibiotics following
surgery unless it will take > 4 hours to get to theatre. As soon as organisms are isolated, antimicrobial
treatment should be adjusted and optimised. In subacute OM with no systemic reaction, oral antibiotics
can be used from the start.
Although there has not been a definitive randomised controlled trial (RCT), a number of observational and
retrospective studies in the literature show that several different antibiotic regimes have been effective in
treating acute haematogenous OM in children, including the use of beta-lactam and macrolide antibiotics.9
The initial antibiotics should always include potent cover against MSSA and GAS, and in younger children
against K. kingae, although the choice will vary according to the age of the child, route of infection and
local resistance patterns.8 Recent data from the USA suggest increases in resistant S. aureus (MRSA), but
these data have not been replicated in UK cohorts.43 Activity against H. influenzae type b is essential in
children who have not been fully immunised against it.
Switch to oral antibiotics and total duration of treatment
Currently there is no international and little UK consensus regarding the route or duration for antibiotic
treatment of acute OAI in children.
Oral switch
Sequential i.v. and oral therapy has become usual as it is less inconvenient and painful for the patient, is
associated with fewer complications and is cheaper than longer courses of i.v. therapy alone.3,7,8 There
is no current evidence to aid the clinical decision of when to switch from i.v. to oral therapy, although
this practice is widely accepted and usually occurs when the patient has shown a marked clinical
improvement.9 A Canadian systematic review of short- (≤ 7 days) versus long-course (> 7 days) parenteral
antibiotic treatment for acute haematogenous OM in children primarily due to S. aureus found no
difference in the overall cure rate after 6 months between short- and long-course parenteral antibiotic
therapy.44 A recent retrospective cohort study of 1969 children in the USA found that early switch to oral
therapy (median 4 days) was as effective as prolonged i.v. treatment,45 a finding also suggested in a
smaller retrospective study of 186 children with SA.46 The laboratory or clinical parameters that would
determine the decision to switch to oral therapy remain undefined.
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Most clinicians continue i.v. antibiotics until the child shows clinical improvement, if afebrile and oral fluids
and medication can be established. Additionally, observing a decrease in inflammatory markers such as
WBC, CRP and ESR is thought to be of value.3 Studies have shown that serum CRP level decreases more
rapidly than ESR in children recovering from acute OM, and that children with a raised CRP level are more
likely to have symptoms or extensive radiographic abnormalities.28,47,48 A recent Finnish clinical trial47,49
reported apparently good long-term results and apparently no failure rates using CRP as the biological
marker of infection.
Failure to improve necessitates repeat blood culture, additional imaging for metastatic infection,
assessment for deep-vein thrombosis and consideration of unusual pathogens such as PVL S. aureus
or Fusobacterium.
No UK consensus currently exists to guide the criteria for oral switch for use in clinical practice or a clinical
trial, which will be determined as part of this feasibility study.
Total duration of antibiotic therapy
The suggested duration for parenteral antibiotic treatment ranges from 3 days up to 6 weeks, resulting
from several, mainly observational, studies with a relatively poor level of evidence.9,50 In the past, the
overall duration of antibiotic treatment has been considered an important factor to improve outcome and
reduce relapse. Several paediatric textbooks recommend at least 4–6 weeks of treatment.3,51
Although there are encouraging data from a recent clinical trial in Finland47,49 and from other review
papers and case series, no recent formal RCT has been conducted to show good evidence for shorter
courses of parenteral antibiotic treatment. There are a number of reasons why the recent Finnish data may
not be directly applicable to practice in the UK or other countries.52 Some historical observational studies
showed an association between a short duration of antibiotic therapy and 15–19% poor outcome or
relapse with courses of ≤ 3 weeks.53–55
Currently there is no consensus about the route or duration for antibiotic treatment of acute OM
in children.
Oral antibiotic choice and dose
Many different regimens are used as oral therapy following switch from oral antibiotics, including
co-amoxiclav, flucloxacillin and clindamycin. Although flucloxacillin and clindamycin have good oral
bioavailability and excellent tissue penetration, both drugs have to be given orally four times per day and
both have poor taste and therefore poor drug adherence of the suspension in small children.56 Although
clindamycin rarely leads to C. difficile disease in children, there is no current evidence or consensus
regarding oral antibiotic choice that will be acceptable to children and parents in terms of both palatability
and dose frequency.
Continuation of intravenous antibiotics for more than 2 weeks
Complex disease requiring continuing i.v. therapy poses problems of vascular access, hospitalisation and
schooling. Most children will require central or peripherally inserted central venous long line [peripherally
inserted central catheter (PICC)] insertion for long-term antibiotic treatment. Delivery of subsequent care is
either in hospital or at home, dependent on local services and the ability to provide outpatient parenteral
antibiotic therapy (OPAT), although OPAT services for children are not yet well developed in the UK.
Central venous lines or PICCs and OPAT has attendant risks, with 3–11% of central venous line-associated
infection noted in the USA.57,58
Additional or second-line antibiotics for complex disease or where resistant pathogens
are identified
When cases are complex, additional antibiotics may be advised by local microbiologists, clinical infectious
diseases specialists or national guidelines, for example PVL-positive S. aureus infection.59
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Complications
Deep-venous thrombosis and thromboembolism have been seen in up to 30% of children with OM and
are associated with a higher risk of disseminated infection.60 In addition, joint stiffness, limb shortening,
dislocation (acutely neonates) and avascular necrosis of affected epiphysis may occur.
Routine follow-up allows most children with simple disease to be discharged without the need for
long-term care or further assessment of growth or function.
In the context of clinical audit or clinical trials, outcome measures may include length of stay in hospital,
total length of therapy, operative procedures required, as well as formal assessment of growth and
function.
Currently accepted clinical equipoise
At this time, all clinical co-investigators have agreed in writing that they agree there is no international and
little UK consensus regarding the route or duration for antibiotic treatment of acute bone and joint
infections in children, and that there is also no clear evidence to aid the clinical decision of when to switch
from i.v. to oral therapy.
Commissioning brief and objectives
Health Technology Assessment-provided background to commissioning brief
Usually treatment with an IV [intravenous] antibiotic is started as soon as possible. This may be
continued for several weeks, with comorbidity caused by the need for prolonged IV access.
Empirically 3–6 weeks has been the usual regimen but there is little hard data upon which to base this
opinion. Evidence is lacking for shorter duration IV antibiotics, but this could avoid the adverse events
associated with protracted intravenous therapy, and still be an effective strategy to adopt in children.
In children with acute osteomyelitis or septic arthritis, can antibiotics be switched to the oral route
after a short IV course to reduce the need for prolonged IV access.
HTA programme background document (provided with commissioning brief)
The HTA programme brief was to assess the feasibility of performing a hospital-based trial of short duration
(3–5 days) i.v. antibiotic therapy followed by oral therapy for the usually recommended duration compared
with a minimum of 14 days’ i.v. therapy prior to oral switch in children who have a clinical diagnosis of
acute OM or SA (these two diagnostic groups should be considered separately) after any primary diagnostic
or therapeutic surgical procedure. The feasibility study was required to identify appropriate non-inferiority
margin and microbiological outcomes through surveys of different communities, and to assess if data will
allow for subgroup analysis by culture status. The expectation was not for children to be actively recruited at
this stage but for researchers to identify willingness of clinicians and families to participate.
Research objectives
In order to assess the feasibility and inform the potential design of a RCT to determine the safety of early
oral switch from i.v. to oral antibiotic therapy we aimed:
1. to understand the current case load, disease spectrum and clinical practice in the diagnosis and
treatment of OM/SA in secondary and tertiary UK care by conducting a service evaluation of OM/SA in
children aged 1 month (the lower limit of the clindamycin licence) to 16 years
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2. to assess if a new molecular test is an appropriate tool to assess the molecular epidemiology of
children’s bone and joint infections by conducting a substudy at six of the service evaluation centres
3. to understand parents’ and children’s views and experiences of bone and joint infection, and gather
their views and perceptions of both participating in a clinical trial and potential trial outcomes by
conducting a qualitative study
4. to develop a core outcome set for use in a future RCT using a systematic literature review of previously
used clinical trial outcomes in children’s bone and joint infections, a web-based clinician survey and
results of the qualitative study to inform a stakeholder consensus meeting.
Patient and public involvement in this project
Patient and public involvement (PPI) was integrated into the design of this project via the National Institute
for Health Research (NIHR) Medicines for Children Research Network (MCRN) PPI representation in the
study initiation (via involvement in the NIHR MCRN Allergy, Immunology and Infectious Diseases Clinical
Studies Group). The PPI representative reviewed the study protocols and all patient and parent facing
materials, and reviewed the qualitative study protocol and study guide in detail. In addition, there was
PPI representation on the study steering committee and consumer involvement at the study consensus
meeting (PPI representative and member of NIHR Comprehensive Research Network: Paediatric Theme
London Young Persons Advisory Group).
DOI: 10.3310/hta21480 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 48
© Queen’s Printer and Controller of HMSO 2017. This work was produced by de Graaf et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
7

Chapter 2 Service evaluation
Aims and objectives
We aimed to conduct a service evaluation captured via an electronic web-based database to record every
case of paediatric bone and joint infection in a 6-month period in participating centres, with 3 months’
clinical follow-up. The research objective was to define the current case load, disease spectrum and clinical
practice in the diagnosis and treatment of OM/SA in secondary and tertiary UK care.
Methods
Service evaluation case record forms
A co-investigator meeting in November 2012 discussed the key items to include and exclude in the service
evaluation, which were then further refined and discussed by the study team and investigators. These
included demographic details and details of hospitalisation(s) including transfers between hospitals; type
and site of disease; routine haematology, biochemistry and microbiology; radiological procedures; surgical
procedures; length of i.v. therapy; antimicrobials used, route and duration; reason/criteria used for oral
switch (if any); and clinical outcomes at 3 months. As per our application, we did not identify adverse
outcomes occurring > 3 months after treatment (e.g. physical injury), which will be evaluated in a later
RCT. The case record forms and service evaluation protocol are included in Service evaluation documents
(see Report supplementary material 1).
Ethics approval was not required
We confirmed with the NHS Research Ethics Committee (REC) that formal REC approval was not required
for the service evaluation data collection, in line with the House of Lords Select Committee report on
‘Fighting infection’,61 which recommended making infection surveillance a clear evidence-based priority,
establishing collaboration between scientists (microbiologists), clinicians and epidemiologists, and
encouraging the use of electronic capture and dissemination of information about infection.
Electronic records
A bespoke web-based data entry system was developed by the Medicines for Children Clinical Trials Unit,
a division of the Clinical Trials Research Centre, a UK Clinical Research Collaboration fully registered clinical
trials unit. The system, which stored and managed the data, was used as part of a national service
evaluation. Data were collected using a custom web-based data entry system written in C#.Net, using
jQuery (https://jquery.com). The data collection system allowed data to be validated on input, providing
help/additional information as required for questions and to allow for the hiding of questions that did not
need to be answered by the clinician.
Study sites
We recruited NHS tertiary and secondary care centres to participate in the service evaluation. Sites
nominated a local principal investigator (paediatric infectious diseases, general paediatrics or paediatric
orthopaedics) and achieved the support of local leads for all clinical stakeholders (paediatric medicine,
orthopaedics, microbiology and radiology). All had the support of NIHR-funded research nurses [NIHR
MCRN local research networks, paediatric clinical research facility or nurses funded by the local NIHR
Comprehensive Local Research Network (from April 2014, the NIHR Comprehensive Research Network)].
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Statistical analysis
A formal descriptive statistical analysis plan (v1.6, November 2014; see Report supplementary material 2)
was developed and used to analyse the data. There were some major additions: notably that statistics have
been generated for complex cases, that many statistics have been further split by diagnosis category (SA or
OM) and some additional analyses have also been carried out (see Report supplementary material 3).
Important definitions appearing in service evaluation tables
Simple cases
Children presenting with SA or OM for the first time, and with no chronic comorbidities. Specifically:
l no orthopaedic surgery 6 months prior to presentation on same limb/joint
l no chronic comorbidities (sickle cell disease, known immunocompromise, indwelling central venous
catheter or PICC, cystic fibrosis or cerebral palsy).
Complex cases
Children presenting with SA or OM who:
l have had any orthopaedic surgery in the 6 months prior to presentation on same limb/joint
l have chronic comorbidities (sickle cell disease, known immunocompromise, indwelling central venous
catheter or PICC, cystic fibrosis or cerebral palsy)
l are presenting because of an infected implant from previous orthopaedic surgery.
Misdiagnosed
Some children captured by the database were treated for SA/OM but were later found to have a
different diagnosis.
Other
Some children had discitis. This is a form of SA, but it is treated differently and so is not of interest to
this study.
Results
Sample descriptive
Participating centres
Fifty-one centres (49 hospital trusts) took part in the study. Eighteen of these were classed as tertiary
centres and 33 as secondary centres.
Together, centres provided data for 356 children. In addition to these, three children were withdrawn as
consent was withdrawn and five were excluded from analysis on the basis of a major lack of data. One
tertiary centre (Chelsea and Westminster) and six secondary centres did not record any cases. For one of
the secondary centres this was because the centre withdrew from the study.
Tertiary centres contributed 68% of the 356 cases (66% of all 218 simple cases). There was wide variation
in the proportion of cases presenting with symptoms of OM/SA that were complex. In tertiary centres this
varied from 0% to 75% (Table 1) and in secondary centres from 0% to 66.7% (Table 2).
Recruitment
The study opened to recruitment in June 2013 and closed 1 year later. During this time frame, sites
recorded all children presenting with SA/OM. Sites did not all open for recruitment at the same time but
most achieved a minimum of 6 months (with the exception of one tertiary centre and six secondary
SERVICE EVALUATION
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centres). The median [interquartile range (IQR)] recruitment time was 8.8 (6–9.4) months for tertiary
centres and 8.5 (6.3–9.3) months for secondary care centres (see Tables 1 and 2).
Accrual rates for simple and complex cases
The monthly rates of case accrual are given in Tables 1 and 2. The median recruitment rate in tertiary
centres was 0.7 (IQR 0.2–1.7) cases per month for simple cases and 0.4 (IQR 0.2–0.7) cases per month for
complex cases. For secondary centres the median recruitment rate was 0.2 (IQR 0.1–0.5) simple cases per
month and 0 (IQR 0–0.1) complex cases per month.
Initial categorisation of types of cases and sample characteristics
A total of 356 children were recorded in the database as presenting with symptoms of SA or OM. Two
hundred and eighteen (61.2%) children were classified as simple cases of OM or SA, 95 (26.7%) were
classified as complex cases, five (1.4%) had discitis and 38 (10.7%) presented with the symptoms of OM
or SA but were found to have a different diagnosis. Discitis is a special case of SA, but it is treated in a
different way and so is not of interest to this study.
Table 3 gives the breakdown of how many children had OM or SA in each case-type group and the types
of diagnosis of misdiagnosed children. Note that, for six children, either there was evidence of both SA
and OM, or the diagnosis was ambiguous in the database, meaning that it could have been either SA or
OM, or both. These children are not included in the analyses split by diagnosis group.
TABLE 3 Case types
Case type n (%) (N= 356)
Simple casesa 218 (61.2)
OM 109 (50)
SA 107 (49.1)
OM/SA or bothb 2 (0.9)
Complex casesc 95 (26.7)
OM 56 (58.9)
SA 35 (36.8)
OM/SA or bothb 4 (4.2)
Misdiagnosed/discitis 43 (12.1)
Misdiagnosed 38 (88.4)
Cellulitis 7 (16.3)
Reactive arthritis 3 (7)
Joint effusiond 2 (4.7)
Soft-tissue abscess 2 (4.7)
Other 22 (51.2)
Unknown/undecided 2 (4.7)
Discitis 5 (11.6)
a Acute SA/OM with no comorbidities.
b Option label available in database for ambiguous cases.
c Chronic SA/OM or acute SA/OM with comorbidities.
d No infection reported.
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A total of 53.9% of participants were male, the median age was 3.4 years and most were of north
European, east European or mid-European origin (73.3%). Table 4 shows the sex, age group and
ethnicity for all 356 children, and also for the 313 children who were diagnosed with SA or OM. When
misdiagnosed children and children with discitis are excluded, the demography of the sample remains
largely unchanged.
Completeness of follow-up
Children were followed up for approximately 3 months post discharge. A total of 72% of simple cases and
80% of complex cases were contactable and followed up. In most cases, failure to follow up was because
children were not contactable (Table 5). In 2.8% and 2.1% of simple and complex cases, respectively,
follow-up data were missing for unknown reasons.
Presentation and diagnosis
For the rest of this report, data are presented for the 313 children who were either simple or complex
cases. The 43 misdiagnosed/discitis children are excluded from further analyses.
TABLE 4 Sample demographics
Demographics All
Misdiagnoses/discitis
excluded (n= 43)
Total number of children in database with data available for analysisa 356 313
Age (years) at presentation, median (IQR) 3.4 (1.4–9) 3.3 (1.4–8.7)
< 1, n (%) 46 (12.9) 40 (12.8)
1–6, n (%) 182 (51.1) 161 (51.4)
6–16, n (%) 128 (36) 112 (35.8)
Male, n (%) 192 (53.9) 173 (55.3)
Ethnicity, n (%)
European north/east/mid 261 (73.3) 228 (72.8)
European south (Mediterranean) 2 (0.6) 2 (0.6)
European Roma 1 (0.3) 1 (0.3)
African/Caribbean (North African) 2 (0.6) 2 (0.6)
African/Caribbean (sub-Saharan) 8 (2.2) 7 (2.2)
African/Caribbean (Afro-Caribbean) 3 (0.8) 2 (0.6)
Asian (Indian subcontinent) 30 (8.4) 26 (8.3)
Asian south-east Asia (Vietnam, Thailand, Indonesia, Malaysia, Philippines) 3 (0.8) 3 (1)
Asian east Asia (China, Japan, Korea) 2 (0.6) 2 (0.6)
Asian west Asia (Afghanistan, Iranian) 1 (0.3) 0
Middle eastern (Turkish) 0 0
Middle eastern (Arab peninsula) 1 (0.3) 0
Other/mixed 37 (10.4) 35 (11.2)
Missing 5 (1.4) 5 (1.6)
a Database contained 361 cases. Four children were excluded because all but demographic data were missing; one child
was excluded as diagnostic data were missing.
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Medical history
Simple cases
Six simple cases had a history of orthopaedic surgery > 6 months prior to presentation (Table 6 shows
details of bones/joints affected). Other medical histories of interest were that 31 (14.2%) children had at
least one pre-existing medical condition not listed in Table 7, 43 (19.7%) children had at least one history
of a severe infection in the 12 months preceding presentation and 29 (13.3%) children had a history of
trauma in the month preceding presentation (Tables 8–10). A total of 18.8% of simple cases had had at
least one antibiotic in the month prior to presentation (Table 11 shows further statistics by route type and
for specific antibiotics).
Complex cases
Eleven complex cases had a history of orthopaedic surgery; six of these were within 6 months of
presentation (see Table 6 for details of bones/joints affected). Thirty-one (33.7%) children had an
indwelling central venous catheter or PICC, four children presented with an infected implant, five children
had sickle cell disease, one child had cystic fibrosis, one child had cerebral palsy and two children were
known to be immunocompromised (see Table 7).
Other medical histories of interest were that 25 (26.3%) children had other pre-existing medical conditions
not listed in Table 7, 26 (27.4%) children had a history of infection in the 12 months preceding presentation
and 15 (15.8%) children had a history of trauma in the month preceding presentation (see Tables 8–10).
Presentation
Where children presented
Most children presented at emergency departments (65% of simple cases and 70% of complex cases).
The next most likely location was at a general practitioner (GP) surgery (28% of simple cases and 14.7%
of complex cases). Outpatient clinics, inpatient clinics and walk-in centres were much less likely places for
children to present (Table 12).
TABLE 5 Completeness of follow-up
Case type Total, n (%)
Diagnosis, n (%)a
SA OM
Simple cases n= 218 n= 107 n= 109
Followed up 157 (72) 78 (72.9) 79 (72.5)
Not contactable 55 (25.2) 26 (24.3) 28 (25.7)
Unknown/missing 6 (2.8) 3 (2.8) 2 (1.8)
Complex cases n= 95 n= 35 n= 56
Followed up 76 (80) 27 (77.1) 45 (80.4)
Not contactable 17 (17.9) 7 (20) 10 (17.9)
Unknown/missing 2 (2.1) 1 (2.9) 1 (1.8)
Misdiagnosed/discitis n= 43
Followed up 30 (69.8) – –
Not contactable 10 (23.2) – –
Unknown/missing 3 (7.0) – –
a Two simple cases and four complex cases could not be categorised as uniquely SA or OM.
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TABLE 7 Comorbidities indicating complex cases
Comorbidities indicating complex case Yes (n) No (n)
Sickle cell diseasea 5 210
Presentation as a result of an infected implant 4 309
Known immunocompromised 2 311
Indwelling central venous catheter or PICC 31 282
Cystic fibrosis 1 306
Cerebral palsy 1 312
a Ninety-eight patients were not tested for sickle cell disease.
TABLE 6 History of orthopaedic surgery
Bone/joint affected
Within 6 months prior to
presentation, n (%)a
Any time prior to presentation, n (%)
Simple cases (N= 218) Complex cases (N= 95)
Cases 6 6 (3.2) 11 (16.8)
Bone/joint types affectedb
Knee – – –
Clavicle – – 1
Radius 1 – 1
Ulna – – –
Humerus – 3 –
Tibia 1 1 2
Femur – 1 1
Ankle – 1 –
Hip 3 – 4
Spine – – 1
Toe – – 1
Elbow – – 1
Skull 1 – 1
Side of body
Right – 4 2
Left 2 2 4
Both 3 – 3
N/A 1 – 2
N/A, data not available.
a Complex by definition.
b Number of patients with at least one prior orthopaedic surgery by bone/joint type (note: one complex case had history of
surgery on three separate bones/joints, and one had surgery on the femur/tibia so both joints have been counted; all
others’ history pertained to a single bone/joint type).
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TABLE 8 Medical history
Medical history Simple cases (N= 218), n (%) Complex cases (N= 95), n (%)
Other medical conditions
At least one 31 (14.2) 25 (26.3)
Congenital cardiac disease 1 (0.5) 2 (2.1)
Diabetes mellitus – 1 (1.1)
Purpura fulminans – –
Malnutrition – –
Othera 30 (13.8) 23 (24.2)
Immune-modulating treatment in last 6 calendar months?
Steroid – 1 (1.1)
Radiotherapy – –
Chemotherapy – –
Azathioprine – –
Ciclosporina – –
Cyclophosphamide – –
Rituximab – –
Leflunomide – –
Tacrolimus – –
Sirolimus – –
Other – 1 (1.1)
Infection history in the last 12 calendar months?
At least one 43 (19.7) 26 (27.4)
Pneumonia 1 (0.5) –
Sepsis – 2 (2.1)
Pyelonephritis – –
Cellulitis/soft-tissue infection 5 (2.3) 1 (1.1)
Meningitis 1 (0.5) –
OAI – 6 (6.3)
Abdominal sepsis – –
Varicella 4 (1.8) 3 (3.2)
Otherb 32 (14.7) 18 (18.9)
History of trauma in the last month? 29 (13.3) 15 (15.8)
Other surgery in previous 12 months? 2 (0.9) 4 (4.2)
a See Table 9.
b See Table 10.
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Joints and limbs affected
The most likely joints/limbs affected were the hip (21.7%), knee (23.3%) and ankle (14.7%). There are
similarities between joints affected in simple and complex cases, although many joints/limbs were more
affected in complex cases (see Table 12).
Septic arthritis was more likely than OM to occur in hips and knees (both simple and complex cases),
whereas OM affected a much larger range of joints/limbs (Table 13).
TABLE 9 Other medical conditions (as input in the database)
Simple cases (N= 30) Complex cases (N= 23)
Asthma (n = 7) Abscess over the site of OM in her humerus drained
July 2012
Asthma, treated for 1 week with antibiotics for a 3-week
dental abscess
ADHD, asthma, growth deficiency, insomnia
Atopic eczema Asthma
Baker’s cyst (summer 2013) Asthma, epilepsy, bilateral disease, death
Bilateral talipes valgus/internal tibial torsion Bilateral AVN, acute chest syndrome
Capillary haemangioma currently undergoing laser treatment Club foot
Chronic ITP Congenital hip dislocation
Cleft lip/palate Eczema (n = 3)
Coeliac disease Fish odour syndrome, microcephaly, postural scoliosis,
clawing of toe
Congenital dislocation of hips G6PD deficiency
Duplication of chromosome 8p11–21 and severe
learning difficultiesa
Gastro-oesophageal reflux
Eczema (n= 3) Leucocyte adhesion deficiency type 1
Haemophiliac Mild asthma
Hydronephrosis (left kidney) MRSA abscess (left neck)
Jaundice, oedema, lymphadenopathy Normocytic normochromic anaemia (possibly secondary
to infection)
Klippel–Trénaunay–Weber syndrome Osteosarcoma
Leucocyte adhesion deficiency type 1b Patient has a small PDA. Born at 32 weeks, patient was in
the NICU and treated with fluconazole for possible fungal
infection (patient born in August 2013). Patient home
1 week before starting symptoms
MRSA Patient is being investigated for autism
Osteogenesis imperfecta type 1a Right MCA abnormality, gastrostomy, sigmoid colostomy
Patient born with neonatal thrombocytopenia, now resolved Spina bifida
Psychotic depression Vitamin D deficiency
Under weather for 4 weeks prior with ear and
chest infections
ADHD, attention deficit hyperactivity disorder; AVN, avascular necrosis; G6PD, glucose-6-phosphate dehydrogenase;
ITP, idiopathic thrombocytopenic purpura; MCA, middle cerebral artery; NICU, neonatal intensive care unit; PDA, patent
ductus arteriosus.
a Medical condition queried and child still classified as a simple case.
b Medical condition later found to denote ‘known immunocompromised’ implying that this case should be reclassified
as complex.
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Blood tests at presentation
Simple cases
A total of 105 (48.2%) children had blood tests taken at presentation. Of those tested, haemoglobin,
WBC count, neutrophils, platelets and CRP were routinely measured in > 84% of cases. ESR was tested
(53.3%) less often. Fifty-three (50.5%) children had both CRP and ESR tested. Of the 99 children with a
CRP test result, 65 (65.7%) had their highest result at presentation (Table 14).
TABLE 10 Other infection history (as input in the database)
Simple cases (N= 32) Complex cases (N= 18)
2 × dental abscess, viral infection starting 19 August 2013 Chest infection
Bronchiolitis (n= 2) Ear infection
Diarrhoea Ear/throat infection
Ear and chest infections Fungal sepsis, patient grew C. albicans sensitive to
fluconazole, premature neonate
Ear infection and tonsillitis Left leg swelling/patient went to theatre for necrotising
fasciitis. Endocarditis. All initially presented to Royal
Berkshire Hospital, Reading
Ear infection, cold Multiple bacterial URTI
Hand, foot and mouth disease OM/Brodie abscess
MRSA Patient initially presented on the 30 June with severe pain in
the right distal tibia. Patient was placed in a back slab and
had 2 weeks of antibiotics
MRSA sepsis and RSV positive Pleural effusion
Non-specific viral illness week before Possible impetigo (nose)
Probable viral URTI Recurrent tonsillitis requiring tonsillectomy
Recurrent bouts of tonsillitis Sinusitis and left frontoparietal subdural empyema
Recurrent ear infections Tonsillitis
Scarlet fever (n= 2) Tonsillitis and inflamed ear
Severe eczema exacerbation Urinary tract infection
Sinusitis Viral tonsillitis/URTI
Sore throat Chronic infected tibia
Tick bite, Lyme serology negative Vomiting illness
Tonsillitis (n= 3)
URTI
URTI – coryzal, sore throat, decreased appetite and a
temperature of 38.3 °C
Urinary tract infection
Viral diarrhoea
Viral illness (n= 2)
Viral illness? migraine
Viral infection
Vomiting and diarrhoea illness
RSV, respiratory syncytial virus; URTI, upper respiratory tract infection.
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TABLE 11 Pre-presentation variables that affect drug choice, dosage and duration (simple cases)
Antibiotic medical history prior to presentation
All simple cases
(N= 218), n (%)
Route, n (%)
Duration > 1 week,
n (%)i.v. Oral
Penicillin allergy 7 (3.2) – – –
1 month pre presentation
At least one antibiotic takena 41 (18.8) 18 (8.3) 26 (11.9) 14 (6.4)
Antibiotics taken
Flucloxacillin 18 (8.3) 9 9 4
Clindamycin 5 (2.3) 2 3 2
Cefuroxime 3 (1.4) 3 0 0
Ceftriaxone 10 (4.6) 9 1 5
Amoxicillin 9 (4.1) 0 9 3
Co-amoxiclav 8 (3.7) 0 8 4
Rifampicin 2 (0.9) 0 2 1
Vancomycin 2 (0.9) 1 1 1
Fusidic acid 1 (0.5) 0 1 1
Teicoplanin 3 (1.4) 2 1 1
Other 1 (0.5) 1 0 1
a Patients may have received multiple antibiotics in the month before presentation.
TABLE 12 Where patients presented and bones/joints affected
Presentation All (N= 313), n (%) Simple cases (N= 218), n (%) Complex cases (N= 95), n (%)
Presenting to
Outpatient clinic 13 (4.2) 8 (3.7) 5 (5.3)
Inpatient 9 (2.9) 5 (2.3) 4 (4.2)
GP surgery 75 (24) 61 (28) 14 (14.7)
Emergency department 207 (66.1) 141 (64.7) 66 (69.5)
Walk-in centre 9 (2.9) 3 (1.4) 6 (6.3)
Bones/joints affecteda
Hip 68 (21.7) 46 (21.1) 22 (23.2)
Shoulder 23 (7.3) 16 (7.3) 7 (7.4)
Knee 73 (23.3) 54 (24.8) 19 (20)
Ankle 46 (14.7) 29 (13.3) 17 (17.9)
Wrist 9 (2.9) 8 (3.7) 1 (1.1)
Skull 5 (1.6) 2 (0.9) 3 (3.2)
Mandible 0 0 0
Humerus 14 (4.5) 5 (2.3) 9 (9.5)
Clavicle 1 (0.3) 0 1 (1.1)
Radius 6 (1.9) 3 (1.4) 3 (3.2)
Ulna 4 (1.3) 2 (0.9) 2 (2.1)
Pelvis 11 (3.5) 4 (1.8) 7 (7.4)
continued
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TABLE 13 Joints/limbs affected (by SA/OM)
Limb/joint affecteda
Simple cases, n (%) Complex cases, n (%)
SA (N= 107) OM (N= 109) SA (N= 35) OM (N= 56)
Hip 31 (29) 15 (13.8) 11 (31.4) 9 (16.1)
Shoulder 7 (6.5) 8 (7.3) 3 (8.6) 4 (7.1)
Knee 41 (38.3) 13 (11.9) 9 (25.7) 10 (17.9)
Ankle 14 (13.1) 14 (12.8) 6 (17.1) 10 (17.9)
Wrist 4 (3.7) 4 (3.7) 1 (2.9) 0
Skull 0 2 (1.8) 0 3 (5.4)
Humerus 1 (0.9) 4 (3.7) 4 (11.4) 5 (8.9)
Clavicle 0 0 0 1 (1.8)
Radius 0 3 (2.8) 2 (5.7) 1 (1.8)
Ulna 0 2 (1.8) 1 (2.9) 1 (1.8)
Pelvis 0 4 (3.7) 1 (2.9) 5 (8.9)
Femur 0 10 (9.2) 3 (8.6) 12 (21.4)
Tibia 0 6 (5.5) 1 (2.9) 5 (8.9)
Fibula 0 4 (3.7) 1 (2.9) 4 (7.1)
Sternum 0 0 1 (2.9) 2 (3.6)
Elbow 7 (6.5) 8 (7.3) 9 (25.7) 5 (8.9)
Foot 0 4 (3.7) 2 (5.7) 4 (7.1)
Calcaneus 0 5 (4.6) 0 0
Lumbar vertebrae 1 (0.9) 1 (0.9) 0 2 (3.6)
Sacrum vertebrae 0 1 (0.9) 1 (2.9) 2 (3.6)
Other 1 (0.9) 1 (0.9) 0 0
a Categories not mutually exclusive, so more than one bone/joint can be recorded per patient.
TABLE 12 Where patients presented and bones/joints affected (continued )
Presentation All (N= 313), n (%) Simple cases (N= 218), n (%) Complex cases (N= 95), n (%)
Rib 0 0 0
Femur 26 (8.3) 16 (7.3) 10 (10.5)
Tibia 14 (4.5) 6 (2.8) 8 (8.4)
Fibula 9 (2.9) 4 (1.8) 5 (5.3)
Sternum 3 (1) 0 3 (3.2)
Elbow 29 (9.3) 15 (6.9) 14 (14.7)
Foot 11 (3.5) 4 (1.8) 7 (7.4)
Calcaneus 6 (1.9) 5 (2.3) 1 (1.1)
Lumbar vertebrae 4 (1.3) 2 (0.9) 2 (2.1)
Cervical vertebrae 0 0 0
Thoracic vertebrae 0 0 0
Sacrum vertebrae 4 (1.3) 1 (0.5) 3 (3.2)
Other 2 (0.6) 2 (0.9) 0 (0)
a Categories not mutually exclusive, so more than one bone/joint can be recorded per patient.
SERVICE EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
22
The prevalence of types of tests carried out was similar in tertiary and secondary centres (see Table 14 for
more details). Table 15 presents median and IQRs for blood test results at presentation. Table 16 splits
these results by diagnosis of SA or OM. Blood test results were similar in these two groups.
Complex cases
Thirty-two (33.7%) children had blood tests taken at presentation. Of those tested, haemoglobin, WBC
count, neutrophils, platelets and CRP were routinely measured in > 71% of cases. All but one had a CRP
measurement (96.9%) and ESR was less tested (34.4%). Eleven (34.4%) children had both CRP and ESR
TABLE 14 Presentation blood tests
Blood test at presentation All, n (%)
Presentation centre type, n (%)
Tertiary Secondary
Simple cases (N = 218) (N = 106) (N = 112)
At least one blood test carried out at presentation
Yes 105 (48.2) 51 (48.1) 54 (48.2)
No 113 (51.8) 55 (51.9) 58 (51.8)
Percentage of children who had a test with
Haemoglobin 89 (84.8) 43 (84.3) 46 (85.2)
WBC 96 (91.4) 44 (86.3) 52 (96.3)
Neutrophils 91 (86.7) 44 (86.3) 47 (87)
Platelets 89 (84.8) 42 (82.4) 47 (87)
CRP 99 (94.3) 47 (92.2) 52 (96.3)
ESR 56 (53.3) 25 (49) 31 (57.4)
CRP and ESR 53 (50.5) 23 (45.1) 30 (55.6)
CRP and not ESR 46 (43.8) 24 (47.1) 22 (40.7)
CRPmax at presentation 65 (65.7)
a 33 (70.2)a 32 (61.5)a
Complex cases (N = 95) (N = 51) (N = 44)
At least one blood test carried out at presentation
Yes 32 (33.7) 18 (35.3) 14 (31.8)
No 63 (66.3) 33 (64.7) 30 (68.2)
Type of test
Haemoglobin 26 (81.3) 15 (83.3) 11 (78.6)
WBC 28 (87.5) 16 (88.9) 12 (85.7)
Neutrophils 25 (78.1) 14 (77.8) 11 (78.6)
Platelets 23 (71.9) 14 (77.8) 9 (64.3)
CRP 31 (96.9) 17 (94.4) 14 (100)
ESR 11 (34.4) 3 (16.7) 8 (57.1)
CRP and ESR 11 (34.4) 3 (16.7) 8 (57.1)
CRP and not ESR 20 (62.5) 14 (77.8) 6 (42.9)
CRPmax at presentation 15 (48.4)
a 6 (35.3)a 9 (64.3)a
a Denominator is those who had CRP measured at presentation.
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tested. Of the 31 children with a CRP test result, 15 (48.4%) had their highest result at presentation
(see Table 14).
The prevalence of types of tests carried out were similar in tertiary and secondary centres, although ESR
was over three times as likely in a secondary centre (see Table 14). Blood tests results were similar in the
SA and OM groups (see Tables 15 and 16).
Clinical timeline
All children in the study spent time in hospital. On average, children went straight to hospital (median time
from presentation to hospital referral was 0 days), and most children presented at accident and emergency
(A&E) (see Table 12).
TABLE 15 Summary of blood test results at presentation
Blood test at presentation
Simple cases Complex cases
n Median (IQR) n Median (IQR)
Haemoglobin (g/dl) 89 117 (109–126) 26 124 (112–134)
WBC (109/l) 96 12.14 (9.6–15.8) 28 12.68 (11–14.5)
Neutrophils (109/l) 91 7.3 (4.7–10.7) 25 7.1 (5.47–8.71)
Platelets (109/l) 89 342 (256–441) 23 333 (280–419)
CRP (mg/l) 99 32 (11.8–66.7) 31 54 (24–141)
ESR (mm/hour) 56 32 (20.5–70) 9a 28 (15–55)
a Two ESR measurements missing.
TABLE 16 Summary of blood test results at presentation (by SA/OM)
Blood tests at presentation
SA OM
n Median (IQR) n Median (IQR)
Simple cases
Haemoglobin (g/dl) 47 116 (108–128) 42 120 (111–124)
WBC (109/l) 48 12.66 (9.8–16.5) 48 11.62 (9.5–15.2)
Neutrophils (109/l) 48 7.89 (5.4–11.0) 43 6.2 (4.68–10.7)
Platelets (109/l) 45 341 (256–431) 44 349.5 (258.5–482.5)
CRP (mg/l) 49 32 (16.2–65) 50 32.7 (10–68)
ESR (mm/hour) 28 29 (14–70.5) 28 35.5 (26–68.5)
Complex casesa
Haemoglobin (g/dl) 12 119.5 (109.5–127) 13 127 (114–137)
WBC (109/l) 13 12.9 (11.2–14.2) 14 11.96 (10.65–14.8)
Neutrophils (109/l) 13 7 (5.55–9.01) 11 7.1 (4.3–8.4)
Platelets (109/l) 12 331.5 (305.5–351.5) 10 413 (269–523)
CRP (mg/l) 15 53 (24–156) 15 54 (16–141)
ESR (mm/hour) 4 57.5 (41.5–91) 4 15.5 (9.5–33.5)
a One complex case could not be classified as only SA or only OM and is excluded here.
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Not all children received i.v. antibiotics (see Table 31). Fifteen (6.9%) simple cases and two (2.1%) complex
cases had either no i.v. treatment or missing data. Of those who did receive i.v. antibiotics, we can use the
date of initiation of i.v. therapy as a proxy for date of diagnosis.
The clinical timeline for first diagnostic X-ray, radiological diagnosis, first diagnostic surgery and the
initiation of i.v. antibiotics are given in Table 17. A total of 61% of simple cases and 59% of complex
cases had at least one X-ray post presentation and prior to initiation of i.v. antibiotics (i.e. had a diagnostic
X-ray). These were usually on the day of or day after presentation (see Table 17).
Diagnostic surgery was carried out in 28% of simple cases at a median of 1 day post presentation (25%
carried out at ≥ 4 days post presentation). For complex cases, the surgery was slightly more likely (30.5%),
at a median of 1 day post presentation (25% carried out ≥ 5 days post presentation).
A radiological diagnosis [an abnormal result via any imaging method (X-ray, ultrasonography, MRI, bone scan
or CT) post presentation and prior to initiation of i.v. antibiotics] was obtained for 51.8% of simple cases (at
a median of 1 day post presentation) and 52.6% of complex cases (at a median of 1 day post presentation).
Differences in clinical timeline between septic arthritis and osteomyelitis
Hospital referral times were more varied for OM (75% referred in 4 days for simple cases and 6 days for
complex cases) than for SA (75% referred in 2 days for simple cases and 3 days for complex cases). The
proportion of children with diagnostic X-rays was similar between SA and OM, as were the times at which
these occurred. Radiological diagnosis was more likely in SA and at an earlier time than in OM. Diagnostic
surgery was also more likely in SA and at an earlier time than in OM (Table 18).
TABLE 17 The clinical timeline for diagnosis
Diagnostic and hospital stay timeline n (%) Median (IQR), days Min., max. (days)
Simple cases (N = 218)
From first presentation to
Hospital referral 218 (100) 0 (0–3) 0, 957
First X-raya 133 (61) 0 (0–1) 0, 957
Radiological diagnosisb 113 (51.8) 1 (0–3) 0, 957
First surgeryc 61 (28) 1 (1–4) 0, 56
Initiation of i.v. antibiotics 203 (93.1) 1 (1–4) 0, 961
CRPmax 202 (92.7) 0 (0–6) 0, 84
Complex cases (N = 95)
From first presentation to
Hospital referral 95 (100) 1 (0–4) 0, 1867
First X-raya 56 (58.9) 0 (0–1) 0, 2345
Radiological diagnosisb 50 (52.6) 1 (0–4) 0, 2345
First surgeryc 29 (30.5) 2 (1–5) 0, 223
Initiation of i.v. antibiotics 91 (95.8) 2 (0–5) 0, 2345
CRPmax 86 (90.5) 4 (1–8) 9, 2345
Max., maximum; min., minimum.
a First X-ray post presentation and prior to initiation of i.v. antibiotics.
b First abnormal result from any imaging method post presentation and prior to initiation of i.v. antibiotics.
c First surgery post presentation and prior to initiation of i.v. antibiotics.
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Diagnosis
Day of diagnosis was defined as the day when i.v. antibiotics were initiated as the standard of care has
always been for i.v. antibiotics to be started as soon as possible in paediatric OM/SA. This can be
pinpointed for 203 (93.1%) simple cases and 91 (94.6%) complex cases (see Table 31 for more
information on children who did not receive i.v. antibiotics).
Blood tests at diagnosis
Simple cases
A total of 148 (72.9%) children who had i.v. antibiotics had blood tests taken on either the day before or
the day of diagnosis. Of these, ≥ 85% had haemoglobin, WBC count, neutrophils, platelets and CRP
measured. ESR was less frequently measured (57.4%), and 80 (54.1%) children had both CRP and ESR
measured. Of the 137 children with a CRP test result, the result was highest at diagnosis in 89 (65%)
(Table 19).
The prevalence of testing was similar in tertiary and secondary centres (see Table 19).
Table 20 presents the medians and IQRs for blood test results at diagnosis.
Complex cases
In 54 (59.3%) children who received i.v. antibiotics, blood tests were carried out either on the day before
or on the day of diagnosis. Among those tested, haemoglobin, WBC count, neutrophils, platelets and CRP
were routinely measured in > 77% of cases. Most had a CRP measurement (88.7%). ESR was less often
TABLE 18 The clinical timeline for diagnosis (by SA/OM)
Diagnostic and hospital stay timeline
SA OM
n (%) Median (IQR), days n (%) Median (IQR), days
Simple cases (N = 218) (N = 107) (N = 109)
From first presentation to
Hospital referral 107 (100) 0 (0–2) 109 (100) 0 (0–4)
First X-raya 66 (61.7) 0 (0–1) 66 (60.6) 0 (0–1)
Radiological diagnosisb 58 (54.2) 1 (0–3) 54 (49.5) 1 (0–5)
First surgeryc 39 (36.4) 1 (1–2) 21 (19.3) 2 (1–10)
Initiation of i.v. antibiotics 104 (97.2) 1 (0–3) 97 (89) 2 (1–5)
CRPmax 101 (46.3) 2 (0–5) 99 (90.8) 3 (0–7)
Complex cases (N = 95) (N = 35) (N = 56)
From first presentation to
Hospital referral 35 (100) 0 (0–3) 56 (100) 1 (0–6)
First X-raya 21 (60) 0 (0–2) 33 (58.9) 0 (0–1)
Radiological diagnosisb 16 (45.7) 1 (0–2) 32 (57.1) 1 (0–4)
First surgeryc 15 (42.9) 2 (1–5) 14 (25) 3 (1–8)
Initiation of i.v. antibiotics 33 (94.3) 2 (0–4) 54 (96.4) 2 (0–6)
CRPmax 33 (94.3) 3 (1–6) 49 (87.5) 4 (1–14)
a First X-ray post presentation and prior to initiation of i.v. antibiotics.
b First abnormal result from any imaging method post presentation and prior to initiation of i.v. antibiotics.
c First surgery post presentation and prior to initiation of i.v. antibiotics.
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measured (33.3%), and in 17 (31.5%) children both CRP and ESR were measured. Of the 48 children with
a CRP test result, (60.4%) the result was highest at diagnosis in 29 (see Table 19).
The prevalence of testing was similar in tertiary and secondary centres, although ESR was more likely to be
carried out in a secondary centre (see Table 19).
Blood results of complex cases at diagnosis are summarised in Table 20.
TABLE 19 Blood tests on the day of or day preceding initiation of i.v. antibiotics
Blood tests at diagnosis All, n (%)
Centre type where i.v. antibiotics initiated, n (%)
Tertiary Secondary
Simple cases (N = 203) (N = 130) (N = 73)
At least one blood test carried out the day of or day preceding initiation of i.v. antibiotics
Yes 148 (72.9) 82 (63.1) 66 (90.4)
No 55 (27.1) 48 (36.9) 7 (9.6)
Children who had at least one blood test had
Haemoglobin 128 (86.5) 72 (87.8) 56 (84.8)
WBC count 133 (89.9) 72 (87.8) 61 (92.4)
Neutrophils 129 (87.2) 72 (87.8) 57 (86.4)
Platelets 127 (85.8) 71 (86.6) 56 (84.8)
CRP 137 (92.6) 75 (91.5) 62 (93.9)
ESR 84 (56.8) 46 (56.1) 38 (57.6)
CRP and ESR 80 (54.1) 43 (52.4) 37 (56.1)
CRP and not ESR 57 (38.5) 32 (39) 25 (37.9)
CRPmax at diagnosis 89 (65)
a 52 (69.3)a 37 (59.7)a
Complex cases (N = 91) (N = 56) (N = 35)
At least one blood test carried out the day of or day preceding initiation of i.v. antibiotics
Yes 54 (59.3) 34 (60.7) 20 (57.1)
No 37 (40.7) 22 (39.3) 15 (42.9)
Children who had at least one blood test had
Haemoglobin 46 (85.2) 28 (82.4) 18 (90)
WBC count 50 (92.6) 31 (91.2) 19 (95)
Neutrophils 46 (85.2) 28 (82.4) 18 (90)
Platelets 42 (77.8) 28 (82.4) 14 (70)
CRP 48 (88.9) 29 (85.3) 19 (95)
ESR 18 (33.3) 9 (26.5) 9 (45)
CRP and ESR 17 (31.5) 7 (20.6) 10 (50)
CRP and not ESR 31 (57.4) 22 (64.7) 9 (45)
CRPmax at diagnosis 29 (60.4)
a 18 (62.1)a 11 (57.9)a
a Denominator is those who had CRP measured at diagnosis.
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Differences between septic arthritis and osteomyelitis
The proportion of children receiving blood tests was similar between SA and OM. Blood cell parameters
were similar between the groups but median CRP and ESR were higher in the SA group of complex cases
than in the OM group (107 mg/l and 60 mm/hour vs. 46 mg/l and 31.5 mm/hour, respectively). Within the
simples cases this difference could not be found (Table 21).
Diagnostic surgery
The types of surgery carried out post presentation and prior to start of i.v. antibiotics are given in Table 22.
In simple cases, the types of surgery carried out most frequently were incision and drainage, and aspiration
(60.7% and 55.7%, respectively), with arthroscopy third (9.8%). In complex cases, incision and drainage
was the most common type of surgery (62.1%), followed by aspiration (24.1%) and debridement (17.2%)
(see Table 22).
TABLE 20 Summary of blood test results at initiation of i.v. antibiotics
Blood test at diagnostic
Simple cases Complex cases
n Median (IQR) n Median (IQR)
Haemoglobin (g/dl) 128 114 (106.5–122) 46 115.5 (110–125)
WBC count (109/l) 133 12.18 (9.5–16.4) 50 12.83 (10–16.2)
Neutrophils (109/l) 129 6.6 (4.7–10.7) 46 7.365 (4.6–11.3)
Platelets (109/l) 127 361 (272–471) 42 331.5 (269–407)
CRP (mg/l) 137 38.3 (20–74) 48 86.7 (29–161)
ESR (mm/hour) 83a 46 (25–78) 17a 40 (21–60)
a One ESR result missing for simple cases and two missing for complex cases.
TABLE 21 Summary of blood test results at the day of or the day preceding initiation of i.v. antibiotics (by SA/OM)
Blood tests at presentation
SA OM
n Median (IQR) n Median (IQR)
Simple casesa
Haemoglobin (g/dl) 66 115 (107–123) 60 114 (106.5–121.5)
WBC count (109/l) 68 13.58 (9.95–17.6) 64 11.2 (8.6–15.2)
Neutrophils (109/l) 65 7.52 (4.9–11.1) 62 6.0 (4.5–9.5)
Platelets (109/l) 64 344 (257.5–449) 61 368 (274–485)
CRP (mg/l) 70 35.5 (21.2–72) 66 39.5 (14–81)
ESR (mm/hour) 41 46 (23–81) 42 47 (26–76)
Complex casesa
Haemoglobin (g/dl) 19 111 (103–122) 25 119 (113–130)
WBC count (109/l) 22 12.4 (8.9–17.2) 25 13.2 (10.7–16.2)
Neutrophils (109/l) 20 5.8 (3.6–10) 23 8.23 (5.5–12.1)
Platelets (109/l) 19 312 (197–354) 20 365 (298.5–459.5)
CRP (mg/l) 22 107.0 (31–168) 23 46 (13.9–110)
ESR (mm/hour) 5 60 (40–103) 10 31.5 (18–48)
a Two simple cases and four complex cases could not be classified as uniquely SA or OM, and are excluded here.
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Some types of surgery were not carried out prior to i.v. treatment: amputation, compartment
decompression, secondary closure, skin graft and other plastic surgery.
Differences between septic arthritis and osteomyelitis
Surgery was carried out more often in children with OM than in those with SA (in 63.6% vs. 37.5% in the
simple cases and in 25.9% vs. 15.5% in the complex cases). Incision and drainage was performed with the
same frequency in both groups, but debridement was performed more often in the OM group (Table 23).
Diagnostic imaging
Radiography was widely used as a diagnostic tool (64.5% of children who received i.v. antibiotics). The
proportion of radiographs that were abnormal was 38% for simple cases and 48% for complex cases.
The next most commonly used imaging method was ultrasonography (41% of simple cases and 31% of
complex cases). Of those imaged, 74.1% detected an abnormality.
Magnetic resonance imaging was used in 19% of simple cases, with an abnormality being detected in
89%, and in 23% of complex cases, with a detection rate of 95%. Table 24 gives the numbers of children
presenting with each bone/joint that had a diagnostic MRI. CT and bone scanning were rarely carried out,
and in only OM cases. In all four cases, CT revealed abnormalities (Table 25).
Differences between septic arthritis and osteomyelitis
X-ray and ultrasonography were equally used for OM and SA cases, and MRI was used more often in OM
cases than in SA cases (30% vs. 9%, respectively) (Table 26). If MRI was performed in OM, the ankle and
hip were most affected (16%), followed by the shoulder (11%) and humerus, pelvis and femur (9%). In
SA, the knee and the hip were most affected (46% and 23%, respectively) (see Table 24). X-rays found
similar percentages of abnormalities for simple cases, but found higher percentages in OM for complex
TABLE 22 Surgical procedures post presentation carried out prior to initiation of i.v. antibiotics
Surgery types Simple cases (N= 203), n (%)a Complex cases (N= 91), n (%)a
At least one of 61 (30) 29 (31.9)
Aspiration 34 (55.7) 7 (24.1)
Incision and drainage 37 (60.7) 18 (62.1)
Drill decompression 2 (3.3) 1 (3.4)
Curettage/excision 1 (1.6) –
Arthrotomy 2 (3.3) 3 (10.3)
Arthroscopy 6 (9.8) 1 (3.4)
Amputation – –
Debridement 6 (9.8) 5 (17.2)
Fasciotomy – 1 (3.4)
Compartment decompression – –
Secondary closure – –
Skin graft – –
Other plastic surgery – –
Other 1 (1.6) 4 (13.8)
a For each surgery type, frequencies are the number of children who had at least one diagnostic instance of that surgery;
the denominator is the number of children who had a known date for initiation of i.v. antibiotics.
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TABLE 23 Surgical procedures post presentation carried out prior to initiation of i.v. antibiotics (by SA/OM)
Surgery types
Simple cases, n (%)a Complex cases, n (%)a
SA (N= 104) OM (N= 97) SA (N= 33) OM (N= 54)
At least one of 39 (37.5) 21 (63.6) 15 (15.5) 14 (25.9)
Aspiration 24 (23.1) 10 (30.3) 5 (5.2) 2 (3.7)
Incision and drainage 26 (25) 11 (33.3) 13 (13.4) 5 (9.3)
Drill decompression – 2 (6.1) – 1 (1.9)
Curettage/excision 1 (1) – – –
Arthrotomy 2 (1.9) – 3 (3.1) –
Arthroscopy 6 (5.8) – 1 (1) –
Debridement 1 (1) 5 (5.2) 1 (3) 4 (7.4)
Fasciotomy – – 1 (1) –
Other – 1 (3) – 4 (7.4)
a For each surgery type, frequencies are the number of children who had at least one diagnostic instance of that surgery;
the denominator is the number of children who had SA/OM and had a known date for initiation of i.v. antibiotics.
TABLE 24 Bones/joints affected where a diagnostic MRI was carried out (by SA/OM)
Limb/joint affecteda
Simple cases, n (%)b Complex cases, n (%)b
SA (N= 9) OM (N= 29) SA (N= 4) OM (N= 16)
Hip 2 (22) 4 (14) 1 (25) 3 (19)
Shoulder 1 (11) 4 (14) – 1 (6)
Knee 4 (44) 1 (3) 2 (50) 2 (13)
Ankle – 3 (10) 2 (50) 4 (25)
Wrist 1 (11) 1 (3) – –
Skull – – – 1 (6)
Humerus – 3 (10) – 1 (6)
Clavicle – – – 1 (6)
Pelvis – 2 (7) – 2 (13)
Femur – 3 (10) – 1 (6)
Tibia – 1 (3) – 2 (13)
Fibula – – 1 (25) 3 (19)
Elbow 1 (11) 2 (7) – –
Calcaneus – 2 (7) – –
Lumbar vertebrae – 1 (3) – 2 (13)
Sacral vertebrae – 1 (3) – 1 (6)
Other – 1 (3) – –
a See Table 12 for total number of children presenting with each joint/limb listed.
b Percentage of children with each joint/limb affected out of those who had diagnostic MRI – by SA/OM.
SERVICE EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
30
cases. Ultrasonography detected a higher percentage of abnormalities in SA than OM in both simple and
complex cases (see Table 26).
Microbiology
Conventional tests: micro-organisms
A total of 244 children (simple and complex combined) are known to have had conventional microbiology
tests, in whom least one test on bone, joint aspirate, blood or periosteal pus was carried out. The results
for these 203 children are summarised in Table 27. Among the simple cases, 38.2% of children tested
positive for at least one micro-organism, compared with 52.5% of complex cases. Of the children with
OM, 58.7% underwent microbiology tests, with at least one micro-organism detected in 43.8%. Of the
children with SA, 73.8% were tested and a micro-organism was found in 34.2% of these.
TABLE 25 Imaging types routinely used to aid diagnosis
Imaging type
Simple cases (N= 203),a n (%)b Complex cases (N= 91),a n (%)b
Abnormal Abnormal
X-ray 133 (66) 51 (38) 56 (62) 27 (48)
CT 3 (1) 3 (100) 1 (1) 1 (100)
Ultrasonography 84 (41) 62 (74) 28 (31) 21 (75)
MRI 38 (19) 34 (89) 21 (23) 20 (95)
Bone scan 4 (2) 3 (75) 0 –
a Denominator represents those where initiation date of i.v. antibiotics is known.
b Number of children with at least one image post presentation, prior to start of i.v. treatment, by image type.
TABLE 26 Imaging types routinely used to aid diagnosis (by SA/OM)
Imaging type
SA, n (%)a OM, n (%)a
Abnormal Abnormal
Simple cases N= 104b N= 97b
X-ray 66 (63) 24 (36) 66 (68) 26 (39)
CT 0 – 3 (3) 3 (100)
Ultrasonography 53 (51) 43 (81) 31 (32) 19 (61)
MRI 9 (9) 8 (89) 29 (30) 26 (90)
Bone scan 1 (1) 1 (100) 3 (3) 2 (67)
Complex cases N= 33b N= 54b
X-ray 21 (64) 8 (38) 33 (61) 18 (55)
CT 0 – 1 (2) 1 (100)
Ultrasonography 11 (33) 9 (82) 16 (30) 11 (69)
MRI 4 (12) 3 (75) 16 (30) 16 (100)
Bone scan 0 – 0 –
a Number of children with at least one image post presentation, prior to start of i.v. treatment, by image type.
b Number of SA/OM where initiation date of i.v. antibiotics is known.
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Among those tested, 20.1% of simple cases were found to have S. aureus, compared with 32.2% of
complex cases. This was the most prevalent micro-organism detected; other microbes were rare (Table 28
shows further details on other microbes that were detected).
Polymerase chain reaction tests (substudy): organisms
Presented fully in Chapter 3, the summarised results of the microbiology substudy are given in Table 29.
Fifty children were tested out of 63 who consented to being part of the substudy. Of the 13 children who
TABLE 27 Summary of results of conventional microbiology tests
Tested
Simple cases, n (%) Complex cases, n (%)
Total Testeda Total Testeda
Children 218 144 (66.1) 95 59 (62.1)
SA 107 79 (73.8) 35 24 (68.6)
OM 109 64 (58.7) 56 32 (57.1)
Detected Tested Yes Tested Yes
At least one micro-organism detected? 144 55 (38.2) 59 31 (52.5)
SA 79 27 (34.2) 24 10 (41.7)
OM 64 28 (43.8) 32 19 (59.4)
Specification of micro-organisms Tested Tested
S. aureus 29 (20.1) 19 (32.2)
PVL 2 (6.9) 1 (5.3)
MRSA 1 (3.4) 1 (5.3)
Erythromycin resistant 0 1 (5.3)
Not tested/missing 26 (89.7) 16 (84.2)
K. kingae 3 (2.1) 1 (1.7)
Streptococcus pyogenes 5 (3.5) 5 (8.5)
Pseudomonas 1 (0.7) 0
GBS 2 (1.4) 2 (3.4)
Salmonella – –
Candida – –
Mycobacterium tuberculosis – –
Otherb 17 (11.8) 7 (11.9)
a Results of bone, joint aspirate, blood or periosteal pus samples only.
b See Table 28.
TABLE 28 Other micro-organisms detected from blood/joint/bone/periosteal pus (as input in database)
Simple cases (n= 17) Complex cases (n= 7)
Diphtheroids (n = 2) Unspecified (n = 7)
Gram-positive cocci
Staphylococcus epidermidis
Unspecified (n= 13)
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were not tested, five attended a centre that failed to carry out tests, six did not have a complete set of
samples taken, one gave partial consent (but not for PCR) and one had no data in the database. Of the
50 children in whom tests were performed, six had no final diagnosis of OM or SA and were excluded
from further analyses. Results are therefore shown for 44 tested cases of OM or SA.
In 75% of the simple cases tested, at least one micro-organism was detected: this is a higher detection
rate than conventional testing. Micro-organisms were detected in 67% of the complex cases tested: this
was a similar detection rate to conventional tests. PCR detection rates were similar between SA and OM
in complex cases, but in simple cases the detection rate for SA was higher than for OM (89% vs. 57%,
respectively).
As in the conventional testing, the most prevalent micro-organism was S. aureus (34.4% in simple cases
and 41.7% in complex cases). However, the prevalence rate of K. kingae in simple cases was higher when
using PCR (21.9%) than when using conventional testing (2.1%).
Conventional tests: types of sample
Simple cases Blood samples were most commonly used for conventional microbiology tests (blood
cultures, 62% of children tested). Joint aspirates were the next most common type of samples (43.6%).
TABLE 29 Summary of results of PCR tests
Cases/micro-organisms
Simple cases (N= 218), n (%) Complex cases (N= 92), n (%)
Total Tested Total Tested
Consented to the microbiology substudy 48 (22.3) 15 (16.3)
Tested
Children 48 32 (67) 15 12a (53)
SA 18 6
OM 14 5
Centre failed to test 4 (8.3) 1 (6.7)
Other reason not tested 4 (8.3) 2 (13.3)
Detected cases Tested Yes Tested Yes
At least one micro-organism detected 32 24 (75) 12a 8 (67)
SA 18 16 (89) 6 4 (67)
OM 14 8 (57) 5 3 (60)
Specification of micro-organisms Tested Tested
S. aureus 11 (34.4) 5 (41.7)
K. kingae 7 (21.9) 0
GAS 2 (6.3) 2 (16.7)
Streptococcus pneumoniae lytA 1 (3.1) 0
Streptococcus pneumoniae ply 0 (0) 1 (8.3)
Staphylococcus epidermidis 3 (9.4) 0
IytA, N-acetylmuramoyl-L-alanine amidase; ply, pneumolysin.
a One case undecided OM or SA.
Note
Data from microbiology substudy (see Chapter 3).
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Bone biopsies were rare. There were some differences in the proportions of children in whom each type of
sample was taken. However, although tertiary centres took more of all sample types except blood, the
relative proportions of different sample types were the same in both types of centres.
We have microbiology test results for 46 centres treating simple cases: 16 tertiary and 30 secondary. Blood
samples were similarly very likely in both types of centre. Of the tertiary centres, 14 took blood samples
(87.5%) and 14 took joint aspirate samples; 56.3% of the tertiary centres took pus/wound swabs.
Secondary centres were just as likely to take blood samples (83.3%) but not as likely to use joint aspirate
(46.7%) or pus/wound swabs (30%) (Table 30).
Complex cases Conventional microbiology tests were most commonly carried out on blood samples
(54.3% of children tested), followed by pus/wound swabs (25.7%). The frequency of use of different
sample types varied between tertiary and secondary centres. As for simple cases, tertiary centres took more
of all sample types except blood, but, in contrast to simple cases, the relative proportions of different
samples types were different in secondary and tertiary centres.
We have microbiology test results for 32 centres treating complex cases: 16 tertiary and 16 secondary.
Blood samples were equally likely in both types of centre. Of the tertiary centres, 10 (62.5%) took at least
one blood sample and other sample types were used with similar frequency. Secondary centres were less
likely to use non-blood samples (see Table 30).
TABLE 30 Conventional testing sample types
Sample types
Children with at least one sample
of each type, n (%)
Centres with at least one example
of each type of sample, n (%)
All Tertiary Secondary All Tertiary Secondary
Simple cases n= 163 n = 98 n= 67 n= 46 n= 16 n= 30
Blood 101 (62) 58 (59.2) 43 (64.2) 39 (84.8) 14 (87.5) 25 (83.3)
Bone biopsy 6 (3.7) 4 (4.1) 2 (3) 5 (10.9) 3 (18.8) 2 (6.7)
Joint aspirate 71 (43.6) 49 (50) 23 (34.3) 28 (60.9) 14 (87.5) 14 (46.7)
Pus (periosteal) 25 (15.3) 17 (17.3) 8 (11.9) 8 (17.4) 6 (37.5) 2 (6.7)
Pus/wound swab 15 (9.2) 12 (12.2) 3 (4.5) 18 (39.1) 9 (56.3) 9 (30)
Other 35 (21.5) 26 (26.5) 9 (13.4) 14 (30.4) 7 (43.8) 7 (23.3)
Missing/unknown 6 (3.7) 1 (1) 5 (7.5) 5 (10.9) 1 (6.3) 4 (13.3)
Complex cases n= 70 n = 48 n= 23 n= 32 n= 16 n= 16
Blood 38 (54.3) 27 (56.3) 13 (56.5) 20 (62.5) 10 (62.5) 10 (62.5)
Bone biopsy 5 (7.1) 5 (10.4) 0 5 (15.6) 5 (31.3) 0
Joint aspirate 17 (24.3) 12 (25) 5 (21.7) 12 (37.5) 8 (50) 4 (25)
Pus (periosteal) 14 (20) 13 (27.1) 1 (4.3) 9 (28.1) 8 (50) 1 (6.3)
Pus/wound swab 18 (25.7) 14 (29.2) 4 (17.4) 10 (31.3) 7 (43.8) 3 (18.8)
Other 16 (22.9) 12 (25) 4 (17.4) 12 (37.5) 8 (50) 4 (25)
Missing/unknown/not applicable 4 (5.7) 3 (6.3) 1 (4.3) 4 (12.5) 3 (18.8) 1 (6.3)
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Treatment
Antibiotic treatment
Clinical timeline
Almost all children received antibiotics both intravenously and orally. Table 31 gives timelines for antibiotic
use when data for start and end dates are available.
A total of 202 (93%) simple cases received i.v. antibiotics, compared with 91 (96%) complex cases.
However, for one simple case discharge antibiotic data were missing, so no end date was known, and for
two complex cases dates for antibiotics were missing. The median time on i.v. antibiotics for simple cases
was 8 days (IQR 5–15 days). For complex cases, time on i.v. antibiotics was, on average, longer: a median
of 17 days (IQR 8–3 days) (see Table 31 for more information on children who were not treated with
i.v. antibiotics).
Not all children who were treated with i.v. antibiotics were switched to oral antibiotics. In some cases, oral
antibiotics were given concurrently with i.v. treatment. A total of 81% of simple cases received some form
of oral antibiotic for a median of 28 days, compared with 66.3% of complex cases, also for a median of
28 days.
The total time from first antibiotic to last antibiotic was a median of 34 days in simple cases and 39 days in
complex cases. Note that a small number of children had breaks in treatment; this measure included these
breaks in the total.
Differences between septic arthritis and osteomyelitis
Duration of i.v. antibiotics is similar for SA and OM, both in complex as well as in simple cases. The median
total antibiotic treatment time is 40 days for OM, compared with 30 days for SA, in simple cases. This
difference is also present in complex cases (42 days vs. 28.5 days, respectively) (Table 32).
TABLE 31 Clinical timeline for antibiotic treatment
Antibiotic treatment timeline n (%) Median (IQR), days Min., max. (days)
Simple cases (n = 218)
Length of time on
i.v. antibioticsa 202b (92.7) 8 (5–15) 0, 220c
Oral antibioticsa 176 (80.7) 28 (16–36.5) 0, 197c
Totald 210 (96.3) 34 (20–45) 0, 220c
Complex cases (n = 95)
Length of time on
i.v. antibioticsa 91e (95.8) 17 (8–38) 0, 112c
Oral antibioticsa 63 (66.3) 28 (16–42) 1, 226
Totald 92 (96.8) 39 (23–53) 1, 236
Max., maximum; min., minimum.
a Number of days taking antibiotics.
b One additional simple case had i.v. antibiotics but only the start date is known, so time on i.v. antibiotics cannot
be calculated.
c Where a child’s treatment was started and stopped on the same day, the length of time is calculated as 0 days.
d Number of days from first to last antibiotic irrespective of route (includes breaks in treatment).
e Two additional complex cases had i.v. antibiotics but start and end dates are missing.
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Antibiotic regimes: overall
At initiation of i.v. treatment, over half of children (both types of case combined) were given one
antibiotic (57.7%).
The timing of the switch from i.v. to oral antibiotics was different in simple cases and complex cases. In
simple cases, switch occurred a median of 7 days after the start of i.v. therapy, whereas in complex cases
this was a median of 13.5 days. Table 33 shows the percentages of children in whom switch dates were
known who switched < 1 week, 2 weeks and > 2 weeks after commencement of i.v. treatment. Figure 1
shows a profile of time-to-switch data in the form of a Kaplan–Meier plot. This clearly shows that in
complex cases the switch to oral antibiotics took place later, and that the time taken for i.v. therapy to be
stopped or switched to oral therapy in half of children was 9 days in simple cases, compared with 21 days
in complex cases (time point at which the curve reaches 0.5 on the y-axis).
In the majority of cases with no known switch date, there was no record of any oral antibiotics having
been prescribed following treatment with i.v. antibiotics.
The proportion of children who received antibiotic treatment for < 6 weeks in total was 63.8% for
complex cases, compared with 51.6% for complex cases. Figure 2 shows that, among simple cases, there
was little difference in time to switch to oral antibiotics between those with OM and those with SA.
Among complex cases, switch timing was similar in the OM and SA subgroups when switch took place
before 2 weeks, but among those who received i.v. antibiotics for at least 2 weeks, children with OM
received i.v. antibiotics for longer, and were switched to oral antibiotics later, than children with SA.
For each antibiotic prescribed, a daily dose per kilogram body weight was calculated. Each dose was
classified as ‘higher formulary’ (recommended intensive dosing as recommended by the current bone and
joint infection guidelines on the treatment of severe infections) or ‘not higher formulary’ [following
standard British National Formulary for Children (BNFC) dosing guidelines for antibiotics62]. The proportion
of children who received a higher formulary initial dose of antibiotics was 40.4% in simple cases,
compared with 29.5% in complex cases. Most children received both higher formulary doses and not
higher formulary doses during their treatment (57% for simple cases and 62% for complex cases). A total
of 13.8% of simple cases received only higher formulary doses throughout their treatment, compared with
9.5% of complex cases (see Table 33).
TABLE 32 Clinical timeline for antibiotic treatment (by SA/OM)
Antibiotic treatment timeline
SA OM
n (%) Median (IQR), days n (%) Median (IQR), days
Simple cases N = 107 N = 109
Length of time on
i.v. antibioticsa 103 (96.3) 7 (4–13) 97 (89) 9 (6–16)
Oral antibioticsa 85 (79.4) 28 (14–34) 90 (82.6) 30.5 (21–42)
Totalb 103 (96.3) 30 (18–41) 105 (96.3) 40 (21–48)
Complex cases N = 35 N = 56
Length of time on
i.v. antibioticsa 33 (94.3) 14 (7–24) 54 (96.4) 18.5 (8–42)
Oral antibioticsa 24 (68.6) 25.5 (14–35) 35 (62.5) 28 (23–42)
Totalb 34 (97.1) 28.5 (15–46) 54 (96.4) 42 (26–57)
a Number of days taking antibiotics.
b Number of days from first to last antibiotic irrespective of route (includes breaks in treatment).
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TABLE 33 Types of antibiotic regimes experienced
Antibiotic regime
Simple cases (n= 218) Complex cases (n= 95)
n (%) Median (IQR), days n (%) Median (IQR), days
Number of different antibiotics given at initiation of i.v. treatment
1 131 (60.1) 53 (55.8)
≥ 2 72 (33) 38 (40)
No i.v. antibiotics given 12 (5.5) 3 (3.2)
Unknown 3 (1.4) 1 (1.1)
Timing of oral switch
Switch date known (weeks) 168 (77.1) 7 (5–13) 62 (65.3) 13 (7–24)
< 1 73 (43.5) 4 (3–5) 12 (19.4) 3.5 (2.5–5.5)
1–2 62 (36.9) 10 (8–13) 21 (33.9) 9 (8–10.5)
> 2 33 (19.6) 21 (16–30) 29 (46.8) 26 (20–41)
No switch date 50 (22.9) 33 (34.7)
Child stayed on i.v. antibiotics 35 (70) 15 (7–30) 29 (87.9) 25 (11–44)
No i.v. antibiotics 15 (30) 4 (12.1)
Total course of antibiotics (weeks)
< 6 139 (63.8) 49 (51.6)
≥ 6 71 (32.6) 43 (45.3)
Had no antibiotics/unknown 8 (3.7) 3 (3.2)
Dose
First dose HFa 88 (40.4) 28 (29.5)
HFa throughout 30 (13.8) 9 (9.5)
No HFa doses given 53 (24.3) 23 (24.2)
Combination 124 (56.9) 59 (62.1)
Unknown 11 (5) 4 (4.2)
Total number of antibiotics prescribed
i.v.
0 15 (6.9) 4 (4.2)
1 88 (40.4) 26 (27.4)
2 81 (37.2) 31 (32.6)
> 2 34 (15.6) 34 (35.8)
Oral
0 41 (18.8) 28 (29.5)
1 129 (59.2) 41 (43.2)
2 43 (19.7) 20 (21.1)
> 2 5 (2.3) 6 (6.3)
HF, higher formulary.
a Higher formulary dose treatments recommended for bone/joint infections.
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The total number of antibiotics prescribed for each route was calculated for each child. So, for example,
in the case of a child for whom there were two records of oral flucloxacillin and one record of co-amoxiclav,
the total number of oral antibiotics recorded would be two. Note that this calculation is limited to instances
of the antibiotics flucloxacillin, clindamycin, cefuroxime, ceftriaxone, amoxicillin, co-amoxiclav, rifampicin,
vancomycin, fusidic acid, benzylpenicillin, teicoplanin, and ‘other’. All ‘other’ antibiotics were combined as
one type for the sake of parsimony. In simple cases, a single i.v. antibiotic and/or a single oral antibiotic was
the most common treatment strategy employed, whereas for complex cases there were cases of one, two or
more than two i.v. antibiotics being used together with a single oral antibiotic type (see Table 33).
Antibiotic regimes in hospital
Tables 33 and 34 summarise the antibiotics that were prescribed during hospital stay.
Simple cases Of the 199 children who received i.v. antibiotics during their hospital stay, flucloxacillin
(47.2%), ceftriaxone (36.7%) and cefuroxime (33.2%) were the antibiotics most frequently prescribed.
These three antibiotics were also the most commonly prescribed as part of the initial treatment (Table 35).
In 78 (35.8%) simple cases at least one oral antibiotic was prescribed. In these cases, flucloxacillin was the
most commonly prescribed antibiotic (43.6%). Oral antibiotics were rarely used in conjunction with the
initial i.v. treatment (see Table 33).
Pr
o
b
ab
ili
ty
 o
f 
n
o
t 
sw
it
ch
in
g
0
0.0
0.2
0.4
0.6
0.8
1.0
50 100 150
Time to oral switch (days)
200
Case
         Complex
         Simple
FIGURE 1 Kaplan–Meier plot showing time to switch.
Pr
o
b
ab
ili
ty
 o
f 
n
o
t 
sw
it
ch
in
g
0
0.0
0.2
0.4
0.6
0.8
1.0
50 100 150
Time to oral switch (days)
200
Case
      Complex (OM)
      Complex (SA)
      Simple (OM)
      Simple (SA)
FIGURE 2 Kaplan–Meier plot showing time to switch (by SA/OM).
SERVICE EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
38
Average doses in mg/kg weight of child, statistics on frequency of dosing and proportion of doses
prescribed for more than a week are given in Table 35.
Complex cases Among the 91 children who received i.v. antibiotics during their hospital stay, the most
frequently prescribed antibiotics were flucloxacillin (52.7%), ceftriaxone (40.7%), clindamycin (27.5%) and
cefuroxime (24.2%). Flucloxacillin was most likely to be prescribed as part of the initial treatment (see Table 36).
Thirty-six (37.9%) complex cases were prescribed at least one oral antibiotic, most frequently clindamycin
(33.3%). Oral antibiotics were not frequently used in conjunction with the initial i.v. treatment (see Table 36).
Average doses in mg/kg weight of child, statistics on frequency of dosing and proportion of doses
prescribed for > 1 week are given in Table 36.
TABLE 34 Types of antibiotic regimes experienced (by SA/OM)
Antibiotic regime
SA OM
n (%) Median (IQR), days n (%) Median (IQR), days
Simple cases N = 107 N = 109
Timing of oral switch
Switch date known (weeks) 85 (79.4) 6 (4–11) 82 (75.2) 8.5 (5–14)
< 1 47 (55.3) 4 (3–5) 26 (31.7) 5 (3–5)
1–2 26 (30.6) 10 (8–12) 35 (42.7) 9.5 (8–13)
> 2 12 (14.1) 26 (18–34) 21 (25.6) 18.5 (15.5–25.5)
No switch date 22 (20.6) 27 (24.8)
Child stayed on i.v. antibiotics 18 (81.8) 14.5 (7–30) 15 (55.6) 17 (7–27)
No i.v. antibiotics 4 (18.2) 12 (44.4)
Total course of antibiotics (weeks)
< 6 79 (73.8) 58 (53.2)
≥ 6 24 (22.4) 47 (43.1)
Had no antibiotics/unknown 4 (3.7) 4 (3.7)
Complex cases (N = 35) (N = 56)
Timing of oral switch
Switch date known (weeks) 23 (65.7) 13.5 (7–21) 35 (62.5) 10.5 (7.5–26)
< 1 5 (21.7) 2 (2–5) 7 (20) 4 (3–6)
1–2 7 (30.4) 9 (7–13) 12 (34.3) 8.5 (8–10.5)
> 2 11 (47.8) 21.5 (18–47) 16 (45.7) 29 (23–41)
No switch date 12 (34.3) 21 (37.5)
Child stayed on i.v. antibiotics 10 (83.3) 38 (11–52) 19 (90.5) 14.5 (8–25)
No i.v. antibiotics 2 (16.7) 2 (9.5)
Total course of antibiotics (weeks)
< 6 22 (62.9) 26 (46.4)
≥ 6 12 (34.3) 28 (50)
Had no antibiotics/unknown 1 (2.9) 2 (3.6)
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Children who did not have intravenous antibiotics
Fifteen simple cases did not receive any i.v. antibiotics: 13 were given oral antibiotics and two had no
record of receiving any antibiotic treatment either in hospital or at discharge.
Four complex cases had no i.v. antibiotics. In two of these, antibiotic data are missing and in two cases
there was no record of any antibiotic treatment either in hospital or at discharge.
Table 37 gives information about the characteristics of these 19 children.
Use of blood tests to determine switch
This section investigates which blood tests were carried out at switch from i.v. to oral antibiotics. Table 38
provides statistics for blood tests on the day of switch or the day before, for children in whom a switch
TABLE 37 Characteristics of children who were given no i.v. antibiotics
Presentation Simple cases (n= 15) Complex cases (n= 4)
Age (years)
< 1 0 2
1–6 9 0
6–16 6 2
Presenting to
GP 6 3
Emergency department 9 1
Limbs/joints affected
Hip 3 1
Shoulder – 1
Knee 3 –
Ankle 2 1
Humerus – 1
Femur – 1
Foot 1 –
Tibia 1 –
Fibula 1 –
Elbow 1 –
Calcaneus 2 –
Not specified 1 –
Diagnosis
OM 11 2
SA 4 2
Given oral antibiotics
Yes 13 0
No 2 2
Missing antibiotics data 0 2
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date could be ascertained. When blood tests were available for both days, the tests on the day of switch
were used.
Among the children with a known switch date, 37.9% of simple cases had a blood test at switch and
22.8% of complex cases had a blood test at switch. Most of these had the full range of measurements,
with the exception of ESR. When blood tests were taken, CRP was measured in 91.8% of simple cases
and 84.6% of complex cases.
Median and IQRs for blood tests are given in Table 38. Forty-two simple cases and nine complex cases had
blood tests both at presentation and at switch. For each of these children, switch results were expressed as
a percentage of diagnosis results. These percentages are summarised in Table 38. Median percentages close
TABLE 38 Blood tests carried out immediately prior to oral switch
Blood testsa
at switchb
Cases with test results at switch,b
n (%)
Median (IQR)
test results
Median (IQR)
percentage of
diagnosis results
Median (IQR)
percentage
of CRPmaxAll Tertiary Secondary
Simple cases n = 161c n = 42d n = 56e
At least one test 61 (37.9) 44 17 –
Haemoglobin 48 (78.7) 32 (72.7) 16 (94.1) 111 (106–120) 99.55
(92.75–105.1)
–
WBC count 47 (77) 32 (72.7) 15 (88.2) 8.9 (7.47–11.3) 70.6 (61.7–85) –
Neutrophils 48 (78.7) 32 (72.7) 16 (94.1) 3.345 (2.5–4.635) 48.95 (29.7–74.5) –
Platelets 46 (75.4) 31 (70.5) 15 (88.2) 470.5 (397–576) 126.5
(106.05–152.05)
–
CRP 56 (91.8) 40 (90.9) 16 (94.1) 9.15 (4.55–21.5) 32.6 (12.5–74.1) 25 (10.2–63.4)
ESR 19 (31.1) 10 (22.7) 9 (52.9) 23 (13–43) 107.2 (46.2–200) –
CRP and ESR 17 (27.9) 9 (20.5) 8 (47.1) – – –
CRP and not ESR 39 (63.9) 31 (70.5) 8 (47.1) – – –
Complex cases n = 57c n = 9d n = 11e
At least one test 13 (22.8) 10 3 – – –
Haemoglobin 9 (69.2) 7 (70) 2 (66.7) 108 (96–111) 100 (88.1–100) –
WBC count 9 (69.2) 7 (70) 2 (66.7) 8.7 (7.9–10.1) 92.9 (46.9–100) –
Neutrophils 8 (61.5) 6 (60) 2 (66.7) 2.25 (1.715–3.2) 51.3 (23.3–80) –
Platelets 11 (84.6) 9 (90) 2 (66.7) 383 (311–569) 108.05
(102.4–177.7)
–
CRP 11 (84.6) 8 (80) 3 (100) 13 (4–26) 28.8 (14.5–100) 25 (9.1–100)
ESR 4 (30.8) 3 (30) 1 (33.3) 35 (15.5–63) 94.6 (57.5–131.7) –
CRP and ESR 3 (23.1) 2 (20) 1 (33.3) – – –
CRP and not ESR 8 (61.5) 6 (60) 2 (66.7) – – –
a See Table 39 for units of measurements.
b On same day or day before switch.
c Total number of children who were switched.
d Total number of children who had at least one blood test both at diagnosis and immediately prior to switch.
e Total number of children who had at least one measurement of CRP at switch.
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to 100 indicate no change on average from diagnosis. For most children’s measurements, haemoglobin
stayed the same, WBC count, neutrophils and CRP dropped to greater or lesser degrees, ESR varied (halving
for some and doubling for others) and platelets rose. The measurement that showed the greatest decline in
median value between diagnosis and switching was CRP. CRP as a proportion of its maximal value prior to
switch was a median of 25% in both simple and complex cases, although the IQRs show that children
varied considerably in this. Table 39 shows a summary of blood test results at switch, split by SA/OM.
Post-diagnosis surgery
A total of 21.6% of simple cases went on to have surgery after the start of i.v. antibiotics, compared with
41.1% of complex cases. In both groups OM and SA cases were equally represented.
The most common procedure among the simple cases was aspiration (7.3%), for complex cases it was
incision and drainage (16.8%), and this was often a wash-out in conjunction with another procedure.
A total of 11.6% of complex cases had at least one debridement (Table 40).
When only one post-diagnosis procedure was carried out, this was most likely to be incision and drainage
as a single procedure (carried out in 52.6% of simple cases and 43.8% of complex cases) (Table 41).
Post-diagnosis imaging
Imaging was carried out post diagnosis, both during hospital stay and after discharge. MRI was the most
used imaging technique in hospital, followed by X-rays and ultrasonography. This was the case in both
simple and complex cases.
Of those undergoing MRI, a high proportion had abnormalities detected both prior to and post discharge
(Table 42).
TABLE 39 Summary of blood tests at switch (by SA/OM)
Blood tests at switch
SA OM
n Median (IQR) n Median (IQR)
Simple cases
Haemoglobin (g/dl) 29 111 (107–123) 19 109 (101–117)
WBC count (109/l) 28 8.85 (7.035–11.065) 19 9.1 (7.98–12.2)
Neutrophils (109/l) 29 3.12 (2.5–3.91) 19 3.5 (2.5–5.1)
Platelets (109/l) 28 495 (390.5–583.5) 18 466 (426–563)
CRP (mg/l) 33 12.4 (6–22) 23 7 (4–16)
ESR (mm/hour) 12 30.5 (18.5–48) 7 13 (12–37)
Complex cases
Haemoglobin (g/dl) 3 100 (89–111) 5 111 (108–111)
WBC count (109/l) 3 4.9 (4.24–7.9) 5 10.1 (9–10.36)
Neutrophils (109/l) 3 1.7 (1.44–3.4) 4 2.75 (2.25–4.645)
Platelets (109/l) 3 312 (202–375) 6 492.5 (311–569)
CRP (mg/l) 4 24.3 (7.8–76) 6 15.35 (4–25)
ESR (mm/hour) 0 – 2 15.5 (8–23)
Note
Two simple cases and four complex cases could not be classified as uniquely SA or OM and are excluded here.
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TABLE 40 Surgery occurring after the initiation of i.v. antibiotics (post diagnosis)
Surgery post initiation of i.v. antibiotics Simple cases (N= 218), n (%) Complex cases (N= 95), n (%)
At least one procedure 47 (21.6) 39 (41.1)
SA 24 17
OM 23 20
Number of procedures
1 19 (8.7) 16 (16.8)
2 21 (9.6) 11 (11.6)
> 2 7 (3.2) 12 (12.6)
Type of procedure: children with at least one
Aspiration 16 (7.3) 8 (8.4)
Incision and drainage 14 (6.4) 16 (16.8)
Drill decompression 2 (0.9) 0
Curettage/excision 2 (0.9) 2 (2.1)
Arthrotomy 3 (1.4) 1 (1.1)
Arthroscopy 3 (1.4) 5 (5.3)
Amputation 0 1 (1.1)
Debridement 5 (2.3) 11 (11.6)
Fasciotomy 0 0
Compartment decompression
Secondary closure 2 (0.9) 1 (1.1)
Skin graft 0 1 (1.1)
Other plastic surgery 7 (3.2) 2 (2.1)
Other 2 (0.9) 0
TABLE 41 Single procedures
Surgery post initiation of i.v. antibiotics Simple cases (N= 19), n (%) Complex cases (N= 16), n (%)
Type of procedure where child had just one post-i.v. surgery
Aspiration 4 (21.1) 3 (18.8)
Incision and drainage 10 (52.6) 7 (43.8)
Drill decompression 1 (5.3) –
Curettage/excision 1 (5.3) 1 (6.3)
Arthrotomy – 1 (6.3)
Arthroscopy – 1 (6.3)
Amputation – –
Debridement 2 (10.5) 2 (12.5)
Secondary closure – 1 (6.3)
Other 1 (5.3) –
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Length of hospital stay
Simple cases The median length of stay in hospital was 7 days, with 50% of children staying for ≥ 6 days
but no longer than 12 days. Children who presented at a tertiary centre stayed in hospital, on average,
3 days less than those presenting to a secondary centre. Older children (aged > 6 years) had longer stays
in hospital than younger children, with a median stay of 10 days (Table 43).
Complex cases The median length of stay in hospital was 9 days, with 50% of children staying for
≥ 6 days but no longer than 18 days. Children who presented at a tertiary centre stayed in hospital, on
average, 1 day longer than those presenting to a secondary centre. The children who had the longest stays
were aged < 1 year, staying in hospital, on average, for > 2 weeks.
TABLE 42 Imaging types routinely used post diagnosis
Imaging type
Cases imaged at least once post
diagnosis, n (%)
Of those imaged, those with at least
one abnormal result, n (%)
Prior to discharge Post discharge Prior to discharge Post discharge
Simple cases (N = 215)
X-ray 28 (12.8) 45 (20.6) 14 (50) 18 (40)
CT 3 (1.4) 0 2 (66.7) –
Ultrasonography 16 (7.3) 6 (2.8) 11 (68.8) 5 (83.3)
MRI 49 (22.5) 14 (6.4) 42 (85.7) 13 (92.9)
Bone scan 5 (2.3) 1 (0.5) 3 (60) 1 (100)
Complex cases (N= 92)
X-ray 24 (25.3) 28 (29.5) 15 (62.5) 14 (50)
CT 3 (3.2) 1 (1.1) 3 (100) 0
Ultrasonography 21 (22.1) 2 (2.1) 18 (85.7) 1 (50)
MRI 36 (37.9) 10 (10.5) 35 (97.2) 9 (90)
Bone scan 2 (2.1) 0 2 (100) –
TABLE 43 Length of stay in hospital by age group and presenting centre type
Presenting Centre Type n
Age group, median (IQR) (days)
All < 1 year 1–6 years 6–16 years
Simple cases N= 27 N = 116a N= 74
All 217a 7 (4–12) 7 (5–12) 6 (3.5–10.5) 10 (6–15)
Tertiary 115 7 (4–11) 7 (5–10) 6 (3–9) 8.5 (5–13)
Secondary 102 9 (4–14) 9.5 (5–19.5) 7 (4–12.5) 10.5 (7–17)
Complex cases N= 13 N = 44 N= 38
All 95 9 (6–18) 16 (9–27) 8 (5–14) 10 (6–16)
Tertiary 54 9 (7–19) 16 (9–29) 8 (6–19) 12 (7–16)
Secondary 41 8 (6–14) 18 (8–27) 6 (3–12) 8.5 (6–15.5)
a One child in whom discharge date was missing is excluded from this table.
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Differences between osteomyelitis and septic arthritis Patients with simple SA tend to have a shorter
hospital stay than the simple OM group (median 6 days vs. 9 days, respectively). In the complex group this
difference is less clear (median 8 days vs. 9 days, respectively) (Table 44).
Discharge antibiotics
A large proportion of children were known to have gone home on i.v. antibiotics (27.1% of simple cases
and 42.1% of complex cases). The proportion of children on i.v. treatment at discharge was not different
in the SA and OM subgroups (Table 45). Among these children, the most frequently prescribed i.v.
antibiotic was ceftriaxone (69.5% for simple cases and 77.5% for complex cases) (Table 46 gives further
details, including a summary of the dose in mg per kg body weight and a median prescribed duration for
each antibiotic).
Oral antibiotics were quite varied. The key antibiotics for both case types were co-amoxiclav, flucloxacillin,
clindamycin and cefalexin (see Table 46).
TABLE 44 Length of stay by SA/OM
Length of stay (days) All
Diagnosisa
SA OM
Simple cases n= 217b n= 106 n= 109
Median (IQR) 7 (4–12) 6 (4–11) 9 (5–13)
Complex cases n= 95 n= 35 n= 56
Median (IQR) 9 (6–18) 8 (6–15) 9 (6–18.5)
a Two simple cases and four complex cases could not be categorised as uniquely SA/OM.
b One child has missing discharge date and is excluded from this table.
TABLE 45 Antibiotics at discharge by SA/OM
Antibiotics at discharge All, n (%)
Diagnosis, n (%)
SA OM
Simple cases N = 218 N = 107 N = 109
Went home on
i.v. antibioticsa 59 (27.1) 30 (28) 28 (25.7)
Oral alone 130 (59.6) 64 (59.8) 65 (59.6)
None/unknown 29 (13.3) 13 (12.1) 16 (14.7)
Complex cases N = 95 N = 35 N = 56
Went home on
i.v. antibioticsa 40 (42.1) 16 (45.7) 23 (41.1)
Oral alone 42 (44.2) 15 (42.9) 24 (42.9)
None/unknown 13 (13.7) 4 (11.4) 9 (16.1)
a Children recorded as having a PICC line or peripheral cannula in situ at discharge and/or had i.v. antibiotics prescribed
at discharge.
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Follow-up
Adherence to discharge antibiotics
Almost three-quarters of children were followed up (71.6% of simple cases and 80.4% of complex cases,
no difference between SA and OM). Of these, almost all reported that antibiotics were completed as
planned (92.4% of simple cases and 92.1% of complex cases) (Tables 47 and 48 give further details of the
reasons for non-adherence in the nine children who did not complete the course of prescribed antibiotics).
TABLE 46 Antibiotic regimes prescribed at discharge
Antibiotica n (%)
Median (IQR) daily dose
per kg weight of child
Median (IQR) days
planned duration
Simple cases (N = 218)
i.v. antibiotics (N= 59)
Ceftriaxone 41 (69.5) 50.7 (49.3–79.4) 7 (3–14)
Flucloxacillin 4 (6.8) 98.05 (43.5–155.7) 28 (14–42)
Clindamycin 2 (3.4) 21.6 (5.3–37.9) 21 (14–28)
Cefuroxime 1 (1.7) 46.7 (46.7–46.7) 14 (14–14)
Other 9 (15.3) 9.7 (9.7–46.7) 17 (8–42)
Unknown 6 (10) – –
Oral antibiotics (N = 156)b
Co-amoxiclav 58 (36.5) 30.4 (13.8–41.8) 28 (21–31)
Flucloxacillin 46 (28.9) 37.45 (14.15–82.3) 28 (14–38.5)
Clindamycin 17 (10.7) 18.1 (6.1–23.6) 34 (25–42)
Cefalexin 20 (12.6) 35 (24.5–91.1) 26.5 (16.5–35)
Other 62 (39) 20.55 (9.3–40.5) 28 (14–42)
Complex cases (N = 95)
i.v. antibiotics (N= 40)
Ceftriaxone 31 (77.5) 65.35 (49–80.3) 14 (10–33)
Flucloxacillin 2 (5) 35.8 (0.2–71.4) 31.5 (14–49)
Clindamycin 3 (7.5) 4 (0.2–8) 28 (13–42)
Cefuroxime 0 – –
Other 5 (12.5) 12 (10.2–55.3) 42 (42–42)
Unknown 4 (10) – –
Oral antibiotics (N = 58)b
Co-amoxiclav 17 (28.8) 23.1 (12.1–47.6) 28 (14–39)
Flucloxacillin 15 (25.4) 41.7 (36.4–54.1) 28 (21–42)
Clindamycin 17 (28.8) 15.1 (6–23.8) 28 (14–38.5)
Cefalexin 2 (3.4) 62 (28.8–95.2) 14 (7–21)
Other 23 (39) 18.7 (6.9–28.7) 24.5 (14–42)
a More than one antibiotic prescription possible per case – numerators may not sum up to denominators.
b All children that had at least one dose of an oral antibiotic prescribed at discharge.
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Complications
A total of 8.3% of simple cases and 16.8% of complex cases experienced at least one complication. Table 49
lists the numbers of types of complication by action taken. The types listed were options given for data
entry; as Table 49 shows, many were not experienced (dislocation, subluxation, pathological complication,
fracture and sinus). The most selected category was ‘other’: text entered to give more detail about these
complications is given in Tables 50 and 51.
TABLE 47 Discharge antibiotic regimes adhered to
Adherence to prescribed antibiotic regimes Simple cases (N= 218), n (%) Complex cases (N= 95), n (%)
Number of children contacted for follow-up 157 (72) 76 (80)
SA 78 (72.9) 27 (77.1)
OM 79 (72.5) 45 (80.4)
Antibiotics completed as planned
Yes 145 (92.4) 70 (92.1)
No 8a (5.1) 3a (3.9)
Stopped early 2 1
Changed 5 3
Unknown 2 0
Stopped early by
Parent 1 0
Hospital 0 1
GP 1 0
Changed by
Hospital 5 3
GP 0 0
Reason for shortening/change of regime
Unpalatable antibiotic 1 0
Diarrhoea 0 1
Rash 1 0
Resolution of symptoms 1 0
Recurrence of infection 2 1
Otherb 2 2
a In one simple case and one complex case it was recorded that antibiotics were both stopped early and changed.
b See Table 48.
TABLE 48 Other reasons for shortening or changing antibiotics (as recorded in database)
Simple cases (n= 2) Complex cases (n= 2)
Patient refused to take medication Parent refusal for ongoing i.v. treatment
PICC line stopped working so swapped to oral Hickman line infection
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Ongoing symptoms
Of the children who were followed up, 27 (17.2%) simple cases had at least one ongoing symptom; 18 of
these were still in pain and other symptoms were less common. Eighteen (24%) complex cases had at least
one ongoing symptom. Types of symptoms were more diverse in this group: eight children were still in
pain, eight had joint stiffness and five had a deformity (Table 52).
TABLE 49 Complication types by action taken
Complication n (%)
Action taken, n
None Surgery
Change of
antibiotic regime
Re-admission
to hospital
Other
actiona
Simple cases (N = 218)
At least one complication 18 (8.3)
SA 8/107
OM 9/109
Complication type
Fever 1 – – – 1 –
Recurrence of infection 3 – 1 1 2 1
Dislocation 0 – – – – –
Subluxation 0 – – – – –
Pathological 0 – – – – –
Fracture 0 – – – – –
Sinus 0 – – – – –
Other (N = 16)b 16 3 2 4 1 7
Complex cases (N = 95)
At least one complication 16 (16.8)
SA 8/35
OM 7/56
Complication type
Fever 0 – – – – –
Recurrence of infection 4 – 3 2 1 1
Dislocation 0 – – – – –
Subluxation 0 – – – – –
Pathological 0 – – – – –
Fracture 0 – – – – –
Sinus 0 – – – – –
Other (N = 13)b 19 0 1 4 2 12
a See Table 51.
b See Table 50.
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TABLE 50 Other complications as they appear in the database
Simple cases (n= 16)a Complex cases (n= 13)a
Possible infectious endocarditis Acute kidney Injury
Allergic reaction – rash Blocked PICC line, replaced under general anaesthesia
Post-traumatic arthritis ankle Cardiac tamponade
Possible development of Brodie abscess Conjunctivitis and dermatitis
Coccydynia pain around scar Fever, abdominal pain and diarrhoea
Diagnosis inconclusive. Patient underwent drilling and
washout of right femur
Forearm rotation reduced
Diarrhoea Hickman line sepsis
Femoral vein thrombus Long line blocked
Increased swelling of knee Long line leaking
Patient experiencing increased pain of the left knee Major haemorrhage post renal biopsy
Phlebitis Needs insoles to stop foot going into varus position as a
result of removal of navicular
Reaction to teicoplanin Numbness to toes
Self-limiting pain episodes Pain, night sweats
Stiffness Pneumococcal meningitis
Urticarial rash on lower abdomen, upper back, left side of
back, behind both knees, right wrist and antecubital fossa
and right leg around patella region
Post-operation complications: S. aureus sepsis/OM
Worsening pain in sacrum Respiratory distress
RSV bronchiolitis
Skin rash
Tracheostomy
RSV, respiratory syncytial virus.
a n is number of children.
TABLE 51 Other actions in response to complications as they appear in the database
Simple cases (n= 8)a Complex cases (n= 13)a
Blood cultures, electrocardiography 48 hours high-frequency oscillation ventilation then
conventional ventilation
Blood tests and ultrasonography Embolisation of left kidney
Cold press Long line removed
Enoxaparin on haematology advice On haemofiltration
Follow-up, ankle fusion required in medium term Pericardial drain in situ
Hand therapist mobilisation Physiotherapy
Bloods and MRI, referral to tertiary hospital Podiatry: insoles
PICC line removed and replaced under general anaesthesia
Repeat MRI
Not specified (n= 4)
a n is number of children.
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Treatment failure
Treatment failure is defined as any of the following complications or ongoing symptoms at follow-up:
l fever
l recurrence of infection
l dislocation
l subluxation
l pathological fracture
l development of a draining sinus
l other (pain, stiffness, mobility problems, swelling, numbness, increase in CRP compared with discharge).
And/or any of the following actions arising from a complication:
l readmission to hospital
l surgery
l change of antibiotics.
Under this definition, 32 (14.7%) simple cases experienced a treatment failure, compared with 24 (25%)
complex cases (see Tables 53–56 for associations between treatment failure and diagnosis, switch timing,
length of time on antibiotics and surgery during hospital stay). Observed associations do not necessarily
imply causal links that explain likelihood of treatment failure.
Diagnosis group
Among simple cases, treatment failure was half as likely in children with SA as in children with OM (9.3%
vs. 19.3%, respectively), whereas among complex cases treatment failure was more likely in children with
SA than in those with OM (28.6% vs. 21.4%, respectively) (Table 53).
Switch timing
In simple cases, treatment failure was less likely the earlier switch occurred. Of the 73 simple cases in
whom oral switch was instituted very early (< 1 week), seven (9.6%) experienced a treatment failure,
compared with 10/62 (16.1%) of those in whom oral switch was early (between 1 and 2 weeks) and 6/33
(18.2%) of those in whom switch was standard (after 2 weeks of i.v. antibiotics). The risk of treatment
TABLE 52 Ongoing symptoms at follow-up
Symptom Simple cases (N= 157), n (%) Complex cases (N= 76), n (%)
At least one ongoing symptom at follow-up 27 (17.2) 18 (23.7)
SA 9/78 6/27
OM 18/79 10/45
Types of symptom
Pain 18 (11.5) 8 (10.5)
Fever > 38 °C 3 (1.9) 2 (2.6)
Joint stiffness 6 (3.8) 8 (10.5)
Immobility 4 (2.5) 3 (3.9)
Fracture 0 0
Sinus 2 (1.3) 0
Deformity 2 (1.3) 5 (6.6)
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failure can also be presented as odds ratios, which show that the risk of treatment failure following very
early switch is half that of associated with switch after 2 weeks. Among complex cases, the risk of
complications was highest in those in whom oral switch occurred after 2 weeks, at 37.9%, and lower in
those undergoing switch very early (25%) or after 1–2 weeks of i.v. antibiotics (19%) (Table 54).
Length of time on antibiotics
In simple cases, treatment failure was equally likely for children who had antibiotics for < 6 weeks as for
those who had courses for > 6 weeks. Among complex cases, however, children given antibiotics for
< 6 weeks were much less likely to experience treatment failure than those given antibiotics for > 6 weeks
(14.3% vs. 37%, respectively) (Table 55).
Surgery during hospital stay
Table 56 shows the numbers of children who experienced treatment failure grouped according to whether
or not surgery was carried out during their hospital stay. There was no indication of an association
between treatment failure and surgery in either simple or complex cases.
TABLE 54 Treatment failure by switch timing
Treatment failure All, n (%)
Switch, n (%)
< 1 week 1–2 weeks > 2 weeks No switch/unknown
Simple cases (N = 218)
Treatment failed 32 (14.7) 7 (9.6) 10 (16.1) 6 (18.2) 9 (18)
No treatment failure 186 (85.3) 66 (90.4) 52 (83.9) 27 (81.8) 41 (82)
Odds ratioa – 0.48 0.87 1.00 –
Complex cases (N= 95)
Treatment failed 24 (25.3) 3 (25) 4 (19) 11 (37.9) 6 (18.2)
No treatment failure 71 (74.7) 9 (75) 17 (81) 18 (62.1) 27 (81.8)
Odds ratioa – 0.55 0.39 1.00 –
a Odds of treatment failure (compared with switch time > 2 weeks).
TABLE 53 Treatment failure by SA/OM
Treatment failure All, n (%)
Diagnosis, n (%)
SA OM
Simple cases n = 218 n= 107 n= 109
Treatment failed 32 (14.7) 10 (9.3) 21 (19.3)
No treatment failure 186 (85.3) 97 (90.7) 88 (80.7)
Odds ratioa – 0.43 1.00
Complex cases n = 95 n= 35 n= 56
Treatment failed 24 (25.3) 10 (28.6) 12 (21.4)
No treatment failure 71 (74.7) 25 (71.4) 44 (78.6)
Odds ratioa – 1.47 1.00
a Odds of treatment failure (SA compared with OM).
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Discussion
This multicentre national UK service evaluation has defined the current case load, disease spectrum and
clinical practice in the diagnosis and treatment of OM/SA in secondary and tertiary UK care to provide
information regarding the feasibility of a future RCT design.
Number of cases who may be offered participation in a future randomised
controlled trial
Any future RCT will need to enrol cases defined as simple, that is, in which there is no underlying chronic
disease, no orthopaedic implants and no history of recent (within 6 months) orthopaedic surgery. Overall,
313 cases had OM and/or SA. Of these, 109 had simple OM and 107 had simple SA. Two cases were
defined as having simple disease but both or undifferentiated OM or SA. The monthly accrual was 0–3
simple cases per month in tertiary centres and 0–0.7 per month in secondary centres. The overall sample
characteristics were as expected from previous literature. Of the 313 children, 55.3% were male, 12.8%
were aged < 1 year, 51.4% were between their 1st and 6th birthday, and 35.8% were aged 6–16 years.
TABLE 55 Treatment failure by length of time on antibiotics
Treatment failure All, n (%)
Total course of antibiotics, n (%)
< 6 weeks ≥ 6 weeks Unknown
Simple cases (N = 218)
Treatment failed 32 (14.7) 20 (14.4) 10 (14.1) 2 (25)
No treatment failure 186 (85.3) 119 (85.6) 61 (85.9) 6 (75)
Odds ratioa – 1.03 1.00 –
Complex cases (N= 95)
Treatment failed 24 (25.3) 7 (14.3) 16 (37.2) 1 (33.3)
No treatment failure 71 (74.7) 42 (85.7) 27 (62.8) 2 (66.7)
Odds ratioa – 0.28 1.00 –
a Odds of treatment failure (compared with ≥ 6 weeks on antibiotics).
TABLE 56 Treatment failure and surgery prior to discharge
Treatment failure All, n (%)
Had any surgery prior to discharge? n (%)
Yes No Unknown
Simple cases (N = 218)
Treatment failed 32 (14.7) 15 (15.6) 17 (14.5) 0
No treatment failure 186 (85.3) 81 (84.4) 100 (85.5) 5 (100)
Odds ratioa – 1.09 1.00 –
Complex cases (N= 95)
Treatment failed 24 (25.3) 16 (28.1) 8 (22.2) 0 (0)
No treatment failure 71 (74.7) 41 (71.9) 28 (77.8) 2 (100)
Odds ratioa – 1.37 1.00 –
a Odds of treatment failure (compared with no surgery).
SERVICE EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
54
The joints/limbs most frequently affected in simple disease were the hip (21.1%), the knee (24.8%) and
the ankle (13.3%). Complex cases showed similar proportions of joints/bones affected (23.2%, 20% and
17.9%, respectively), although often with multiple rather than single joint/bone infections. SA was more
common in the hips and knees than in other joints in both simple and complex cases, whereas OM
affected a much larger range of joints/limbs.
In considering the health-care environment to which children first presented, most attended emergency
departments (65% of simple cases and 70% of complex cases). Only one-third presented to primary care
(28% simple and 14.7% complex) and very few to hospital outpatient clinics (3.7% of simple cases, 5.3%
of complex cases).
Although not likely to impact on RCT choices, it was interesting to note that, of simple cases, nearly 20%
were described as having had a severe infection in the 12 months preceding the presentation, 13.3% had
a history of trauma and 18.8% had at least one antibiotic in the month before presentation.
The diagnosis of osteomyelitis and septic arthritis in children
As described in Chapter 1, making a diagnosis of bone or joint infection in children involves history, clinical
examination and non-specific and specific investigations. Our data suggested inconsistency between
treating UK centres that appears unrelated to whether the patients presented to, or were treated by,
secondary or tertiary centres.
Blood tests
In order to inform diagnostic decisions, we organised our data collection to record the details of blood
tests both at presentation and on the day of or the day preceding the diagnosis. It was perhaps surprising
that, in our cohort, only 105 (48.2%) of the children with simple disease were recorded as having blood
tests taken at presentation (see Table 14). The fact that these data also show only 33.7% of complex case
children to have had a blood test at presentation is surprising, as this figure might have been expected to
be higher than for simple cases. At first glance this suggests that our database question may not have
been worded with enough clarity for the research staff to extract the correct information from the clinical
records, or that not all blood tests carried out were recorded. However, we also collected information on
the blood tests performed on the day of or the day immediately preceding the initiation of i.v. antibiotics
(see Table 19), the time point at which, for most cases, there is an assumption that the diagnosis was
made. It is also likely that clinicians performed blood tests at any point from presentation (with or without
definitive symptoms suggestive of the diagnosis) or at any point up to when the diagnosis was actually
made. As clinicians try to avoid repeated blood tests in children unless there is clinical change or clinical
uncertainty, it is probable that the blood test data are valid but that in some cases only the results of blood
tests carried out at presentation are available, whereas, in others, only the results of blood tests just before
initiation of antibiotics (i.e. just before diagnosis) are available and in yet other cases results at both time
points are available.
We analysed whether WBC/neutrophil counts, CRP and ESR were measured at presentation or before
diagnosis as well as the values of these parameters to inform decisions regarding potential entry to a
clinical trial (i.e. the usefulness in making the diagnosis of bone and/or joint infection). We also tried to
establish at which point the CRP reached the maximum (CRPmax) recorded value to inform both diagnostic
and subsequent monitoring decisions. These data need to be interpreted in light of the fact that the CRPmax
recorded may have occurred before or after the initiation of antibiotics.
Of the currently available and routinely requested non-specific blood test biomarkers, the diagnosis of OM
or SA was usually based on the CRP measurement alone (although a low CRP does not exclude OM or SA).
At presentation, CRP was higher in complex disease than simple disease (simple cases: median 32mg/l, IQR
11.8–66.7 mg/l; complex cases: median 54 mg/l, IQR 24–141 mg/l), which was not true for ESR (simple cases:
median 32 mm/hour, IQR 20.5–70 mm/hour; complex cases: median 28 mm/hour, IQR 15–55 mm/hour)
(see Table 15). At this time point, neither CRP nor ESR was able to distinguish between SA and OM
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(CRP: SA median 32 mg/l, IQR 16.2–65 mg/l; OM median 32.7 mg/l, IQR 10–68 mg/l; ESR: SA median
29 mm/hour, IQR 14–70.5 mm/hour; OM median 35.5 mm/hour, IQR 26–68.5 mm/hour) (see Table 16).
As expected, the number of ESR results available for analysis was only around half of the number of
CRP results (an ESR result was available in 56/218 simple cases and 9/95 complex cases, whereas a CRP
measurement was available in 99/218 simple cases and 31/95 complex case, (see Table 15). This was
probably due to both the perceived lack of need (many paediatric clinicians are less likely to request ESR in
current practice) and the related fact that ESR is a technically harder test to perform than CRP because of
the blood volume required and laboratory processes. A similar analysis is available for the blood tests
performed on the day of or preceding the day of diagnosis. At this time point, CRP was also higher in
complex disease than in simple disease (simple cases: median 38.3 mg/l, IQR 20–74 mg/l; complex cases:
median 86.7 mg/l, IQR 29–161 mg/l), which was, again, not so for ESR (simple cases: median 46 mm/hour,
IQR 25–78 mm/hour; complex cases: median 40 mm/hour, IQR 21–60) mm/hour) (see Table 20). Neither
CRP nor ESR was able to distinguish between SA and OM (CRP: SA median 35.5 mg/l, IQR 21.2–72 mg/l;
OM median 39.5 mg/l, IQR 14–81 mg/l; ESR: SA median 46 mm/hour, IQR 23–81 mm/hour; OM median
47 mm/hour, IQR 26–76 mm/hour) (see Table 21). Again, the number of ESR results available for analysis
was half the number of CRP results (an ESR result was available in 83/218 simple cases and 17/95 complex
cases, whereas a CRP result was available in 137/218 simple cases and 48/95 complex cases) (see Table 20).
Overall, CRP reached its highest recorded value at the start of the illness in simple disease and a few days
after presentation in complex disease [in simple disease CRPmax occurred on median day 0 (IQR day 0–6)
and in complex disease on median day 4 (IQR day 1–8)] (see Table 17).
The total WBC or specific neutrophil counts at both presentation or just prior to initiation antibiotics were
not shown to be of clinical use in determining whether to suspect or confirm SA or OM. Although the
normal ranges of total WBC and neutrophil counts vary at different ages, there was overlap for both
parameters between the normal range and WBC/neutrophil values recorded for children with simple or
complex OM and SA (see Tables 15, 16, 20 and 21). As for many other serious infections in children, a
raised WBC and/or neutrophil count can indicate bacterial infection, but normal results do not preclude
such a diagnosis and must not be used to rule out OM or SA.
Imaging
The use of imaging performed prior to i.v. antibiotics (prior to diagnosis of bone or joint infection) was
determined. Overall, a radiological diagnosis was obtained for 51.8% of simple cases (at a median of 1 day
post presentation, IQR 0–3) and 52.6% of complex cases (median of 1 day post presentation, IQR 0–4 days)
(see Table 17), although, as can be seen from the detailed discussion in the next paragraph, these data may
be skewed by soft-tissue abnormalities reported in formal X-ray reports. Regardless of the caution needed
in interpreting this result overall, MRI has been shown to offer very high pick-up rates of abnormalities
compared with X-ray or ultrasonography, and has almost completely replaced technetium bone scanning in
current UK practice (see Tables 25 and 26). In detail, X-rays were commonly used (66% of simple cases of
OM or SA combined, 62% of complex cases), ultrasonography was used in 41% of simple cases and 31%
of complex cases and MRI was used in 19% of simple and 21% of complex cases. CT and technetium bone
scanning were rarely used (1% of children with simple or complex disease underwent CT, whereas 2% of
children with simple disease but none with complex disease underwent bone scanning) (see Table 25).
X-ray and ultrasonography were used with equal frequency in simple cases of OM and SA (see Table 26).
Around two-thirds of children with simple or complex SA and OM underwent radiography before initiation
of i.v. antibiotics (see Table 18). Of the children with simple SA, 66 (63%) had an X-ray, of which 24
(36%) were abnormal. Of the children with simple OM, 66 (68%) had an X-ray, of which 26 (39%) were
reported as abnormal. Among those with complex disease, X-rays taken prior to antibiotics were abnormal
in 8 of 21 (38%) of those with SA, compared with 18 of the 33 (55%) of those with OM. Because of the
nature of the data collection in the study, these data must be interpreted with caution as it is likely that
abnormalities recorded in the database included soft tissue changes visible (and reported by radiologists)
and not just bony abnormalities that would not be expected to be present early in the OM disease process.
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Ultrasonography was carried out in 53 (51%) simple SA cases and was reported abnormal to be abnormal
in 43 of these (81%). Eleven children with complex SA underwent ultrasonography (33% cases), and was
reported to be abnormal in nine (82%). In complex OM there were 16 scans (30% cases), of which 11
(69%) were reported as abnormal.
Magnetic resonance imaging was used more often in children with OM cases than in those with SA and
picked up a large number of abnormalities (see Table 26). Twenty-nine (30%) children with simple OM
underwent MRI, in 26 (90%) of whom the results were reported as abnormal, and 16 (30%) children with
complex OM underwent MRI, in all of whom the results were reported to be abnormal. MRI was also very
successful in the diagnosis of SA. MRI was carried out in nine (9%) children with simple SA, with abnormal
results reported in eight (89%), and in four (12%) children with complex SA. with abnormal results
reported in three (75%).
Among children with OM, whether simple or complex, MRI revealed abnormalities in many different
bones, whereas in children with SA abnormalities on MIR were seen only in large joints (see Table 24).
The ability of MRI to detect a wide range of abnormalities explains the low frequency with which technetium
bone scanning was performed over the course of the evaluation period. Bone scanning was performed in
no children with complex SA or OM, in only one child with simple SA (in whom the result was abnormal)
and only in three children (3%) with simple OM, of whom two (67%) showed an abnormality. CT was not
used at all in children with SA, and in only three children (3%) with simple OM (100% abnormal) and one
child (2%) with complex OM, in whom the results were was also abnormal (see Table 26).
Surgery
Surgery is carried out before starting i.v. antibiotics in children with clinically severe SA or OM either to
prevent destructive outcomes or to obtain surgical specimens to aid a microbiological diagnosis, or where
there is diagnostic dilemma.
Diagnostic surgery prior to i.v. antibiotic therapy was carried out in a higher proportion of SA cases than
of OM cases [39/107 (36.4%) simple and 15/35 (42.9%) complex cases of SA, compared with 21/109
(19.3%) simple and 14/56 (25%) complex cases of OM]. On average, surgery was carried out earlier in
children with SA than in those with OM. Among those with SA, the first surgery was carried out a median
of 1 day after presentation, with 75% of first surgical procedures being carried by day 2 in simple cases
and by day 5 in complex cases. Among children with OM, the first surgery was carried out a median of
1 day after presentation in simple cases, with 75% of first surgical procedures performed by day 10, and a
median of 3 days after presentation in complex cases, with 75% of first surgical procedures performed by
day 8 (see Table 18).
The types of surgery most often carried out before i.v. antibiotics were started were, in simple cases
(both OM and SA), ‘incision and drainage’ (performed in 60.7%) and ‘aspiration’ (in 55.7%), followed by
arthroscopy (9.8%), and, in complex cases, incision and drainage (62.1%), then aspiration (24.1%) and,
third, debridement (17.2%) (see Table 22).
Surgery was carried out more often in children with OM than in those with SA (63.6% vs. 37.5%, respectively,
in simple cases and 25.9% and 15.5%, respectively, in complex cases). From discussion at the investigator
meeting (see Chapter 5), there remains the possibility that, although the database has been populated
directly from terms used in the clinical records, there may be overlap between the different technical terms
used by orthopaedic surgeons for ‘incision and drainage’ and ‘aspiration’. At database design we had
intended ‘aspiration’ to record needle aspiration (expected to be mainly of infected joints in suspected SA)
and ‘incision and drainage’ to represent a more formal, open surgical procedure (expected to be carried
out in cases of both OM and SA). We found that incision and drainage was performed with approximately
equal frequency in both groups (simple SA 25%, simple OM 33%, complex SA 13.4%, complex OM
9.3%) but there were also no reported differences in aspiration rates between SA and OM (simple cases
SA 23.1%, OM 30.3%; complex cases SA 5.2%, OM 3.7%).
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Surgical treatment after the initiation of antibiotics
A total of 21.6% of children with simple disease went on to have surgery after the start of i.v. antibiotics,
compared with 41.1% of children with complex disease. In both groups, OM and SA cases were equally
represented (see Table 40).
The most common procedure carried out in simple cases was aspiration (7.3%); in complex cases it was
incision and drainage (16.8%), and this was often a wash-out in conjunction with another procedure.
In 11.6% of all complex cases, debridement was performed at least once (see Table 40).
Conventional microbiological tests
As for any invasive infections in children or adults, clinical best practice in OM and SA is to take samples
for microbiological diagnosis prior to starting empirical antibiotics. The aim of tests is to make a
microbiological diagnosis in order to determine further, more specific antibiotic therapy and, in the case of
infection with some specific pathogens such as PVL-positive Staphylococcus, to consider more complex or
prolonged treatment regimens. Routinely available NHS microbiological tests are reported here, with a
summary of the molecular data from a new targeted PCR test reported in Chapter 3.
In only 144 out of 218 (66.1%) children with simple OM or SA, and 59 out of 95 (62.1%) children with
complex OM or SA, was at least one diagnostic test performed on blood or tissue samples (bone, joint
aspirate or periosteal pus) (see Table 27). Blood culture was performed in only 62% of simple cases and
54.3% of complex cases. Blood culture reporting rates did not differ between secondary and tertiary
centres (see Table 30).
A blood, tissue or synovial fluid sample tested positive for at least one micro-organism in 38.2% of
children with simple disease, compared with 52.5% of complex cases. Among those children with OM,
microbiology tests were carried out in 58%, and at least one micro-organism was detected in 49% of
cases tested. The proportion of children with SA tested was 73%, and a micro-organism was found in
36% (see Table 27).
S. aureus was found in 20.1% of blood, tissue or synovial fluid samples taken from simple cases and in
32.2% of samples from complex cases; other pathogens were far less commonly detected by routinely
available tests (see Table 27). PVL-positive S. aureus and MRSA were detected with similar frequency in
simple and complex cases regardless of sample type [PVL-positive S. aureus: 2/29 (6.9%) simple cases and
1/19 (5.3%) complex cases; MRSA: 1/29 (3.4%) simple cases and 1/19 (5.3%) complex cases]. In only one
case (complex) was erythromycin-resistant S. aureus reported (see Table 27). GAS, K. kingae and GBS were
not commonly detected by conventional microbiology (see Table 27).
Medical treatment: intravenous course length and time before oral switch
All children in the study spent time in hospital. Most children with SA or OM went straight to hospital
[median time from presentation to hospital referral 0 days (IQR 0–3 days) in simple cases and 1 day
(IQR 0–4 days) in complex cases] (see Tables 17 and 18).
Not all children received i.v. antibiotics, although most did [104/107 (97.2%) simple SA cases, 33/95
(94.3%) complex SA cases, 97/109 (97%) simple OM cases and 54/56 (96.4%) complex OM cases].
In 15 (6.9%) simple cases and four (4.2%) complex cases, either no i.v. antibiotic treatment was given
or the data are missing (see Tables 17 and 18). Among those who were treated with i.v. antibiotics,
treatment was initiated, on average, a little earlier in children with SA [simple cases, median 1 day
(IQR 0–3 days); complex cases, median 2 days (IQR 0–4 days)] than in those with OM [simple cases,
median 2 days (IQR 1–5 days); complex cases, median 2 days (IQR 1–5 days)] (see Table 18).
SERVICE EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
58
Although there was no difference in overall duration of antibiotic treatment between simple and complex
SA cases or between simple and complex OM cases, duration of i.v. therapy was longer in children with
complex disease, whether SA or OM, than in those with simple disease (see Table 32):
l Among the 103 children with simple SA treated with antibiotics, the median duration of total
treatment was 30 (IQR 18–41) days, with a median duration of i.v. therapy of 7 (IQR 4–13) days.
l Among the 34 children with complex SA treated with antibiotics, the median duration of total
treatment was 28.5 (IQR 15–46) days, with a median duration of i.v. therapy of 14 (IQR 7–24) days.
l Among the 105 children with simple OM treated with antibiotics, the median duration of total
treatment was 40 (IQR 21–48) days, with a median duration of i.v. therapy of 9 (IQR 6–16) days.
l Among the 54 children with complex OM treated with antibiotics, the median duration of total
treatment was 42 (IQR 26–57) days, with a median duration of i.v. therapy of 18.5 (IQR 8–42) days.
These data suggest that in any potential clinical trial of antibiotics in simple OM or SA, although the
duration of total may need to differ between OM and SA, it may be possible to plan for a similar length of
initial i.v. therapy for both conditions.
The timing of switch from i.v. to oral antibiotics was related to disease complexity and type of disease:
SA or OM. Intravenous antibiotics treatment was of shorter duration in children with simple disease than
in those with complex disease (see Figures 1 and 2 and Tables 32 and 33). Among children in whom the
switch date is known, a blood test at the time of the switch was carried out in only 37.9% of those with
simple disease and 22.8% of those with complex disease (see Table 38).
When the switch date was recorded in the database, the median duration of i.v. therapy could be calculated:
l Among 107 simple cases of SA, the switch date was known in 85 (79.4%). Switch occurred after a
median of 6 (IQR 4–11) days of i.v. antibiotic treatment.
l Among 109 simple cases of OM, the switch date was known in 82 (75.2%). Switch occurred after a
median of 8.5 (IQR 5–14) days of i.v. antibiotic treatment.
l Among 35 complex cases of SA, the switch date was known in 23 (65.7%). Switch occurred after a
median of 13.5 (IQR 7–21) days of i.v. antibiotic treatment.
l Among 56 complex cases of OM, the switch date was known in 35 (62.5%). Switch occurred after a
median of 10.5 (IQR 7.5–26) days of i.v. antibiotic treatment.
As described above, the Kaplan–Meier plot of time to switch (by SA/OM; see Figure 2) shows that time to switch
to oral antibiotics differed little between those with OM and SA in the simple cases group. Among complex
cases, switch timing was similar in those with OM and SA when the switch took place before 2 weeks, but after
this time point switch to oral antibiotics occurred later in those with OM than in those with SA.
Overall, 63.8% of those with simple disease (OM/SA) received antibiotic treatment for < 6 weeks in total,
compared with 51.6% of those with complex disease (see Table 33). Simple OM and SA were most
commonly treated with a single i.v. antibiotic and/or a single oral antibiotic, whereas in complex SA/OM
cases more than two i.v. antibiotics were used, most often together with a single oral antibiotic type
(see Table 33).
Medical treatment: initial empirical antibiotics
In order to design a randomised clinical trial, consensus needs to be reached regarding the initial empirical
antibiotic to be started intravenously, and also regarding the post-switch oral antibiotic(s) to be used for
the cases in which there is or is not a formal microbiology diagnosis. Although not investigated in this
study, data from Finland suggest that children with culture-negative signs and symptoms of SA or OM
can be treated in a similar fashion to children in whom the organism is identified in respect of type and
duration of antimicrobial therapy.63 The aim of the microbiology component of this study was to establish
the most appropriate initial empirical therapies.
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Beta-lactam antibiotics, either ‘simpler’ penicillin or second- or third-generation cephalosporins, are widely
used in UK practice for the treatment of SA and OM. Among the 199 children with simple SA or OM who
received i.v. antibiotics at any point during their hospital stay, the initial i.v. treatment was flucloxacillin in
85 (42.7%), clindamycin in 13 (6.5%), cefuroxime in 60 (30.2%), ceftriaxone in 51 (25.6%), benzylpenicillin
in 16 (8%) and co-amoxiclav in 13 (6.5%) [24 (12.1%) children received other antibiotics] (see Table 35).
Of the 91 children with complex SA or OM who received i.v. antibiotics at any point during their hospital
stay, 38 (41.8%) received flucloxacillin, 10 (11%) received clindamycin, 17 (18.7%) received cefuroxime,
19 (20.9%) received ceftriaxone, 10 (11%) received benzylpenicillin and 10 (11%) received co-amoxiclav
[with 19 (20.9%) children receiving other antibiotics] as part of their initial treatment (see Table 36).
Oral antibiotics were uncommon as part of initial therapy. Seventy-eight (35.8%) children with simple
disease were prescribed at least one oral antibiotic. Flucloxacillin (34 cases, 43.6%), clindamycin (17 cases,
21.8%) and co-amoxiclav (18 cases, 23.1%) were all prescribed prior to discharge from hospital (see
Table 35). Thirty-six (37.9%) children with complex disease were prescribed at least one oral antibiotic
while in hospital, with the range of antimicrobials prescribed similar to those prescribed for simple disease,
although ‘other’ antibiotics were used more often in children with complex disease than in those with
simple disease (Tables 35 and 36).
Medical treatment: antibiotic at hospital discharge
Children with OM or SA were discharged on either i.v. or oral antibiotics. At discharge, 30 (28%) of
107 children with simple SA and 28 (25.7%) of 109 children simple OM remained on i.v. antibiotics. Around
60% [SA, 64 cases, (59.8%); OM, 65 cases (59.6%)] of children were taking only an oral antibiotic, and
similar numbers of children with simple SA and OM either were on no antibiotic or the data are missing
[SA, 13 children (12.1%); OM, 16 children (14.7%)]. Children with complex disease were more likely to
remain on i.v. medication at discharge [of 95 children with complex SA/OM, 40 (42.1%) were on i.v.
antibiotics, 42 (44.2%) were on oral antibiotics and 13 (13.7%) children were on none or this information
was unknown] (see Table 45).
As expected, owing to the formulations available for outpatient or home-based therapy, the range of
drugs prescribed was narrower than those used in hospital. Most children with simple disease were
prescribed ceftriaxone for post-discharge i.v. therapy (41/59; 69.5%), although a few remained on
flucloxacillin (4/59; 6.8%), clindamycin (2/59; 3.4%), cefuroxime (1/59; 1.7%) or other drugs (9/59,
15.3%). Children with complex disease were also treated after discharge mostly with ceftriaxone (31/40;
77.5%), but a few were treated with flucloxacillin (2/40; 5%), clindamycin (3/40; 7.5%) or other drugs
(5/40; 12.5%) (see Table 46). Note: for 10% of cases known to have been discharged on i.v. antibiotics,
the antibiotic type was not recorded, and children could be discharged on more than one antibiotic.
Of the oral drugs prescribed at discharge, co-amoxiclav was used in approximately one-third of cases
[58/156 (36.5%) simple cases, 17/58 (28.8%) complex cases] and flucloxacillin in about one-quarter of
cases [46/156 (28.9%) simple cases, 15/58 (25.4%) complex cases]. Oral clindamycin was used more
frequently in complex than in simple cases [17/156 (10.7%) simple cases, 17/58 (28.8%) complex cases].
Cefalexin was used in simple SA/OM but infrequently in complex disease [20/156 (12.6%) simple cases,
2/58 (3.4%) complex cases] (see Table 46).
Medical treatment: dose of intravenous and oral antibiotics prescribed
Adequate dosing is a major concern of modern antimicrobial stewardship to ensure clinical cure with
minimal risk of intrapatient and in-hospital interpatient antimicrobial resistance.64 Recent legislative changes
to clinical trial legislation65 ensure that newly available drugs are properly tested in children to establish
dosing regimens and efficacy. However, almost all the widely used paediatric doses of antibiotics have been
included in paediatric formularies, having been established by opinion and practice rather than formal clinical
trial. With much variation in international practice, the UK BNFC62 has recently begun to revise the
recommended doses of commonly used antibiotics, for example in 2014 doubling the recommended age
band doses of oral amoxicillin. In addition, the UK BNFC is set out so that minimum and maximum doses for
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weight or age are specified. Many specialists in paediatric infection and paediatric microbiology, and National
Institute for Health and Care Excellence guidelines where they exist,66–68 consider the high quoted doses to
be the correct doses for serious (in-hospital) infections and that the low quoted doses are suboptimal. In
order to inform the dose strategy for a future clinical trial, it was important to assess the antibiotic doses
used in current practice in the context of overall reported clinical outcomes.
Overall, only 40.4% of simple cases received a higher formulary initial dose of antibiotics, compared with
29.5% of complex cases. Only 30 (13.8%) simple cases and nine (9.5%) complex cases received the
higher formulary dose of antibiotic treatment throughout (see Table 33).
Specifically, for the most commonly prescribed i.v. empirical antimicrobials in hospital:
l For simple disease (see Table 35), flucloxacillin, clindamycin and cefuroxime were prescribed at
or near to the recommended formulary higher doses [flucloxacillin: median 188.1 (IQR 100.8–200)
mg/kg/24 hours, formulary higher dose 200 mg/kg/24 hours; clindamycin: median 39.9
(IQR 18.5–40.6) mg/kg/24 hours, formulary higher dose 40 mg/kg/24 hours; cefuroxime: median
151.5 (IQR 83.7–150.) mg/kg/24 hours, formulary higher dose 150 mg/kg/24 hours]. However,
ceftriaxone was generally prescribed at the lower formulary dose [median 50.3 (IQR 50–79.3)
mg/kg/24 hours, formulary higher dose 80 mg/kg/24 hours].
l For complex disease (see Table 36), however, prescribing trends suggest that inadequate dosing (less
than the higher formulary dose) was more common. Although ceftriaxone was generally prescribed
at the higher formulary dose when it was used (as initial treatment in 20.9% of cases, and in 40.7%
of complex cases overall) [median 77.7 (IQR 49–8) mg/kg/24 hours, formulary higher dose 80 mg/kg/
24 hours, EMA-approved maximum dose 100 mg/kg/24 hours], flucloxacillin, clindamycin and cefuroxime
were all prescribed at less than the formulary higher doses [flucloxacillin: median 142.6 (IQR 98–198.5)
mg/kg/24 hours, formulary higher dose 200 mg/kg/24 hours; clindamycin: median 33.3 (IQR 24.1–39.2)
mg/kg/24 hours, formulary higher dose 40 mg/kg/24 hours; cefuroxime: median 128 (IQR 83.3–150)
mg/kg/24 hours, formulary higher dose 150 mg/kg/24 hours].
Doses of i.v. and oral antimicrobials prescribed following discharge were also generally lower than higher
formulary doses. The i.v. empirical antimicrobial most commonly prescribed at discharge (for use out of
hospital) (see Table 46), in both simple and complex cases, was ceftriaxone, because of its once-daily regimen
(prescribed in 69.5% of children with simple disease receiving i.v. home-based therapy and 77.5% of children
with complex disease). At discharge, ceftriaxone was generally prescribed at the lower formulary dose in simple
cases [median 50.7 (IQR 49.3–79.4) mg/kg/24 hours, formulary higher dose 80mg/kg/24 hours], although
in complex disease the dose was slightly higher but still not at the higher formulary dose [median 65.4
(IQR 49–80.3) mg/kg/24 hours]. When used out of hospital, i.v. flucloxacillin and clindamycin for both simple
and complex disease were generally prescribed at below the lower formulary recommended doses (flucloxacillin:
simple disease, median 98.1 mg/kg/24 hours; complex disease, median 35.8 mg/kg/24 hours; clindamycin:
simple disease, median 21.6 mg/kg/24 hours; complex disease, median 4mg/kg/24 hours) (see Table 46).
In the case of orally prescribed out-of-hospital antibiotic treatments, comparison with formulary doses is more
complicated as a result of the age band variations in the current BNFC.62 For reference, the recommended
dose ranges for co-amoxiclav (expressed as mg/kg/24 hours of amoxicillin component) are as follows:
l age 1 month to 6 years: low dose 18.75 mg/kg/24 hours; high dose 37.5 mg/kg/24 hours
l age 6–12 years: low dose 22.5 mg/kg/24 hours; high dose 45 mg/kg/24 hours
l age 12–18 years: low dose 15 mg/kg/24 hours; high dose 30 mg/kg/24 hours.
For flucloxacillin, the recommended dose ranges are as follows:
l age 1 month to 2 years: low dose 31 mg/kg/24 hours; high dose 62 mg/kg/24 hours
l age 2–10 years: low dose 43.3 mg/kg/24 hours; high dose 46.5 mg/kg/24 hours
l age 2–18 years: low dose 25 mg/kg/24 hours; high dose 50 mg/kg/24 hours.
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For all age groups, the recommended oral dose of clindamycin is 12 mg/kg/24 hours (low dose) to 24 mg/kg/
24 hours (high dose) and of cephalexin is 25 mg/kg/24 hours (low dose) to 50 mg/kg/24 hours (high dose).
In most children with simple disease, the prescribed doses of the four most common oral antibiotics were
nearer to the lower end of the dose range (see Table 46):
l co-amoxiclav: median 30.4 mg/kg/24 hours (IQR 13.8–41.8 mg/kg/24 hours)
l flucloxacillin: median 37.5 mg/kg/24 hours (IQR 14.2–82.3 mg/kg/24 hours)
l clindamycin: median 18.1 mg/kg/24 hours (IQR 6.1–23.6 mg/kg/24 hours)
l cefalexin: median 35 mg/kg/24 hours (IQR 24.5–91.1 mg/kg/24 hours).
Perhaps worryingly, children with complex disease who were prescribed co-amoxiclav or clindamycin
(respectively 28.8% and 28.8% of children with complex disease given oral antibiotics) appear to have
received lower doses of these drugs than children with simple OM or SA. Among children with complex
disease prescribed oral antibiotics at discharge, the median dose of co-amoxiclav was 23.1 mg/kg/
24 hours (IQR 12.1–47.6 mg/kg/24 hours), the median dose of flucloxacillin was 41.7 mg/kg/24 hours
(IQR 36.4–54.1 mg/kg/24 hours) and the median dose of clindamycin was 15.1 mg/kg/24 hours
(IQR 6–23.8 mg/kg/24 hours) (see Table 46).
Follow-up (3 months): completion of antimicrobial courses as planned at discharge
One of the key concerns in any clinical trial of oral therapies, and of antibiotics in particular, is the course
completion rate. Although not all children with OM or SA were followed up (the reported follow-up rates
were 72.9% of children with simple SA, 72.5% of children with simple OM, 77.1% of children with
complex SA and 80.4% of children with complex OM), course completion rates among those who were
followed up were very high (92.4% among those with simple disease and 92.1% among those with
complex disease) (see Table 47). The reported reasons for non-completion of therapy were reassuring for
future trial planning, when, to study clinical outcomes in relation to length of therapy, it will be important
to know that prescribed medication is being given as planned. Among children with simple disease, there
were only four for whom failure to complete treatment was reported, with the reported reasons being
unpalatable antibiotic, rash, symptom resolution and refusal to take the medication.
Hospital stay
Overall, the median length of hospital stay among children with simple disease, whether OM or SA, was
7 days (IQR 4–12 days), with 50% of children staying for ≥ 6 days but no longer than 12 days. In complex
cases the median length of stay in hospital overall was 9 days (IQR 6–18 days), with 50% of children
staying for ≥ 6 days but no longer than 18 days (see Table 43).
Children with OM spent longer in hospital than those with SA, and this was true for both those with
simple disease and those with complex disease (see Table 44). The median length of stay for simple SA
was 6 days (IQR 4–11 days), compared with 9 days (IQR 5–13 days) for simple OM. The median length of
stay for complex SA was 8 days (IQR 6–15 days), compared with 9 days (IQR 6–18.5 days) for complex
OM. In the case of children with simple SA or OM, the median length of hospital stay was similar to the
time on i.v. therapy prior to oral switch (oral switch occurring after a median of 6 and 8.5 days, respectively),
but children with complex SA or OM were more likely to still be on i.v. therapy at the time of hospital
discharge (oral switch occurring after a median of 13.5 and 10.5 days, respectively).
Younger (aged < 1 year) and older (aged 6–16 years) children were more likely to stay in hospital longer than
the 1–6 years age group, which is probably a reflection of the difficulties of imposing bed rest on the younger
mobile children than on babies and older children. Among those with simple disease, the median length
of stay was 7 days (IQR 5–12 days) for those aged < 1 year and 10 days (IQR 6–15 days) for those aged
6–16 years but only 6 days (IQR 3.5–10.5) for those aged 1–6 years. Among those with complex disease,
the median length of stay was 16 days (IQR 9–27 days) for those aged < 1 year and 10 days (IQR 6–16 days)
for those aged 6–16 years, but only 8 days (IQR 5–14 days) for those aged 1–6 years (see Table 43).
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The finding that children treated in secondary care centres spent slightly longer in hospital than those
treated in tertiary centres (see Table 43) is difficult to explain fully, but may be a reflection of the fact that
some children are transferred back to their secondary care centre prior to final discharge from hospital and
this may incur delays overall prior to discharge home.
Follow-up (3 months): complications of the disease and therapies, and treatment failure
Complications and ongoing symptoms were recorded as separate items during data collection to try to
capture all post-treatment events and problems that may need to be included as future clinical trial outcomes.
A total of 8.3% of children with simple disease and 16.8% of those with complex disease experienced at
least one complication (see Table 49). In only three (of 218) children with simple disease and four (of 95)
children with complex disease was recurrence of infection requiring medical or surgical intervention
reported. Other complications were reported only once and were related to the disease (clinical outcomes,
e.g. stiffness or pain), antibiotic therapy (e.g. possible allergy or drug reaction) or mode of giving the drug
(e.g. phlebitis) (see Table 50). The complications of complex disease were generally more severe than those
reported for simple disease, including acute kidney injury, Hickman line sepsis, pneumococcal meningitis
and tracheostomy (see Table 50).
Twenty-seven (17.2%) children with simple disease and 18 (24%) with complex disease had at least one
ongoing symptom. Eighteen of 157 (11.5%) children with simple SA or OM and 8 of 76 (10.5%) children
with complex SA or OM followed up were still in pain. Six (3.8%) children with simple disease and eight
(10.5%) with complex disease reported joint stiffness, and four (2.5%) children with simple disease and
three (3.9%) with complex disease reported immobility of some kind. Other symptoms were less common
and no fractures were reported (see Table 52).
To capture all possible cases of failure of initial empirical antibiotic and/or surgical therapy, necessitating
further treatment, we used a broad definition of treatment failure (including fever, recurrence of infection
including increase in CRP or development of draining sinus), dislocation, subluxation, pathological fracture,
pain, mobility problems, swelling, numbness, hospital readmission, surgery and change of antibiotics.
Using these criteria, 32 of 218 (14.7%) children with simple disease experienced a treatment failure,
compared with 24 of 95 (25%) children with complex disease (see Table 53). Among those with simple
disease, treatment failure was half as likely in those with SA (9.3%) as in those with OM (19.3%), whereas
among those with complex disease treatment failure was more likely in those with SA (28.6%) than in
those with OM (21.4%) (see Table 53).
These data demonstrate that treatment failure is less likely in children with simple disease in whom switch
to oral antibiotics occurs early, suggesting that those with complex disease are more likely to fail initial
therapy or require additional interventions, which is very important for the design of a RCT of reduced
duration of i.v. and/or total antibiotic therapy. Of the 73 children with simple disease in whom oral switch
occurred very early (< 1 week), 9.6% experienced a treatment failure, compared with 16.1% of those in
whom switch occurred early (between 1 and 2 weeks) and 18.2% of those in whom switch took place
after 2 weeks or more of i.v. antibiotics. Among children with complex disease, switching to oral
antibiotics after 2 weeks or more was also associated with a higher risk of complications (37.9%) than very
early switch (25%) or switch between 1 and 2 weeks (19%) (see Table 54).
Regarding the total length of therapy, among those with simple SA or OM, treatment failure was equally
likely among those treated with antibiotics for < 6 weeks and those treated for > 6 weeks. Among those
with complex disease, children given antibiotics for < 6 weeks were much less likely to experience
treatment failure than those given antibiotics for > 6 weeks (14.3% compared with 37%), although this is
likely to be a reflection of disease severity itself and not the treatments given (see Table 55).
Chapter 8 presents a detailed discussion of how the service evaluation data impact, with other study
components, on potential RCT design.
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Chapter 3 Microbiology substudy
Background
The current ‘gold standard’ for detection of bacteria associated with OM/SA is bacterial culture, although
in the UK the pathogen detection rate from culture in children’s bone and joint infections is low.1 This
means that the true spectrum of organisms causing bone and joint infections in the UK is not known, and
treatment is usually empirical.
New molecular techniques can enhance diagnostic detection rates. The use of 16S real-time PCR has
become available in some specialist centres; however, in the UK it is available at one centre with a
turnaround time of days to weeks. 16S real-time PCR is expensive and, although capable of detecting
many pathogenic and non-pathogenic organisms, it has low sensitivity because the load of bacteria in the
primary sample needs to be sufficiently high to allow detection.
Species-specific reverse transcription polymerase chain reaction (RT-PCR) to identify bacteria associated
with OM/SA has been used in specialist centres to enhance the detection of certain organisms, in particular
K. kingae, which is difficult to grow in routine culture. However, although it is much cheaper than 16S
PCR, species-specific PCR is not routinely available in most UK or European Union laboratories.
Aims and objectives
This study evaluated the potential for the species-specific RT-PCR to be used both to establish the baseline
UK microbiology of paediatric bone and joint infections more rigorously than would have been possible by
culture alone and to assess the use of the test in a larger RCT.
We also aimed to understand the pathophysiology of K. kingae by using PCR to test throat swabs (taken
from patients who have provided consent) for K. kingae to determine how many had concurrent
pharyngeal colonisation with this organism.
Methods
Clinical cases
Children presenting with bone and joint infection at one of the six participating centres were approached
by the Dinosaur study research team and recruited after informed consent was obtained. Clinical data
were collected as part of the standard Dinosaur service evaluation.
Inclusion criteria
1. Children between the ages of 1 month and 16 years with a clinical diagnosis of OM or SA.
2. Written informed consent of participant or parent/legal guardian, and assent where appropriate for:
¢ PCR to be done on routine samples taken for culture and microscopy
¢ throat swab to be taken for PCR and culture and microscopy
¢ additional 5-ml blood sample to be taken and stored for future analysis.
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Exclusion criteria
Patients for whom informed consent is not obtained (parents/patients could decline consent for certain
procedures, e.g. additional blood aliquot, but still give consent for others, such as PCR on routine samples).
The culture and preparation of control organisms
Sample handling and preparation
Samples from routinely collected blood and tissue cultures were taken in the local microbiology laboratory
and processed in accordance with the study standard operating procedure (see Report supplementary
material 4) before storage and transfer to the central laboratory (Southampton Public Health England
South East Regional Laboratory) for PCR analysis.
All samples were taken for PCR after initial bacterial culture had been carried out. For blood cultures, an
aliquot of sample was removed after at least 19 hours’ incubation (unless the sample had already been
identified as positive) using a sterile needle and syringe, from which 1 ml was placed into a sterile
nuclease-free skirted 2-ml tube before being capped and labelled and placed in storage at –80 °C until
extraction and PCR was to be carried out. For liquid samples such as synovial fluid, pus and blood or joint
washouts, 500 µl was taken from the original sample (where limited sample volume remained, 200 µl was
used, thus allowing for repeat culture or further analysis using another method). Solid samples were
divided and, where sample quantity allowed, a minimum of two aliquots of tissue or bone weighing
around 10 mg each were taken and placed in to a sterile nuclease-free skirted 2-ml tube and stored at
–80 °C. All samples were handled in a class 1 cabinet to prevent contamination.
For throat swabs, after swabbing, the cotton end was snipped off using sterile scissors into a flat-bottom
2-ml tube containing 1 ml of skimmed milk, tryptone, glucose and glycerine media, used to preserve
bacteria while being frozen at –80 °C.
Polymerase chain reaction analysis
Control bacteria used in this study were sourced from Pro-Lab Diagnostics (Birkenhead, UK) and the UK
National Culture Collection (Salisbury, UK). Bacterial deoxyribonucleic acid was extracted by standard
methods and multiplex PCR used for analysis. Table 57 shows the multiplex panels used for all samples.
Table 57 shows the constituent elements to each of the multiplexes. Two separate targets were used to
detect S. pneumoniae as the pneumolysin (ply) gene is also common to other closely related streptococcal
TABLE 57 Elements to each of the multiplexes
Multiplex 1 Multiplex 2 Multiplex 3
K. k. for Sal. spp. for GBS for
K. k. rev Sal. spp. rev GBS rev
GAS for S. a. for H. inf. for
GAS rev S. a. rev H. inf. rev
S. pn. ply for S. epi. for S. pn. lytA for
S. pn. ply rev S. epi. rev S. pn. lytA rev
K. k. Sal. spp. GBS
GAS S. a. H. inf.
S. pn. ply S. epi. S. pn. lytA
for, forward primer; H. inf., H. influenzae; K. k., K. kingae; lytA, N-acetylmuramoyl-L-alanine amidase; ply, pneumolysin;
rev, reverse primer; S. a., S. aureus; Sal. spp., Salmonella species; S. epi., Staphylococcus epidermidis; S. pn., S. pneumoniae.
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species including Streptococcus mitis, Streptococcus oralis and Streptococcus pseudopneumoniae. The
N-acetylmuramoyl-L-alanine amidase (lytA) gene was later chosen as it occurs only in S. pneumoniae.
Results
Although seven sites took part in the study, samples from only six of the sites were processed because of
incorrect sampling at one site, an error subsequently acknowledged by the local principal investigator.
The total number of samples and patients consented to the study from each site is shown in Table 58.
Table 58 shows the number of patients consented to the study at each site and the number of samples
(both throat swabs and native bone and joint samples). Site number refers to tables below.
A total of 151 samples were received from 50 patients. Of these, 113 were bone, fluid and blood culture
samples, which were collected from 44 patients across six geographical sites. The remaining 38 samples
were from throat and wound swabs. For five participants only throat swab samples were obtained, and for
one participant only skin swab samples were obtained.
Of the 113 native tissue samples collected, 39 were blood cultures, in 16 of which pathogenic bacteria
were identified using the RT-PCR panel. Sixty of the total native samples collected were joint fluids
including pus, of which 46 were positive using the RT-PCR panel. Eleven tissue samples and three bone
samples were collected, of which 10 and 1, respectively, were positive using the RT-PCR panel.
Of the 16 blood culture samples that were found to be positive, nine were identified as S. aureus whereas
no K. kingae was detected in this sample type. Other notable results identified in blood cultures were three
positives for Staphylococcus epidermidis, two positive for GAS, one positive for H. influenzae and one for
S. pneumoniae (ply).
Of the 46 positive joint fluid samples that included aspirates and pus, 19 were identified as positive for
S aureus. K. kingae was identified in 10 and GAS in 11 different samples. S. epidermidis and S. pneumoniae
(lytA) were also identified in four and one sample, respectively. In three samples of this type that were
positive for S. epidermidis, another more pathogenic organism was actually identified, and in these cases
S. epidermidis was assumed to be a contaminant.
Of the 11 tissue samples received as part of this study, 10 were positive by RT-PCR, of which eight were
positive for S. aureus with one sample each positive for K. kingae and GAS. Three bone samples were also
received, of which one was positive for S. aureus.
TABLE 58 Total number and patients consented to the study according to geographical site
Geographical site
(site number)
Number of
throat swabs
Number of samples
excluding throat swabs
Total number
of samples
Total number
of patients
Oxford (1) 9 25 34 11
Birmingham (2) 1 4 5 1
Imperial (3) 0 22 22 4
Bristol (4) 11 28 39 12
Liverpool (5) 9 18 27 10
Southampton (6) 8 16 24 12
Total 38 113 151 50
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Overall, excluding any data from skin or throat swabs, 32 of the 44 patients (72.7%) were PCR positive for
one or more of the target organisms included in the RT-PCR panel (see Tables 59–67 for detailed results).
Table 59 shows the number of positive samples detected for each target organism from all of the six sites
for all sample types (including skin and throat swabs), expressed as a percentage of the total sample
number from each location.
Table 60 identifies the number of positives for each PCR target detected based on all sample types across
all geographical sites.
Table 61 shows the number of positive organisms in samples taken from usually sterile sites (excluding skin
and throat swabs) from each geographical site expressed as a percentage of the total number of fluid,
tissue, bone and blood samples collected at each location.
Table 62 shows that a small number of tissue and fluid samples were positive for more than one of the
target organisms in the bone and joint PCR panel.
Table 63 shows the number of positives for each PCR target detected based on blood, tissue and fluid
sample types only across all geographical sites.
TABLE 59 Number of organisms detected by PCR according to geographical site
Site
number (n)
Organism, n (%)
K. k. GAS
S. pn.
(ply)
S. pn.
(lytA) Sal. spp. S. a. S. epi. GBS H. inf.
1 (34) 6 (17.6) 0 (0) 9 (26.4) 1 (2.9) 0 (0) 14 (41.1) 8 (23.0) 1 (2.9) 4 (8.8)
2 (5) 0 (0) 0 (0) 1 (20.0) 0 (0) 0 (0) 3 (60.0) 1 (20.0) 0 (0) 1 (20.0)
3 (22) 0 (0) 11 (50.0) 0 (0.0) 0 (0) 0 (0) 8 (36.3) 1 (4.5) 0 (0) 0 (0)
4 (39) 3 (10.3) 1 (3.44) 6 (20.6) 0 (0) 0 (0) 7 (24.1) 2 (6.8) 0 (0) 4 (13.7)
5 (27) 1 (3.7) 4 (14.1) 8 (29.6) 0 (0) 0 (0) 8 (29.6) 5 (18.5) 0 (0) 2 (7.4)
6 (24) 1 (4.1) 5 (20.8) 7 (29.1) 1 (4.16) 0 (0) 11 (45.8) 4 (16.6) 0 (0) 2 (8.3)
Total (151) 11 (7.2) 21 (13.9) 31 (20.5) 2 (13.2) 0 (0) 51 (33.7) 21 (13.9) 1 (0.6) 13 (8.6)
H. inf., H. influenzae; K. k., K. kingae; S. a., S. aureus; Sal. spp., Salmonella species; S. epi., S. epidermidis; S. pn., S. pneumoniae.
TABLE 60 Number of organisms detected by PCR according to sample type
Sample type
Organism, n
K. k. GAS S. pn. (ply) S. pn. (lytA) Sal. spp. S. a. S. epi. GBS H. inf.
Throat swab 0 6 30 1 0 14 14 1 12
Blood culture 0 2 1 0 0 9 3 0 1
Joint fluid/aspirates/pus 10 11 0 1 0 19 4 0 0
Tissue 1 1 0 0 0 8 0 0 0
Bone 0 0 0 0 0 1 0 0 0
Swabs 0 1 0 0 0 0 0 0 0
Total (n = 151) 11 21 31 2 0 51 21 1 13
H. inf., H. influenzae; K. k., K. kingae; S. a., S. aureus; Sal. spp., Salmonella species; S. epi., S. epidermidis; S. pn., S. pneumoniae.
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Table 64 shows the total number of samples positive for any of the target organisms by sample type; these
data exclude throat swabs and skin/wound swabs.
Table 65 shows the number of positives detected for each of the multiplex targets based on patient
number rather than the actual number of samples from each geographical location (i.e. combining results
from duplicate samples from individual patients). These data exclude throat and skin swabs.
TABLE 61 Number of organisms detected by PCR from usually sterile sites according to geographical site
Site
number (n)
Organism, n (%)
K. k. GAS
S. pn.
(ply)
S. pn.
(lytA) Sal. spp. S. a. S. epi. GBS H. inf.
1 (25) 6 (24.0) 0 (0) 1 (3.8) 0 (0) 0 (0) 9 (36.0) 3 (12.0) 0 (0) 1 (4.0)
2 (4) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (50.0) 0 (0) 0 (0) 0 (0)
3 (22) 0 (0) 11 (50.0) 0 (0) 0 (0) 0 (0) 8 (36.3) 1 (4.5) 0 (0) 0 (0)
4 (28) 3 (10.7) 0 (0) 0 (0) 0 (0) 0 (0) 6 (21.4) 1 (3.5) 0 (0) 0 (0)
5 (18) 1 (5.6) 1 (5.6) 0 (0) 0 (0) 0 (0) 4 (22.2) 1 (5.6) 0 (0) 0 (0)
6 (16) 1 (6.2) 2 (12.5) 0 (0) 1 (6.2) 0 (0) 8 (50.0) 1 (6.2) 0 (0) 0 (0)
Total (113) 11 (9.7) 14 (12.3) 1 (0.8) 1 (0.8) 0 (0) 37 (32.7) 7 (6.1) 0 (0) 1 (0.8)
H. inf., H. influenzae; K. k., K. kingae; S. a., S. aureus; Sal. spp., Salmonella species; S. epi., S. epidermidis; S. pn., S. pneumoniae.
TABLE 62 Patients in which multiple organisms were identified
Patient number Site number Specimen type Organisms identified
1 1 Blood culture S. pn. (ply); S. a.; S. epi.; H. inf.
2 1 Aspirate K. k.; S. epi.
3 4 Tissue S. a.; S. epi.
4 5 Synovial fluid K. k.; S. a.
5 6 Tissue GAS; S. a.
6 3 Pus GAS; S. epi
H. inf., H. influenzae; K. k., K. kingae; S. a., S. aureus; S. epi., S. epidermidis; S. pn., S. pneumoniae.
TABLE 63 Number of organisms detected by PCR from usually sterile sites according to sample type
Sample type
Organism, n
K. k. GAS S. pn. (ply) S. pn. (lytA) Sal. spp. S. a. S. epi. GBS H. inf.
Blood culture 0 2 1 0 0 9 3 0 1
Joint fluid/aspirates/pus 10 11 0 1 0 19 4 0 0
Tissue 1 1 0 0 0 8 0 0 0
Bone 0 0 0 0 0 1 0 0 0
Total 11 14 1 1 0 37 7 0 1
H. inf., H. influenzae; K. k., K. kingae; S. a., S. aureus; Sal. spp., Salmonella species; S. epi., S. epidermidis; S. pn., S. pneumoniae.
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PCR results according to simple and complex cases are summarised in Table 66.
Table 67 shows the number of positive throat swabs for each of the target organisms taken from the six
geographical sites, also expressed as a percentage of the total of throat swabs collected at each location.
TABLE 64 Total number of positive samples according to sample type
Sample type Total number of each sample type
Total PCR positive for any target organism
included in the PCR panel, n (%)
Blood culture 39 16 (41)
Joint fluid/aspirates/pus 60 46 (76)
Tissue 11 10 (91)
Bone 3 1 (33)
Total 113 73 (64.6)
TABLE 65 Number of patients with organisms detected by PCR according to geographical site
Site number
Organism
K. k. GAS S. pn. (ply) S. pn. (lytA) Sal. spp. S. a. S. epi. GBS H. inf.
1 3 0 1 0 0 4 1 0 0
2 0 0 0 0 0 1 0 0 0
3 0 1 0 0 0 1 0 0 0
4 2 0 0 0 0 4 1 0 0
5 1 1 0 0 0 2 1 0 0
6 1 2 0 1 0 4 0 0 0
Total (n = 32) 7 4 1 1 0 16 3 0 0
H. inf., H. influenzae; K. k., K. kingae; S. a., S. aureus; Sal. spp., Salmonella species; S. epi., S. epidermidis; S. pn.,
S. pneumoniae.
TABLE 66 Summary of the results of the PCR
Cases detected
Simple cases (N= 218)a Complex cases (N= 95)b
Tested, n Yes, n (%) Tested, n Yes, n (%)
Samples Cases Samples Cases Samples Cases Samples Cases
At least one micro-
organism detected?
32 24 (75) 12 8 (67)
Blood 31 22 12 (39) 8 (36) 9 8 3 (33) 3 (38)
Synovial fluid 30 20 25 (83) 18 (90) 3 3 3 (100) 3 (100)
Pus 7 2 6 (86) 2 (100) 14 6 12 (86) 4 (67)
Tissue 5 5 5 (100) 5 (100) 5 4 5 (100) 4 (100)
Bone 1 1 1 (100) 1 (100) 0 0 0 0
a 32 (14.7%) samples tested.
b 12 (12.6%) samples tested.
Note
PCR was performed on samples of six patients with no OM/SA (misdiagnosed), which are not shown in the table.
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Discussion
The microbiology substudy has demonstrated the diagnostic yield of the relatively cheap species-specific
RT-PCR compared with routinely used microbiology culture based techniques in children’s bone and joint
infections, achieving a definitive bacterial diagnosis in 32 of 44 patients [24/32 simple cases (75%) and
8/12 complex cases (67%)] in whom the test was used (see Table 66). Although the substudy was not
designed to estimate formal sensitivity and specificity, a positive diagnosis in around 65–70% overall is
higher than the reported yields of 40–50% (where tissue samples are achieved at surgical intervention) or
9–22% (where only blood cultures are achieved).15,27
The study has also demonstrated the feasibility of the test being performed centrally or locally/regionally in
a future randomised clinical trial. The protocol of the easy-to-perform, species-specific PCR panel is such
that routine NHS molecular microbiology laboratories could adopt the test, or it could be performed on
a regional or national basis for UK practice. A future trial could use results from locally or nationally
performed tests depending on availability, as long as results were obtained in NHS/Public Health
England-accredited laboratories performing routine molecular microbiological investigations.
The microbiology substudy has also provided important data on the current UK molecular epidemiology of
children’s bone and joint infections. S. aureus remains the most commonly detected pathogen. Although
pilot data (and anecdotal use of the species-specific panel on an ongoing basis at the Southampton site in
routine clinical practice) suggested that K. kingae is almost as common in young children as S. aureus,
these data also suggest that overall, during the period of this study, GAS (four cases detected by PCR) was
as common cause of OM/SA as K. kingae (seven cases detected by PCR). In this study, GAS was identified
by PCR in children aged between 2.3 and 12.4 years, whereas K. kingae was identified only in children
aged 0.8–2.3 years. GAS caused simple (two cases) and complex (two cases) disease, whereas K. kingae
caused only simple OM or SA. Although numbers are not high, our data confirm previous reports that
K. kingae bone and joint infection primarily affects very young children. As expected, other pathogens
were found more rarely.
The S. aureus data correlate with the existing literature and clinical experience as, historically, S. aureus has
been known to be the most common cause of infection in both native and prosthetic bone and joint
infections.69 Thirty-seven native tissue samples from 16 patients (11 simple disease, five complex disease;
age range 2.5–15.9 years, median 11.4 years) were positive for S. aureus using PCR, including eight tissue
samples, nine blood cultures, one bone sample, one wound swab and 19 fluid samples (this includes joint
TABLE 67 Number of organisms detected by PCR from a throat swab according to geographical site
Site
number (n)
Organism, n (%)
K. k. GAS
S. pn.
(ply)
S. pn.
(lytA) Sal. spp. S. a. S. epi. GBS H. inf.
1 (9) 0 (0.0) 0 (0) 8 (88.8) 1 (11.1) 0 (0) 5 (55.5) 5 (55.5) 1 (11.1) 3 (33.3)
2 (1) 0 (0) 0 (0) 1 (100) 0 (0) 0 (0) 1 (100) 1 (100) 0 (0) 1 (100)
3 (0) 0 (0) 0 (0) 0 (0.0) 0 (0) 0 (0) 0 (0.0) 0 (0.0) 0 (0) 0 (0)
4 (11) 0 (0) 0 (0) 5 (45.4) 0 (0) 0 (0) 1 (9.0) 1 (9.0) 0 (0) 4 (36.3)
5 (9) 0 (0) 3 (33.3) 8 (88.8) 0 (0) 0 (0) 4 (44.4) 4 (44.4) 0 (0) 2 (22.2)
6 (8) 0 (0) 3 (37.5) 8 (100) 0 (0.0) 0 (0) 3 (37.5) 3 (37.5) 0 (0) 2 (25.0)
Total (38) 0 (0.0) 6 (15.7) 30 (78.9) 1 (2.63) 0 (0.0) 14 (36.8) 14 (36.8) 1 (2.6) 12 (31.5)
H. inf., H. influenzae; K. k., K. kingae; S. a., S. aureus; Sal. spp., Salmonella species; S. epi., S. epidermidis; S. pn.,
S. pneumoniae.
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fluids, pus and aspirates). S. aureus is a known coloniser of the upper respiratory tract, so to identify it in
throat swabs is not uncommon. One patient (site 1) had significant levels of S. aureus in eight out of
nine samples that had been taken, including pus and blood culture samples. Another patient (site 4) had
high levels of S. aureus in both blood culture and pus, whereas in another (site 5) S. aureus was identified
in three out of six samples tested.
A total of 11 samples taken from seven patients (all simple disease, age range 0.8 months to 2.3 years,
median 1.15 years) were positive for K. kingae. These included 10 samples of joint fluids and aspirates and
one other tissue sample. Although one group in Israel has reported that culture of tissue in blood culture
bottle systems can increase the culture yield of this fastidious organism,17 this study has demonstrated
again that species-specific PCR on routine blood culture samples or directly on tissue samples can formally
diagnose K. kingae.19
Four children (two with simple disease and two with complex disease; age range 2.3–12.4 years, median
6.7 years) had OM/SA caused by GAS detected by PCR from a total of 14 native tissue samples. Eleven
samples were fluids including pus, two were blood cultures and one was tissue. Although a higher
frequency than previously reported,1 this study was conducted during the time of a reported outbreak of
GAS infections nationwide in the UK.70
Two patients (ages 5.2 years and 0.8 months) were found to have OM/SA due to S. pneumoniae. One
blood culture sample from one patient was positive for the ply gene of S. pneumoniae. One other
joint sample from a different patient was positive for the more specific target for the lytA gene. The
species-specific panel uses two targets to identify the presence of S. pneumoniae (the ply gene and the
lytA gene). This is because the ply gene shows a degree of cross-reactivity between S. pneumoniae and
S. mitis, S. oralis and S. pseudopneumoniae. The lytA target was chosen71 as it is common only in
S. pneumoniae.
Haemophilus influenzae was identified in one blood culture from one patient aged 5.2 years but not from
any PCR test. As expected, this was an unusual organism but potentially an important factor in the
potential antibiotic choice in the ≥ 5 years age group1 in a future RCT.
No native tissue samples in this study were positive for GBS, included in the panel because of their
frequency in neonatal OM/SA.1 As no children aged ≤ 2 months were included in this microbiology
substudy, this finding is not unexpected as GBS infections are rare in older infants and children.
No samples were found to be positive for Salmonella spp., an organism included in the PCR panel because
of the reported frequency in OM/SA in children with sickle cell anaemia.72
Staphylococcus epidermidis is generally considered a contaminant in skin and surface swabs, and in
OM/SA infections overall in the absence of prosthetic material.73 However, in the absence of other
pathogens detected from usually sterile sites, and when S. epidermidis is detected in samples from those
previously sterile sites, the role of this organism in the pathophysiology of bone and joint infections is
undergoing more detailed investigation. In this study three blood cultures and four fluid samples were
positive for S. epidermidis. One patient positive for this organism was also positive for GAS in 12 different
samples, whereas another patient was positive for S. aureus but at low levels. Our data concur with the
overall concept that in children without prosthetic joints or artificial implants of any kind, S. epidermidis is
an unlikely pathogenic cause of SA/OM even when detected in sterile samples.
Our study also investigated K. kingae and other pathogens detected by PCR in throat (oropharyngeal)
swabs74 to further investigate the relationship between OM/SA and respiratory tract carriage reported by a
French group during the conduct of this study.75 Thirty-eight throat swabs were received in total, among
which K. kingae was identified in none. Thirty swabs were positive for S.pneumoniae (ply), of which only
one was positive for the lytA gene, indicating that in 29 throat swabs the RT-PCR was detecting S. mitis,
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S. oralis or S. pseudopneumoniae as a result of ply gene cross-reactivity. Fourteen swabs were positive for
S. aureus, 14 were positive for S. epidermidis, 12 were positive for H. influenzae, six were positive for GAS
and one was positive for GBS.
The ability to perform species-specific RT-PCR in a local laboratory setting can benefit both patient and
health-care system. By enabling antibiotic therapy targeted to a known organism, the switch from i.v. to
oral therapy is facilitated, resulting in a shorter hospital stay. Although this study was not big enough for
us to conduct a formal health-economic analysis, it is intuitive that being able to use directed therapy will
result in shorter hospital stays as a result of earlier oral switch, as well as a reduction in treatment failure,
cost, time and use of unnecessary antibiotics, and minimising the risk of antimicrobial resistance and
nosocomial infections (the acquisition of which is proportional to length of stay, among other things).
Rapid identification of a bacterial organism causing OAI is important for a number of reasons. The use of
conventional culture and microscopy can take a minimum of 48 hours, of which 24 hours is needed to
establish organism growth (providing that it is a non-fastidious species) and 24 hours for identification and
sensitivity profiling in order to correctly target antibiotic therapy. This process can be speeded up slightly
by the use of matrix-assisted laser desorption/ionisation time of flight spectrometry, which can identify
bacteria to a species level, providing that a pure culture can be grown initially.76 The use of species-specific
RT-PCR on bone and joint samples can speed up the identification process to a matter of hours.77
Conclusions
This study evaluated the potential for the species-specific RT-PCR to be used both to establish the baseline
UK microbiology of paediatric bone and joint infections better than would have been obtained by culture
alone and to assess the use of the test in a larger RCT. We have established that the test identifies a
pathogenic organism more frequently than conventional culture methods alone. The multiplex assay used
has provided additional information on the UK molecular epidemiology of OM/SA in children in addition
to the conventional culture results collected as part of the service evaluation (see Chapter 2). The test is
feasible to use in a larger RCT and would be cheap and useful to implement in local microbiology
laboratories for routine clinical care in the UK.
Data gained in the service evaluation and PCR substudy showed that the predominant pathogens in
bone and joint infections in children in the UK are antibiotic-sensitive S. aureus in simple and complex
disease in children of all ages outside the neonatal period; K. kingae in simple disease in young children
(aged < 4 years in this study but < 6 years if currently unpublished data collected outside the time frame
of the service evaluation and substudy is included); and GAS in simple and complex disease in children of
all ages.
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Chapter 4 Qualitative interviews with families and
children treated for bone and joint infections
Background
There has been little previous qualitative research exploring the views of previously healthy children, or
their parents, about treatment for, or the impact of, acute bone and joint infections on family life during
and after admission to hospital with infection. Patient and parent perceptions and understanding of risks
of complications, disability or adverse effects of treatment have also been previously underexplored.
In exploring the feasibility of a future RCT to identify the optimum point of switch from i.v. to oral
antibiotics in the treatment of OM or SA, it is critical that the views of affected children and their parents
are included in the data used to inform decision-making. We were also interested in understanding what
information might help children and parents to make an informed decision about participating in such
a trial, and in understanding what both children and parents view as important and meaningful outcomes
that indicate that treatment has been successful. These data could potentially help to optimise meaning,
acceptability and recruitment within a future RCT.
Aims
The overall purpose of the interviews was to explore parents’ and children’s views, understanding and
experiences of both bone and joint infections and treatment, and willingness to participate in a future
RCT. Our aims were:
1. to explore the experiences of parents and children treated with i.v. and/or oral antibiotic therapy for
bone and joint infection about their condition and understanding about treatment
2. to identify which clinical outcomes are most important to parents and young people with bone and
joint infections, in order to contribute to the wider stakeholder Delphi and stakeholder consultation
process
3. to explore the views of parents and children admitted to hospital with bone and joint infections about
participating in a RCT, in particular focusing on:
¢ information required in order to provide informed consent
¢ views about and acceptability of potential interventions
¢ willingness to be randomised to either arm (i.e. treatment or control)
¢ influences on the above factors.
Methods
Research approach
In line with the service evaluation and Delphi study included as part of the overall feasibility work, this
qualitative study acknowledged the external reality of the experiences of both parent and child
participants, drawing on a realist research tradition. However, in line with a critical or subtle realist research
position,78 we argue that in recounting these experiences accounts will be mediated by subjective views
and perspectives of those being interviewed.79 This subtle realist approach has a number of implications for
the conduct of this qualitative research, which we have identified and addressed in Table 68.
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Semistructured interviews
Semistructured interviews were employed to explore the views and experiences of parents and children
treated for bone and joint infections within the previous year. Semistructured interviews are
characterised by:
l an interactional exchange
l a topic-centred dialogue, but with a flexible structure
l an acknowledgement that, within an interview context, meaning and knowledge are co-produced.80
As recommended by Mason,81 the interview guides for parents and children were developed with
reference to existing literature (e.g. qualitative work in this field, factors impacting on participation in RCTs,
qualitative research interviews with children), researchers with expertise in this subject area and in working
with children, and in consultation with our PPI contributors.
Interviews took the form of a conversation in which respondents initially told the story of their child’s
(or their own) experience of bone and joint infection. Throughout the narrative, respondents were
encouraged to describe both the events happening and the feelings and responses associated with them.
Interviews covered a number of topics, with prompt materials used at various points as described in the
following sections.
Experiences of becoming ill and diagnosis
l Experiences of becoming ill with bone and joint infection, symptoms experienced.
l Experiences of seeking treatment and diagnosis.
l Treatments/interventions given, both in hospital and at home, including i.v. and oral antibiotic
(antibiotic) therapy.
l Experience of both i.v. and oral antibiotics.
l Emotional responses to events happening.
TABLE 68 Implications of subtle realist approach for the conduct of this qualitative research
Implication Strategy
Interview guides are designed not to uncover objective
facts, but to explore subjective reflections of events
Open questions are designed to orientate to the
interviewees’ agendas, allowing them space to explore and
describe subjective impressions associated with experiences
When possible, children were interviewed in addition to
parents, acknowledging the potential for different perspectives
The researcher’s role in making sense of and interpreting
interview accounts is acknowledged
Field notes and a research diary were kept to promote
reflection by the researcher about how she made sense of
the data
These reflections were further surfaced during supervision
with the senior researcher. Interpretation is partial,
acknowledging the potential for multiple readings
The proposed quality criteria against which it is suggested
that this research should be evaluated acknowledge the
subjective and co-constructed nature of the findings
(see Rigour)
The researcher kept reflective notes to highlight her own
role in interpretation
Interviewees were offered the opportunity to revisit the
synthesised findings and to comment if they felt that their
own views/experiences were insufficiently represented
The junior and senior qualitative researchers carried out
independent analysis of a transcript to facilitate discussion
about how meaning was created from the interviews
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A ‘timeline’ was used during the early section of the interview. The timeline consisted of three parallel,
horizontal lines. The top horizontal line was labelled ‘becoming ill’, the second ‘hospital’ and the lowest
‘at home/getting better’. As respondents talked about their experiences, the researcher scribed key points/
events on to the timeline in relevant places, with depiction of frequency, duration etc. Initially we had
intended that respondents should scribe the timelines themselves as they spoke. However, during early
pilot interviews it became apparent that this was distracting for respondents and interrupted the flow of
their narratives. On the other hand, once the researcher began scribing, the timeline became a useful
visual depiction of events. It also served as a reference point at later points during the interview.
Participants’ understandings and perceptions about aspects of antibiotic therapy
l Perceptions about clinical reasons, advantages and disadvantages of both forms of antibiotic therapy
(i.v. and oral).
l Perceptions about length of treatment arms (i.v. and oral) and about point of switch from i.v. to oral.
Perspectives about the success of the treatment overall and important outcomes of recovery
l Signs that indicated child was getting better.
l Judgement of overall success of treatment and factors important when assessing level of success.
Views about participation in a hypothetical future randomised controlled trial
(Prompt material: RCT process diagram and information – see Report supplementary material 5.)
l Initial reactions.
l Information required (content and delivery) to assist decision-making.
l Feelings about being randomised.
l Views on alternative treatment arms.
l Level of willingness to participate and why.
The prompt material describing the trial was altered during the course of fieldwork to reflect the finding
that most patients were now receiving shorter courses of i.v. antibiotics rather than the traditional
‘standard’, and that the switch was being determined by a blood test. Initially, the adult prompt
description of the trial showed the following process diagram (Figure 3).
This was replaced by Figure 4 to show that the difference between trial arms would relate to length of
overall antibiotic treatment and that the point of switch would be guided by blood tests.
Because of the broad age span of children involved, three age-appropriate versions of interview guides and
prompt material were developed:
1. Young children up to the age of 7 years – this interview guide (see Report supplementary material 5)
consisted of simple questions about children’s experiences and understandings, involving the use of a
doctor glove puppet and a dinosaur toy. Because of the complex issues involved, this interview guide
did not include a section on the proposed RCT. As detailed in Findings, however, no children in this age
group took part in interviews. This was primarily because parents did not wish to involve younger
children in talking about an event that had often been upsetting and traumatic for them.
2. Children aged 8–12 years – this interview guide (see Report supplementary material 5) involved
simplified language, but did cover all topics identified above, including seeking views about proposed
trial (‘test’).
3. Young people aged ≥ 13 years and adults – the same guide (see Report supplementary material 5) was
used for both young people and adults.
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Participants
A purposive sample of children aged 0–16 years was identified from four of the seven centres in the south
of England that had participated in the main Dinosaur service evaluation and microbiology substudy: Bristol
Children’s Hospital, Oxford Children’s Hospital (University Hospitals Oxford NHS Trust), University Hospital
Southampton NHS Foundation Trust and St George’s Hospital London. The purposive sampling strategy
addressed variation with regard to age, sex and ethnicity.
1. Information and
explanation given
about the clinical trial
2. Decision about
whether or not to 
take part in trial 
made by family/child
3. Random allocation to one of the following
treatments done by a computer
(that holds no information about the child)
Treatment A
(indicative ‘standard’ 
treatment):
2 – 4 weeks i.v. antibiotics 
followed by 2 – 3 weeks 
oral antibiotics
Treatment B
(indicative ‘test’ 
treatment):
1 – 2 weeks i.v. antibiotics 
followed by 4 – 6 weeks 
oral antibiotics
Time to think, ask questions
Yes
No
Standard care for
hospital
Start
Finish
FIGURE 3 Initial process diagram.
1. Information and
explanation given
about the clinical trial
2. Decision about
whether or not to 
take part in trial 
made by family/child
3. Random allocation to one of the following
treatments done by a computer
(that holds no information about the child)
Time to think, ask questions
Yes
No
Standard care for
hospital
Start
Finish
1.  i.v. antibiotics (length of course
     determined by blood test)
2.  Oral antibiotics
Total treatment time: 14 – 27 days
Treatment B
(indicative ‘test’ treatment)
1.  i.v. antibiotics (length of course
     determined by blood test)
2.  Oral antibiotics
Total treatment time: 28 – 42 days
Treatment A
(indicative ‘standard’ treatment)
FIGURE 4 Amended process diagram.
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The inclusion criteria identified were:
l parents and children aged from 3 months to 16 years, treated for OM and/or SA
l children who had been treated for bone and joint infections at one of the seven sites participating in
the main service evaluation and microbiology substudy
l parents/children who had taken part in the main Dinosaur study and also consented to take part in this
qualitative study.
Procedure
At the point of initial consent for participation in the larger study, participants (i.e. children and their
families) were asked if they would be willing to be contacted later about possible participation in a smaller
qualitative study. Only families who had already participated in the larger study, and who had expressed
willingness to be recontacted, were invited to participate in the interviews.
Once ethical and site-specific approvals were received, the qualitative researcher made contact with each
site to arrange the procedure to be followed to contact potential respondents. In one site, a member of
nursing staff at the hospital telephoned pre-consented families to check that they were still happy to
be contacted by the qualitative researcher. The qualitative researcher then contacted those agreeing, by
telephone.
In the remaining three sites, the qualitative researcher made the initial contact with families by telephone.
During this initial telephone call the qualitative researcher described the interview process to families and
asked if they would be interested in taking part. Provisional appointments were made, and a letter
confirming arrangements was sent, with a participant information sheet, by e-mail or post. Contact details
of the researcher were included in case families needed to change or cancel the appointment, or if they
had any subsequent questions. The researcher also telephoned respondents on the day of (or the day
before) the agreed appointment to check that it was still convenient for the family. If not, the appointment
was rescheduled or, on one occasion, cancelled. Signed consent was provided by families interviewed in
person just prior to the interview, and those interviewed by telephone were asked to sign and return the
consent forms by post.
Ethics
Ethics approval for the qualitative interviews with parents and children was obtained from the National
Research Ethics Committee (NRES Committee Yorkshire & The Humber – Leeds West, reference 14/YH/1166).
All parents gave informed written consent to their participation and the use of quotations from their
interviews for dissemination purposes. Assent was obtained from children. Because of the age of the
children involved and the fact that families were being asked to talk about experiences that had been
difficult and upsetting, the interview format and appointment times were kept flexible according to the
needs and wishes of individual families and children. Parents of children who were aged ≤ 7 years were,
in general, not willing to involve their children directly in interviews revisiting experiences that they had
found upsetting or traumatic. These parents therefore opted to take part in an interview while their child
was at school. Very young children (babies or toddlers) were often present in the room, although too
young to be directly involved with answering questions.
Older children were more likely to be involved, and interview appointments were therefore arranged for
times when they would be at home. Children chose whether they wished to be interviewed along with
their parents or separately. Eight children were interviewed along with (in seven cases) or separately from
(one case) their parents, according to the preferences of the child and their family. Children could
participate in interviews as they wished – for example, one child joined in answering questions early in the
interview but then drew her own (separate) timeline later as she became tired. A range of family members
contributed to interviews including mothers, fathers, child treated, siblings and (on one occasion)
grandparents.
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Analysis
Interviews mainly took place at the respondents’ homes between January and March 2015. Three interviews
were conducted over the telephone because of issues of location and availability. The interviews were
digitally recorded, with permission from the families and children. The recordings were transcribed by a
professional transcribing agency and returned to the qualitative researcher for analysis.
Thematic analysis82 was employed in this study. Thematic analysis is a method for identifying, analysing
and reporting patterns (themes) across a data set. The following stages were followed:
1. familiarisation with the data
2. generating initial codes
3. searching for themes
4. reviewing themes
5. defining and naming themes
6. producing the report.
Data were stored and managed through the use of NVivo 10 (QSR International, Warrington, UK). Using this
software package, transcripts were read in detail and coded, with codes being renamed, regrouped, merged or
disregarded as issues emerged and re-emerged in subsequent transcripts. The coding frame was increasingly
refined, discussed among members of the research team, and used as a basis for analysis and writing. Coding
was both deductive (themes identified in interview guide/research questions were looked for within the text)
and inductive (codes that have not been pre-conceived were allowed to ‘emerge’ from within the data).
Rigour
Based on guidelines for producing good-quality qualitative research, we employed the following strategies:
l Reflexive notes were made during data collection by AL, in which she recorded contextual information
and emerging ideas relating to analysis.
l Data were sought from a diverse group of respondents in terms of factors thought to be pertinent to
experiences of SA or OM (e.g. age of child, infection, location of treatment, ethnicity, sex).
l CB and AL conducted some ‘double’ coding of transcripts initially; the broader research team (with a
variety of experience and expertise) were also involved in discussions about analysis and coding.
l Member checking – a summary of the study’s findings was circulated to all participants, who were
contacted to seek their views about the study, to ask if findings ‘rang true’ and if there was anything
they would like to add.
l We invited all interview participants to attend a stakeholder day at which findings from the qualitative
study were presented to the wider clinical team involved in the service evaluation and Delphi study.
Findings
Demographic data
Twenty-six families were recruited to the study. Families recruited represented children ranging in age from
0 to 16 years at the time of treatment. Seventeen children were male and nine were female. The majority
of families were white British, with two families being European, one Pakistani and one Chinese/Caucasian.
In terms of specific condition treated, 11 were treated for OM, 11 for SA and four children had both SA
and OM. The parent of one of these four OM/SA children reported that the infection had been caused by
GAS and the parent of another reported the cause as PVL-positive S. aureus. Children had been treated in
Southampton (n = 11), Bristol (n = 4), Oxford (n = 9) or London (n = 2).
Themes
The key themes that emerged from the data are discussed below. After each theme a short discussion of
its implications for the feasibility of a future trial, and more broadly, is presented.
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Theme 1: experiences of diagnosis and seeking treatment
One of the most striking issues to emerge during the course of interviews was the length of time reported
to have elapsed between children first presenting with symptoms and a diagnosis being given/treatment
starting. Although this information was not explicitly sought as part of the interview guide, this point was
repeatedly mentioned by interviewees. It also appears to have some relevance to parents’ subsequent
thinking about the design of the potential RCT (discussed further in Theme 4: views on proposed
randomised controlled trial).
Respondents often described a process of to-ing and fro-ing between GPs and A&E (or equivalent
departments) at local hospitals over a period of days or weeks before a diagnosis was made. In a number
of cases, children were admitted to local hospitals for investigations during the pre-diagnosis period.
Children presenting at GP surgeries were often referred immediately to a local hospital, but once their
symptoms could be attributed to a range of factors other than bone or joint infection (such as injury,
irritable hip, synovitis or Erb’s palsy). This period of delay in diagnosis, at a time when parents were
convinced that there was something more serious wrong with their child, was described as frustrating and
anxiety provoking:
I took him to the GP the following day and he was just complaining of a pain in his knee. Basically for
the next 2 weeks we kept going backwards and forwards to the GP. I was told to take him to hospital
to get his knee X-rayed, which they did, and that all came back fine and I was told he had some soft
tissue damage. I felt that there was something wrong with him. I was very worried, but then I suppose
I was beginning to think am I just being neurotic because five different doctors have told me that he’s
fine, so are we just being neurotic?
Mother, patient 365
A number of families also spoke of how much their child deteriorated during this period:
We didn’t go to his GP, we bypassed it to (local) hospital . . . They said, ‘Look, the best thing is come
back in a day or so, come back and we’ll put his leg in plaster. It may improve in that period of time’.
So we go, no painkillers, no anything. We then went for this other appointment and they turned
around and said, ‘Look, we’ve made an appointment with a bone specialist’. So we go to the bone
specialist, this appointment, which was another week or so on again. In the process, he turned around
and said, ‘We can’t really find any particular damage or crack or anything’, this is what this bone
specialist said. He said, ‘Give it another week, then come back’. Within that last week he then was in
dire straits with pain. He was in terrible pain . . . he’s to the point he’s literally got his head on my
shoulder, he can’t go on any longer. We’re in the waiting room, he was literally slumped over me and
I’ve got him in my arms.
Grandfather, patient 349
Issues including an apparent lack of pain, absence of fever, referred pain and pursuing alternative diagnoses
were all highlighted as factors contributing to delay in diagnosis. Rarity of OM/SA was seen also seen as
contributing to a slower diagnosis, as was the lack of experience of a number of health professionals, in
particular within A&E departments where staff may be more junior.
Consultants with relevant expertise (or other professionals recognising symptoms, wherever they were
located in the system) were praised for their expert knowledge. Contact with these experts after a period
of delay in which parents felt untrusting of advice they were given was experienced as very reassuring and,
at times, even life-saving:
If it hadn’t have been for him I think we were in big trouble. I’ll tell you that now. What his name was,
who he was, I don’t know but if I could shake his hand I would do because he was the one who got it
under way. He knew there was something . . . wrong with [name of child], it was him who done it . . .
DOI: 10.3310/hta21480 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 48
© Queen’s Printer and Controller of HMSO 2017. This work was produced by de Graaf et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
81
Being fair with you, when we went for the X-ray, they didn’t come up with the right answers so
weeks and weeks were going past. That was the problem but he sussed it. He knew straightaway. He
said, ‘And what sort of pain?’ and that was it, he’d already come to me, he said, ‘I’m not happy with
this at all’, then it kicked off. Thank heavens it was for him . . . I don’t know where we’d be today if
they hadn’t have got behind it and that fellow. If it had been left another few days I don’t think we’d
have had [name of child] back here, that’s how bad it was.
Grandfather, patient 349
For these families, experience of treatment was often described as being in two halves: an unsatisfactory
experience up to diagnosis, characterised by period of delay and frustration, followed by the treatment
period with antibiotic and operation as necessary, often perceived by parents to be much more successful,
in the hands of trusted experts.
A smaller number of families, however, did report positive experiences of diagnosis and swift
commencement to treatment. In these cases, alignment of expert professionals occurred such that referral
between different treatment locations went smoothly and symptoms were recognised without delay.
Positive experiences at the start of the illness offered a number of benefits for families:
l Early experience of treatment/seeking diagnosis was less anxiety provoking and frustrating overall.
l Families felt that their concerns were being listened to and acted on.
l The child’s condition was less likely to deteriorate because of early commencement of treatment.
l Overall experience was less negatively impactful, with potential ramifications for thinking about
potential clinical trial.
Respondents recognised that a number of factors about the condition itself could confound an early
diagnosis (e.g. symptoms like that of an injury, absence of temperature or visible swelling/red patch on
skin). However, it did often appear that the level of awareness and expertise of the professional with
whom they came into contact directly affected how quickly symptoms were recognised to indicate bone or
joint infections. This was evidenced by a number of instances in which children with unchanged symptoms
were quickly diagnosed when a second opinion was sought from a practitioner with more experience in
this field. Such experiences suggest that increased awareness among health professionals, in general, of
the possibility of bone/joint infection may enhance trajectories of care:
I understood all of that but I guess after 2 weeks when it wasn’t better I just wonder whether there
are better guidelines that GPs or A&E practitioners could have in terms of – there must be decision
trees and it could have been irritable hip but it’s not getting better as quickly as it should have done
with irritable hip, so what other things could it be? Instead of being fixated on irritable hip and
carrying on X-raying my daughter’s hip and not her knee, what else could we look for and check for?
She had a slightly hot knee and she had one knee slightly bigger than the other and I could see it and
the private consultant could see it but nobody in A&E or the GP could really see it.
Mother, patient 281
Theme 2: experiences and understanding of antibiotic therapy
This theme reflects the experiences, knowledge and views of parents and children about both i.v. and oral
antibiotic treatment. All participants understood the need for the use of i.v. antibiotics and identified the
positive benefits of making them/their child better in the fastest, most effective, way possible:
It seemed to be really, really important that the antibiotics were administered in that way and the
explanation I was given seemed to make sense to me as somebody without any medical knowledge at
all. I understood that it was really important that the antibiotics really got to where they needed to go
as quickly as possible and that time was really important at this stage and that that was the best way
of treating. So, I was totally in favour of having that treatment, if they’d said, ‘Look, let’s not bother
with the cannula, let’s just go to oral’, having had that explanation before, I would’ve been really
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uneasy with that. I wanted him to have the i.v. treatment . . . I just felt that it would just get rid of the
bug that was making him ill and get rid of it as quickly as possible and make him better and also to
reduce the possibility of long-term complications and any damage to the joint.
Mother, patient 204
Most participants understood i.v. antibiotics to be an intensive, strong form of treatment that, because
injected straight into the bloodstream, would reach the site of infection in the shortest possible time.
As alluded to in the quotation below, a smaller number of respondents also pointed out the benefit of
the guaranteed delivery of antibiotic:
Mother: I mean it was horrible just to get the cannula for the whole week, but also it was reassuring
to know that he was getting all the antibiotic because you never know. Sometimes when he was in
there with the oral one sometimes he spit a little bit so you were worried, you’re not allowed to waste
any of this because it might be really necessary for you.
Father: Yes, that’s true. The most reassuring thing is that you know that everything that should go in,
the treatment, is going in.
Mother: Everything was going through.
Parents, patient 178
Notwithstanding the perceived need for i.v. antibiotic treatment, a number of negative experiences related
to the i.v. delivery was reported. Of particular significance was pain associated with insertion of the
cannula, which was often described as a difficult and stressful process. Parents used emotive language
to convey the distress this caused their children, and therefore also to them, using descriptors such as
‘traumatic’, ‘grim’, ‘horrible’ and even ‘barbaric’:
[T]hey could not cannulate him, it was just this horrific scenario of two or three doctors in the room
with me trying to hold this baby who’d been through so, he was only 13 months at the time, he’d
been through so much I felt. He was just being prodded and poked and he was, as you would, trying
to wriggle away and I was trying to hold him down so they could do this and it just felt really, really
wrong and horrible, because I was the person that he trusted and that I was helping this to happen
and he didn’t understand. I knew that it was being done for the right reasons, but it just, from his
point of view, I could just feel this must be awful for him that the people he trusts are basically
contributing to making this really, really traumatic situation. So, it still makes me emotional, as you can
see, talking about it.
Mother, patient 204
There was a suggestion by some parents that health professionals did not always show sufficient empathy
of the level of distress children and parents were experiencing at this time. Other negative experiences
reported were allergic reactions to antibiotics administered intravenously (resulting in rashes and abdominal
pains), pain when the drug was being administered and need to re-insert the cannula (or replace with PICC
line) if it was pulled out or veins collapsed. A number of children also expressed their discomfort at the
administration of i.v. antibiotics:
. . . it felt like something biting me with only one tooth.
Patient 233
Yes, which I didn’t like it. It really hurt.
Patient 276
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It is also important to note that not all patients experienced distress at the administration of i.v. antibiotics.
He was amazing with it really. I don’t know if it was his age, he just didn’t let it bother him too much.
Mother, patient 285
In particular, parents spoke highly of the skill of community nurses who came to administer i.v. antibiotics
in the child’s home in putting children at ease and making delivery of antibiotics as easy as possible.
In contrast, parents often described oral antibiotics as a less intensive treatment, used to finish off the
course, more as a backup or precaution than a first-line treatment. Oral antibiotics were also perceived as
a more convenient way of taking medicine that fitted better with the family’s routine and enabled the
child to be at home. Often parents reported that their child took the medicine with no problems. For
others, though, administering oral antibiotics to children who really disliked the taste was challenging and
in a number of cases resulted in tummy upsets and sickness. One child completely refused oral antibiotics,
resulting in a longer course of i.v. antibiotics. Two parents reported that their children’s teeth had suffered
brown staining from the use of oral antibiotics.
The patient quoted below made her distaste for the medicine clear:
Patient: It was cream and [makes a disgusted-sounding noise]. Oh, I don’t even know, it just smelt
gross . . . and then when mum had to mix it up a few days later there was loads of bits in it, and I was
like [makes a disgusted-sounding noise], ‘I’m not drinking that’, but I had to . . . So I literally went
[demonstrates swallowing fast].
Interviewer: Did you have to have some chocolate or something afterwards?
Patient: No, just water [makes a disgusted-sounding noise].
In line with this, a small number of parents (and children) expressed that they would prefer a longer course
of i.v. treatment rather than a combined course including oral antibiotics. Despite the reported challenges,
parents and children persevered with the oral course of treatment, coming off these medicines only when
the course was finished, or on specific medical advice.
Participants were specifically asked about their views about the point during treatment when children were
‘switched’ from i.v. to oral antibiotics. Respondents were in general happy about the timing of the switch,
feeling that their child had made sufficient progress by this time. Often this was perceived to have been
guided by the results of blood tests and respondents were happy to follow the doctors’ lead as to the
timing of the switch.
Respondents also indicated that they felt that the medical team had listened to their own particular
concerns regarding a desire to leave hospital and try oral antibiotics:
He wanted to come home, I mean we’d been in there that long but they were still . . . They were a bit,
like, whether to let him home but as long as he took the antibiotics orally but if anything happened
we were to go straight back. Well there was a specialist from [another hospital], a lady specialist . . .
She said, ‘that’s where I am. If there’s any indication you’re not happy, either bring him or ring me
and then we’ll get things under way, we’ll bring him back in’. She was just like, ‘Ring our line
straightaway and one of us will be here waiting for you’. They were brilliant, they were really good.
Grandfather and mother, patient 349
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In a small number of cases the parents had experienced some anxiety that their children were being
switched to oral antibiotics too early:
My only concern was that we’d been told that you normally treat the osteo, they do three weeks of
i.v. antibiotics and I suppose I was probably over-thinking it. I was thinking that, although he’s had
3-and-a-half weeks, he had 1 week of an antibiotic that effectively didn’t do anything because it
wasn’t for the right bacteria, so in terms of the right antibiotic he’d only had that for 2 weeks 4 days I
think so I felt a little bit concerned about that and I asked about that and was just told that you don’t
know for sure what exactly is the right number of days. Is it 2 weeks or is it 3 weeks? I think based on
his progress and bloods and X-rays they decided that that was all right, so I did feel slightly anxious
about that.
Mother, patient 365
In two cases, parents expressed concerns that their children had not been ready to leave hospital, resulting
in them being re-admitted at a later stage.
Theme 3: signs and outcomes of recovery
This theme reflects participants’ views about factors, such as activity levels, that indicated to them
personally that children were recovering from OM/SA, and also their longer-term evaluation of treatment.
Parents were asked how they first recognised that their children were getting better. In order of frequency,
comments were made in relation to resumption of movement/walking/weight bearing, being ‘better in
themselves’ and improved appetite (with associated weight gain in some cases). In terms of speed of
recovery, responses were varied, with a number of parents commenting that their children seemed to
‘bounce back’ very quickly, but others reflecting that recovery was a slow and gradual process.
When asked which outcomes were important to them in judging the success of the treatment, the
following were offered: no ill effects on bone/joint/growth, activity levels resumed, infection gone and no
recurrence of infection. In the majority of cases parents reported that there were no long-term impacts of
the condition:
Yes, successful, because then we had a follow-up appointment at the end of February of that year
where he had an X-ray and a consultation with the orthopaedic consultant and she was really happy
with how it looked and then we had another follow-up in the August, so 6 months later where they
said, ‘This is totally fine, there’s been absolutely no impact on the growth or anything. Please just
forget about it. Don’t worry about it’.
Parent, patient 204
There were a small number of exceptions to this. The parents of one child who was newborn at the time
of infection reported that the infection had affected her growth plate, but that the impacts of this were as
yet unknown.
Mother: They say it has definitely affected the growing.
Father: And then it will just catch up or it won’t catch up they said . . . They said that the top of her
humerus isn’t as visible as it should be.
Mother: Yes, so it was definite that the infection has affected it.
Mother and father, patient 343
In another instance, doctors had been unable to resolve the infection despite repeated courses of
antibiotics and the child continued to experience painful symptoms, with ongoing visits to the hospital to
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try to resolve the situation. This appeared to be due to a longstanding infection present since an earlier
abscess. The longevity of the condition was upsetting and wearing for the child and her family:
One of the doctors, the surgeons, she said maybe she will need more surgery, because the infection
hasn’t gone yet, it’s still there, because it went chronic. It was there for a long time . . . they’re not
sure if it was something to do with the first operation when they took the abscess out and they left
the wound open, just to heal from inside out. So they don’t know if it was from there or not . . . She
keeps on complaining. Every day she takes tablets for the pain. Every day. Yes, she has temperatures,
she has night sweats every day. She can’t sleep when she’s in pain. She has to wake up 6 o’clock in
the morning to go to school and she feels really tired and it’s hard sometimes when she comes,
‘Mummy, I’m so tired, can I stay at home?’.
Mother, patient 202
Two other children, although recovered from their bone or joint infections, had ongoing bone problems
and therefore continued to experience discomfort and undergo further medical treatment and potentially
further operations.
Despite physical recovery of their children, a number of parents continued to experience a level of anxiety
and heightened vigilance with regards to the possibility of a re-emergence of the condition. Parents often
described the whole episode of their child being unwell as highly anxiety provoking and distressing:
We have had one bit where we got a bit scared thinking perhaps was he getting it again, but it didn’t.
So I guess what I’m trying to say is we’re very aware of it.
Father, patient 250
He didn’t have any significant cuts that had obviously been infected, so if it was through a cut it was
one small one that I hadn’t really noticed. I’ve now got a little thing of Dettol spray [Reckitt Benckiser,
Slough UK], so I drive him mad by every time he gets a little scratch I’m chasing him round spraying
this stuff on him to clean him.
Mother, patient 365
Theme 4: views on proposed randomised controlled trial
In response to the question ‘Would you be willing for your child to take part in a (hypothetical) trial?’
supported with the process diagram and additional description of trial (see Report supplementary material 5),
parents were a little more likely to respond positively than negatively. Those who expressed positive views
about the trial gave the following reasons for being supportive in principle: personal interest and belief in
medical research; belief that enrolment in a trial would ensure good care and better provision of information
about treatment; and being supportive of the aim to reduce antibiotic therapy (and shorten treatment time),
illustrated in the following excerpt:
Although personally, I normally say yes to trials because it often means we get better care – or at least
more follow-up and stuff. But yes, so I suppose that’s just a thought that crossed my mind. I think it’s
a good idea to want to not overtreat, basically, isn’t it, not give antibiotics longer than you have to.
You need to have evidence about whether that’s an effective thing to do, to cut down the length
of antibiotics.
Mother, patient 214
Those who gave negative opinions about the trial presented two main concerns: fears about the risks
of a potentially shorter course of treatment and that a ‘set’ or ‘scheduled’ trial treatment would not be
sufficiently flexible to respond sufficiently to the individual needs of patients, putting them at unnecessary
risk. There appeared to be some link (although not in every case) between families’ views about participation
in a potential trial and how seriously ill their child had been, including the length of time taken for diagnosis
and, thus, how much deterioration (and fears of long-term damage) had taken place during this time.
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The two quotations below illustrate this. In the case of patient 349, the delay in diagnosis led to the
patient becoming seriously ill, whereas a less prolonged delay in the case of patient 350 led to parental
fears about possibilities of long-term damage:
Reading through your reasons for proposing the study, which is to reduce the length of time and
hopefully not reduce the risk, sorry not increase the risk. If the situation was different and we had a
diagnosis on the first day, then my decision might have been different, but, no, I was glad it was of
the length that it was and I wouldn’t have questioned, as a precaution, if they wanted it to be longer
still. I would have had concerns if it was shortened, but that was because of our situation that we
were in, that the 8 days, I think it was 9 days from when we first noticed the symptoms to seeing him
and actually having the first [signal breaks up] . . . so my concern was that the longer that the infection
had a hold, the greater the risk that there might be a long-term problem, either [signal breaks up]
eradicate the infection totally or having any deterioration in his joint in the long term.
Father, patient 350 (expressing that a desire for a longer treatment period would
make him unwilling for his son to join the trial)
If it had been left another few days I don’t think we’d have had [child] back here, that’s how bad it
was. I would recommend no set pieces. Let the doctors decide what they’re going to do, let them
have the say, no set guidelines on that one, that’s crazy. Let them do what they’ve got to. That’s what
they did with him, they didn’t hesitate. There was no set pieces. They put this into motion. Whatever
he needed, they gave him, that was it.
Grandfather, patient 349
Such findings suggest that heightened concerns about the risks of harm to children may reduce potential
willingness to participate in a trial. This was indicated in other ways by respondents. Families positively
disposed to participation in such a trial nevertheless required reassurances about safety in information
presented. Information required included details of how their child would be monitored to ensure that
infection was being treated successfully, the trajectory of care in case of failure to recover on a shorter
course of antibiotics, data to support the safety of shorter arm and equipoise:
I guess it would be in the way it’s presented and the information that patients have, as in the
outcomes maybe of those other areas where they have used a shorter course and they still had
positive outcomes. I guess also would there be those caveats that, say you had been allocated the
treatment B and at the end of day 25 or 26, that there was a noticeably, that wasn’t working or there
was still an issue, surely there’d be a duty of care or something to put in that you wouldn’t just take
them off anyway and see what happened? Or would there be? Do you know what I mean?
Mother, patient 350
Some parents suggested that children with more severe or difficult to treat OM/SA would be less suited to
enrolment in a trial:
And I suppose it depends where it goes, where you get it as well. Because her feet are like, the blood
supply is not very good and the chances are that they couldn’t do it there because it wouldn’t get
through and it’s so deep in the bottom of her foot. Whereas if you have it in your knee, the antibiotics
might work within 2 days, mightn’t they? That would depend how poorly your child is, wouldn’t it?
It depends how ill you were wouldn’t it? It would depend how bad it is.
Mother, patient 248
Other factors that may dissuade parents from participating would be the need for additional invasive
interventions or significant disruption of families’ routines.
The way in which information about the trial is presented was recognised as critical by respondents – who
delivered it appeared less important – other than it should be done by someone knowledgeable and that
consistent messages about the trial should be delivered by all those involved in a child’s care. Above all,
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parents would be looking for reassurance that participation in the trial would not be putting their child at
increased risk:
I guess I’d have wanted to. I mean I work in a university where research is really important, so I would
have wanted to. If I was given the right information and I thought that it was safe, then I would have
done. If I was in any doubt that it might not have been safe, then I would have said no.
Mother, patient 247
Theme 5: timings, parental anxiety and capacity to absorb information
The final theme emerging from data analysis concerns the level of anxiety and distress experienced by
parents at the time of their child’s illness and treatment. Key or ‘pinch’ points of anxiety for parents
included the lead-up to diagnosis (especially in case of delays), occasions on which the child experienced
distress (e.g. during insertion of a cannula), fears about their child receiving a general anaesthetic and
some follow-up anxiety around the potential for future impacts or recurrence of infection.
Reflecting on these feelings, respondents reported that their capacity to think about, and remember,
important information (about treatment as well as potentially about the trial) was reduced during this
time – exacerbated by fear, heightened emotions, the strangeness/unexpected nature of the situation and
input from many different professionals:
Because it’s quite an awkward time, when your child’s poorly and you’re not quite sure what’s wrong
with them and you’re all a bit all over the place, your headspace is not really right and you don’t really
know what’s going on and you’re just being led by what doctors and nurses are telling you, you’re
quite terrified.
Mother, patient 174
So I think there were three, and that was why it was a little bit confusing because obviously one
doctor is trying to co-ordinate these other two deciding what antibiotics and how much and this and
that and then the other person looking after her joint. Yes, it was very confusing, and a lot of the time
I think you are just so tired you don’t really take it all on and you are on your own, and then your
husband comes along and says, ‘Oh, what happened this morning?’. I can’t really remember all of it.
Mother, patient 267
Bearing these responses in mind, participants suggested that the timing of the invitation to participate in
the trial, along with associated information and the manner in which it is delivered, is likely to be key.
Once antibiotics have been started and parents feel reassured that their child is receiving treatment,
capacity to consider trial information is likely to be enhanced:
I personally think, yes, in order to make any sort of rational decisions about anything you have to
know your child is safe. Particularly as, yes, I don’t know if your research would – I don’t think there’d
be any reasons not to wait (until treatment had started), would there? Maybe there are, but I can see
obviously if you’re testing something in the emergency period, you have to approach people before
the thing happens. But if you don’t have to then I think you would be more likely to engage parents.
Mother, patient 214
A need for sensitivity and awareness of parental vulnerability at this time (in inviting participation in a trial,
but also throughout the care trajectory) was also stressed:
. . . just remembering that sensitivity, that the person that you’re talking to, it’s the first time they’re in
this situation and it’s very stressful and emotional. It’s just that giving a little bit of time I guess to
process that information.
Mother, patient 350
If I’d been approached in a not very positive way it probably would have put me off to be honest.
Mother, patient 174
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Discussion
In this section, we discuss findings arising from the thematic analysis of the interview data, particularly with
reference to a future RCT. Some limitations of this qualitative study are also highlighted. We conclude with
some brief recommendations for practice and for research.
Many families described the early stages of their child’s illness and seeking/commencement of treatment as a
highly distressing and an anxiety-provoking time. However, once a working diagnosis had been obtained,
expert advice given and antibiotic treatment commenced, parents began to feel reassured and less anxious,
especially when signs of improvement were noted in their children. In the main, despite its challenges,
families were satisfied with treatment for OM/SA and the outcomes achieved, most importantly, those of ‘no
ill effects on bone/joint/growth’, ‘activity levels resumed’, ‘infection gone’ and no ‘recurrence of infection’.
One of the major issues highlighted by this empirical work was the delay experienced by many of the
families in obtaining a diagnosis, and the consequent stress and anxiety experienced. Although not the
direct focus of this qualitative study, the obvious concern experienced by families around the issue of
diagnosis has led us to identify some recommendations both for future research and for practice. In terms
of implications for participation in a future clinical trial, it is important to recognise that some children and
families approached for recruitment may have experienced a long period of uncertainty and interaction
with primary and secondary care prior to the definitive diagnosis. The child may have become seriously ill
prior to a diagnosis being reached. These circumstances might increase family anxiety about long-term
harm to their child and negatively impact on willingness to expose their child to any further uncertainty or
‘risk’. It is therefore important that research staff recruiting for a trial understand what the child and family
have experienced prior to admission/recruitment and explore any continuing concerns.
Similarly, with regard to prior experiences of both i.v. and oral antibiotic therapy for OM/SA, although
understanding the rationale for the different modes of delivery, parents and children in our study had both
positive and negative experiences of both forms. It will therefore be important to provide an opportunity to
discuss this, prior to inviting participation in the trial. Potential randomisation to either standard care or the
intervention arm could therefore lead to anxiety about ‘more of the same’, and it may be important to
provide reassurance in either eventuality.
From interviews, it is apparent that both children and parents had clear views about both how they knew
they/their children were recovering and also on what they based their judgements about the success or
otherwise of treatment for OM/SA. Some of these measures reflect clinical tools used both in everyday
practice and in research, but others are less well reflected in commonly used measures in this specialism.
Our recommendations for the future RCT, for practice and for general research reflect children/parental
perspectives about indications of recovery and outcomes.
Although we recognise that participants in our study are probably more enthusiastic about research
participation within a general sample of children with OM/SA and their parents (by virtue of having
accepted the invitation to participate in this qualitative study), it was encouraging to note that more were
positive than not about participation in a trial, at least in theory. The concerns of those who were
potentially unwilling or not sure reflected anxiety about reduced courses of treatment and that rigid trial
protocols might put their own child at risk. The previous section (see Theme 4: views on proposed
randomised controlled trial) highlights a potential (albeit subjectively observed) correlation between length
of time to diagnosis (and seriousness of child’s condition) and willingness to participate in a trial, which
might perhaps suggest either an inclusion criterion or, at a minimum, the need to sensitively explore prior
experiences and provide tailored reassurance and data. Families positively disposed to participation in such
a trial would also require reassurances about safety in information presented. Information required
included details of how a child would be monitored to ensure that infection was being dealt with, trajectory
of care in case of failure to recover on shorter-course antibiotics, data to suggest safety of the shorter arm and
equivalence/equipoise about treatment in both arms.
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As highlighted previously (see Theme 1: experiences of diagnosis and seeking treatment), levels of anxiety
and distress experienced by parents at the time of their child’s illness and treatment were at times high.
Key or ‘pinch’ points of anxiety appeared to be during the lead-up to diagnosis, periods of child distress,
anxiety about general anaesthetic and some follow-up anxiety around the potential for future impacts or
recurrence of infection. Parents reported that they had diminished capacity during these times to attend
to, absorb and reflect on information, relating to both treatment and potentially an invitation to participate
in a trial. Awareness and empathy at these ‘pinch points’, plus avoidance of these where possible in
presenting information, would be helpful and useful.
Limitations
l Participants in this study had initially responded positively to an invitation to take part in the service
evaluation phase of the study, and also to being approached with regard to inclusion in the qualitative
interview phase. They are therefore unlikely to be representative of the general population of children/
parents treated for OM/SA.
l Via purposive sampling, invitations to participate in this phase were extended to those treated within
four centres in the south of England, and findings may not therefore represent those receiving different
treatment regimens at different centres.
l Although most of our interviews were carried out in person, a few were conducted over the telephone.
Although there did not appear to be any difference in terms of the quality of data generated, it is
possible that as a result of the difficulty in responding to non-verbal cues, these interviews were slightly
less responsive to participants’ emotions/agendas.
l For practical reasons of time/convenience, interviews with children were usually carried out in the
presence of parents, reducing the opportunity to explore differences in perspective.
Recommendations
For a future randomised controlled trial
l There is an opportunity for parents and children to share their experiences with research staff prior
to invitation to participate in the trial, and reassurance that inclusion in the RCT will not further
compromise the child’s health.
l This is also an opportunity for the child and their family to discuss previous experiences (including negative)
of both modes of antibiotic delivery, and provide reassurance about randomisation to either arm.
l Pre-trial information given should provide:
¢ clear information about the oral to i.v. antibiotic switch criteria and reassurance that the trial
protocol would not over-ride the individual needs of the child in terms of when the switch from
i.v. to oral antibiotics is made
¢ data to support the switch point in both standard care and the experimental intervention
¢ details of how the child would be monitored to ensure that infection was being dealt with
¢ trajectory of care in case of failure to recover in shorter treatment arm
¢ data to demonstrate safety of the shorter arm
¢ information regarding the equivalence/equipoise about treatment in both arms.
l Consideration should be given to short-term outcomes that accord with children and parents’
observations (i.e. appetite and weight, temperature, pain, weight bearing on affected limb, functional
movement in activities of daily living, X-ray findings).
l Longer outcome measures that reflect children’s and parents’ perspectives and priorities (i.e. functional
activity and mobility levels, pain, end of infection with no recurrence, impact on bone/joint/growth)
should be included.
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l Consideration should be given to whether or not an exclusion criterion relating to the seriousness of
child’s condition and/or previous trajectory leading to diagnosis should be included.
l If no exclusions are made based on severity, particular care and attention to explanations about
treatment and risk in a trial will be needed for those with difficult prior experiences, attending to the
children’s and parents’ specific concerns about risk.
l Where possible, researchers should avoid ‘pinch points’ of anxiety/distress when inviting trial
participation. If such timing is unavoidable, parents and children will need to be offered clear, written
information, supported by verbal explanation, with time to reflect and several opportunities to revisit/
ask questions.
l Discussion about perceptions of risks, precautions and safety within the context of a trial will be
required to check understanding.
For practice
l Information about signs, symptoms and diagnosis of OM and SA could be more readily available to
frontline clinicians (e.g. GPs, junior doctors in A&E), with access to more experienced colleagues for a
second opinion.
l Clinicians could provide more clarity around:
¢ orientation to parents’/families’ concern about the child and trust in their judgement as a stimulus
to further clinical tests, in the absence of any clinical diagnoses
¢ understanding and empathy with child/family during the course of both i.v. and oral antibiotic
treatment, recognising that previous experience might lead to anxiety
¢ discussion with parents about strategies for addressing problems with administration of oral
antibiotics (e.g. objection to taste, teeth staining, upset stomach and vomiting)
¢ exploration of potential of health-care providers to safely administer i.v. antibiotics at home, in
order to facilitate faster discharge
¢ sharing switch criteria (e.g. blood test results) and decision-making from i.v. to oral antibiotics with
child and parents
¢ reassurance and explanation about routes to infection in OM/SA
¢ discussion and explanation about how children- and parent-focused outcomes are reflected/used in
clinical decision-making
¢ discussion about understandings of risks and outcomes in relation to OM/SA both during treatment
and at follow-up appointments.
l The provision of written resources to support information provision at particularly stressful times during
the care trajectory may be useful, for example about treatment, risk and outcomes.
l Signposting to reliable and trustworthy information on a website might also prove reassuring and helpful.
For future research more generally
l It may be useful to:
¢ explore and evaluate strategies to improve the speed and accuracy of diagnosis among
non-specialist primary and secondary care providers at initial point of contact
¢ research improved delivery mechanism of oral antibiotics for children (e.g. taste, consistency)
¢ develop and test sensitive and robust patient-reported outcome measures for children recovering
from OM/SA, including quality-of-life measures
¢ investigate the possible correlation between prior negative OM/SA illness experiences (e.g. serious
illness, long time to diagnosis) and willingness to participate in RCT, plus effectiveness of strategies
to address specific concerns (e.g. child/parent-focused information provision)
¢ explore mitigating strategies as times of maximum stress during the child’s illness trajectory
(e.g. optimum level of information provision, whether or not critical information provided through
more than one medium is more easily retained).
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Chapter 5 Systematic literature review
Aims and objectives
The aim of this component of the study was to use a systematic review to inform development of a core
outcome set to use in a future RCT of shortened duration of antibiotic therapy for paediatric bone and
joint infections.
Methods
Types of study included in the review, types of intervention and types of participant
The research group recognised that there is a lack of high-quality data in this clinical area and that
previous RCTs investigating the duration of antibiotic treatment have generally been small. As no large
RCTs were expected to be found, the review aimed to include:
l large or small RCTs, retrospective cohort studies and case series
l any study investigating duration of antibiotic therapy used for bone and joint infection, regardless of
what antibiotic agent was used, or the duration of i.v. versus oral antibiotic therapy
l all children from birth to 16 years treated with systemic antibiotics for bone and joint infections,
regardless of surgical intervention, comorbidities or site affected.
Exclusion criteria
Studies investigating the use of surgically placed antibiotic beads or other local antibiotic treatment were
excluded. In addition, predominantly adult studies with small numbers of children were also excluded
because the criteria for adult treatment are not the same as for paediatric cases, and there are different
outcome risks.
Search strategy
EMBASE and MEDLINE databases were searched using the search strategy shown in Appendix 1. All
publications from 1946 to the present were included in the search. The search was carried out in May
2012 and updated in July 2014.
Results
Eligibility of studies
Of 1321 papers identified, 218 were reviewed in detail. The remainder were excluded based on reviews of
the title and, where necessary, the abstract.
Of the 218 papers that were reviewed in detail, 208 were excluded. Many were review articles discussing
the existing literature, with no clear focus on intervention or outcome. All of the papers used in these
articles were included in the original search. Articles comparing imaging techniques and surgical techniques
were also excluded as the outcomes were not relevant to our study investigating antibiotic duration.
Two systematic reviews were selected, and the papers used analysed in detail. Le Saux et al.44 found 12
prospective studies including one RCT comparing duration of antibiotics for acute haematogenous OM.
The numbers of patients included in these studies were small, in some cases fewer than 10. However,
overall, the conclusion was that there is no difference in outcome between long and short courses of
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antibiotic treatment. Of the papers used in this systematic review, three were selected for this analysis.
The remainder did not have clearly stated outcomes or follow-up for patients.
Howard-Jones and Isaacs83 also published a systematic review of treatment of subacute and chronic
pyogenic OM in 2010. This review looked at both studies comparing duration of antibiotic treatment and
studies comparing different antibiotic agents. Of the papers used in this analysis, five were selected by the
reviewers. Two of these had also been included in Le Saux et al.44 One study was excluded because it
predominantly included children with cellulitis and soft-tissue infection, and therefore outcomes would not
be comparable to a group with only bone and joint infections. The other excluded papers did not clearly
state the outcome measures used to define ‘cure’.
All of the studies reviewed in detail and selected for use in the stakeholder survey are detailed below.
We used the following criteria for assessing papers and identifying outcomes:
1. Is the primary outcome clearly stated?
2. Is the primary outcome clearly defined so that another researcher would be able to reproduce
its measurement?
3. Are any secondary outcomes clearly stated and defined?
4. Do the authors explain the use of the outcomes they have selected?
Extraction of data
Data were extracted from each of the papers by a single reviewer (PS) and checked by a second reviewer
(SNF). These outcomes were then discussed with study clinical co-investigators, who also had the
opportunity to review the papers, until there was consensus that all of the available outcomes had
been extracted.
All of the papers are exclusively paediatric. The following data were extracted in the first instance: authors,
journal and year of publication, type of study, number of cases included in the study and exclusion criteria.
These are detailed in Table 69.
TABLE 69 Summary of results from selected papers
Paper Interventions
Study design and
number of
participants Outcome measures
Pääkkönen et al. (2012)84
Scand J Inf Dis
Shortened hospital stay for
childhood bone and joint
infections: analysis of 265
prospectively collected
culture-positive cases
in 1983–2005
2–4 days of i.v. antibiotics and
up to 20 or 30 days of oral
antibiotics for OM, up to 10
or 30 days of oral antibiotics
for SA
RCT (culture positive
only, culture negative
excluded)
265
l Time to normalisation of
CRP and ESR
l Duration of hospital stay
l Sequelae at 1 year
Peltola et al. (2010)49
Pediatr Infect Dis J
Short- versus long-term
antimicrobial treatment for
acute haematogenous
osteomyelitis of childhood:
prospective, randomised trial
on 131 culture-positive cases
2–4 days i.v. antibiotics;
9–108 days oral antibiotics
RCT (culture positive
only, culture negative
excluded)
131
l As above
l Pain/deformity at
3 months and 1 year
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TABLE 69 Summary of results from selected papers (continued )
Paper Interventions
Study design and
number of
participants Outcome measures
Bachur and Pagon (2007)85
Clin Pediatr
Success of short-course
parenteral antibiotic therapy
for acute osteomyelitis
of childhood
≤ 7 days i.v. antibiotics vs.
> 7 days i.v. antibiotics
Median 4 days i.v. antibiotics
Retrospective cohort
29, all uncomplicated,
acute haematogenous
OM
l Absence of symptoms
1 year after stopping
antibiotics
l Number needing to be
put back on i.v.
antibiotics from oral
Zaoutis et al. (2009)58
Pediatrics
Prolonged intravenous
therapy versus early
transition to oral
antimicrobial therapy for
acute osteomyelitis
in children
Prolonged i.v. antibiotics vs.
early oral switch
Retrospective cohort
1969
l Rehospitalisation with
bone and joint infection
within 6 months of
discharge
l Chronic OM
l Surgical procedure after
treatment with antibiotics
l Myositis/arthritis/
complication of OM
l C. difficile
l Line-related complication
l Adverse drug reaction
associated with antibiotic
(e.g. agranulocytosis,
allergic reaction,
neutropenia)
Messina et al. (2011)86
Pediatr Infect Dis J
Trimethoprim-
sulfamethoxazole therapy
for children with
acute osteomyelitis
Trimethoprim-
sulfamethoxazole, median
duration 31 days
Prospective cohort
20
l Adverse event to
antibiotic
l Resolution of symptoms
at end of therapy
Tetzlaff et al. (1978)87
J Pediatr
Oral antibiotic therapy for
skeletal infections of
children. II. Therapy of
osteomyelitis and
suppurative arthritis
7 days’ i.v. antibiotics then up
to 6 weeks’ oral antibiotics
Blood antibiotic
concentrations monitored and
dose adjusted
Prospective cohort
35
l Resolution of symptoms
l Chronic OM
Ballock et al. (2009)46
J Paediatr Orthop
A comparison of early versus
late conversion from
intravenous to oral therapy
in the treatment of
septic arthritis
Prolonged i.v. antibiotics vs.
early oral switch, prolonged
total duration (median
7.4 days vs. median
18.6 days)
Two different
hospitals compared
Retrospective cohort
186
l Duration to defervescence
l Duration to normalisation
of ESR
l Number of complications
(specifically avascular
necrosis)
Kolyvas et al. (1980)88
Pediatrics
Oral antibiotic therapy of
skeletal infections in children
72 hours of i.v. antibiotics
then total of 4 weeks’ oral
antibiotics vs. 4 weeks.
i.v. antibiotics
RCT
15
l Time to ESR of
< 20mm/hour
l Resolution of symptoms
l Relapse
continued
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Conclusion
The key outcomes were combined and summarised, all of which are shown in Table 70. These were then
discussed with the clinical co-investigator group, including paediatric infectious disease consultants,
orthopaedic surgeons, general paediatricians and radiologists. Following this discussion, the important
outcomes for a potential future RCT were identified (see Chapter 7).
TABLE 69 Summary of results from selected papers (continued )
Paper Interventions
Study design and
number of
participants Outcome measures
Jaberi et al. (2002)89
J Paediatr Orthop
Short-term intravenous
antibiotic treatment of acute
hematogenous bone and
joint infection in children: a
prospective randomized trial
All had surgical drainage prior
to antibiotic treatment
7 days’ i.v. antibiotics vs.
14 days’ i.v. antibiotics for SA
10 days’ i.v. antibiotics vs.
21 days’ i.v. antibiotics
for OM
RCT
33
l Scoring system used twice
a month for 6 months
l Scored on pain, gait,
ability to walk and use of
walking aids
l Radiological changes on
plain X-ray
l Sinus or discharge
Jagodzinski et al. (2009)90
J Paediatr Orthop
Prospective evaluation of a
shortened regimen of
treatment for acute
osteomyelitis and septic
arthritis in children
Assessed after 3 days’ i.v.
antibiotics for oral conversion
86% converted to oral after
5 days
All had 3 weeks’
oral antibiotics
Prospective cohort
70
l Followed up for 1 year
l Time to normalisation
of fever
l Time to CRP of < 20mg/l
l X-ray changes
l Pain, disability, deformity
at 1 year
TABLE 70 Outcomes identified from the systematic review
Outcome category Specific outcome
Infection-related Number of days to CRP of < 5 mg/l
Duration to resolution of fever
Duration of hospital stay
Duration to resolution of pain
Need for one or more non-diagnostic surgical procedures
Chronic OM
Chronic arthritis
Chronic myositis
Amputation or fasciotomy
Duration to CRP of < 20mg/l
Duration to CRP of less than one-third of highest value
Duration to ESR of < 20mm/hour
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TABLE 70 Outcomes identified from the systematic review (continued )
Outcome category Specific outcome
Line- or antibiotic-related complication Vomiting/diarrhoea/gastrointestinal
Agranulocytosis or neutropenia
C. difficile infection
Rash/adverse drug reaction
Line infection
Need for line removal or replacement
Long-term outcome Pain at 3 months
Pain at 12 months
Limp/disability at 3 months
Limp/disability at 12 months
Number of cases symptom free at 12 months
Treatment failure/recurrence of infection within 18 months
Growth plate involvement/damage
Rehospitalisation within 6 months
Limb shortening or deformity (time frame hard to decide in future RCT,
as could be 3–5 years’ follow-up)
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Chapter 6 Delphi survey to identify oral switch
criteria, develop core outcomes and assess the overall
feasibility of a future randomised controlled trial in
children with bone and joint infections
Aims and objectives
Through a Delphi process we aimed to:
l identify the oral switch criteria for use in a future RCT
l develop a core outcome set for use in clinical trials of children with bone and joint infections
l assess the overall feasibility of a future randomised clinical trial in children with bone and joint infections.
Methods
Delphi clinical stakeholder survey
Two rounds of Delphi process were performed. Programming for the online system was carried out by the
Liverpool Medicines for Children Clinical Trials Unit (director, co-investigator PW).91
Participants
Prior to the study, the national societies of the clinical stakeholder groups agreed that the Delphi survey
could be sent to members via the society e-mail lists [those of the Royal College of Paediatrics and Child
Health (RCPCH) Speciality Group for General Paediatrics, the British Paediatric Allergy, Immunology and
Infection Group, British Society for Children’s Orthopaedic Surgery, the British Society or Paediatric
Radiology and the British Society for Antimicrobial Chemotherapy]. In addition, as a result of the general
rarity of the condition and the study requested, the study also made use of the wider RCPCH regional
mailing lists to try to be able to invite a larger group of general paediatricians.
Clinical stakeholders were asked to participate if they had personally treated a child with SA or OM in
the previous 12 months or had been part of a wider multidisciplinary team providing that clinical care.
Although some of the participants were also principal investigators for the service evaluation, the survey
was not limited to sites participating in the service evaluation in order to obtain as wide a range as possible
of clinical opinion and views. In the invitation e-mail, all participants were also reminded of the importance
of completing both rounds of the Delphi process.
Delphi round 1
The survey was presented in an online format (see Report supplementary material 6), with participants allocated
a unique identifier (via name and e-mail address) to allow identification of individuals completing all rounds of
the Delphi exercise. All participants were asked to record their grade and clinical role. At the beginning of the
survey, participants were presented with selected information from the study service evaluation.
Questions that were asked:
l What outcomes influence your decision to switch from i.v. to oral antibiotics when treating a child
with OAI?
l What outcomes influence the total duration of antibiotics when treating a child with OAI?
DOI: 10.3310/hta21480 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 48
© Queen’s Printer and Controller of HMSO 2017. This work was produced by de Graaf et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
99
l What line or treatment-related complications are important when using prolonged courses
of antibiotics?
Participants were invited to score each of the outcomes listed using the Grading of Recommendations,
Assessment, Development and Evaluations scale of 1 to 9, with 1–3 labelled ‘not important’, 4–6 labelled
‘important but not critical’ and 7–9 labelled ‘critical’. Participants were provided with an option to add
additional outcomes that they think are relevant, together with a score for each outcome added.
Outcomes were listed alphabetically to avoid potential weighting of outcomes caused by the order in
which they were displayed. For each outcome, the number of participants who scored the outcome and
the distribution of scores (percentages of who had scored each outcome) were summarised by the
stakeholder group. All outcomes were carried forward to Delphi round 2.
Predefined Delphi survey outcomes were the total number of registrations, a breakdown of respondents
who had completed the survey and their inclusion in the initial e-mail invitation, the total number of
respondents who completed the round, the total number of respondents in each stakeholder group, the
percentage of respondents compared with potential respondents as identified from the information
provided by clinical leads and the percentage of respondents from other sources (not included in the
original e-mail invitation).
Following initial screening by two senior investigators (SNF and PW), the clinical co-investigators reviewed
the additional outcomes added during round 1 and assessed if these differed significantly from those
already on the list. Additional outcomes were added prior to round 2 for additional scoring.
Delphi round 2
In the second round of the Delphi process, each participant was presented with their individual scores from
round 1 together with the number of respondents and distribution of scores for each outcome for their
particular stakeholder group. As a result of the low numbers of paediatric microbiology respondents, the
microbiology and clinical paediatric infection data were presented together.
Participants in round 2 were asked if they would be willing to participate in a future RCT.
Results
Participants
As a result of the national society e-mail distribution lists used to send out the invitation to as many clinical
stakeholders as possible, it was not possible to accurately assess the denominator number of clinicians sent
invitations for the general paediatrics and paediatric radiology clinical stakeholder groups. In addition, the
number of orthopaedic surgeons actually in clinical paediatric practice was not accurately represented by
the mailing list of the national society.
Engagement reflected both the expected uncommonness of the condition in general paediatric practice and
that the most interested groups are paediatric orthopaedic specialists and paediatric infection specialists.
Of note, only around 80 consultants are members of the RCPCH general paediatric special interest group.
The ‘denominator’ of the number of paediatricians sent the invitation e-mail was impossible to establish with
accuracy as we also attempted to send the e-mail to all RCPCH active members, but this was not reflected in
co-investigator RCPCH members receiving the e-mail apparently ‘sent’. The responses of paediatric radiologists
reflected the general literature opinion that treatment outcomes are clinical rather than radiological.
Approximately half of British paediatric infection specialists participated, and approximately half of the known
number of paediatric orthopaedic surgeons. Approximately 15 microbiologists were invited via the specialty’s
e-mail list. Further accuracy of these data is unobtainable.
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In round 1, 37 general paediatricians, 38 paediatric orthopaedic specialists, 34 paediatric infection
specialists, four paediatric microbiologists and 13 paediatric radiologists took part. Of the 13 paediatric
radiologists, seven answered ‘unable to score’ for every outcome.
The response rates in round 2 are shown in Table 71.
Response bias was assessed between rounds 1 and 2 by comparing the average round 1 score from those
responding in both rounds to those responding in round 1 only. There is no evidence of attrition bias.
Figure 5 shows the participant distribution of percentage of outcomes with changed scores between
rounds 1 and 2 for the group as a whole. Three participants did not change their score for any outcome.
These results suggest that including a second round in the Delphi was a useful exercise.
Summary of the answers from the Delphi process
A summary of the results is shown in Tables 72–76. Detailed tables on voting results are included in
Appendix 2.
TABLE 71 Response rate to clinical stakeholder survey
Specialty R2 response rate (number/R1 response) % of R1 response
General paediatricians 31/36a 86.1
Orthopaedic surgeons 21/36b 58.3
Radiologists 8/9c 88.9
Microbiologists 4/4 100
Paediatric infectious disease specialists 33/33d 100
R1, round 1; R2, round 2.
a R2 non-response (known reasons) denominator reduced: one general paediatrician – an ongoing issue meant that they
could not complete R2.
b R2 non-response (known reasons) denominator reduced: two surgeons – one had moved abroad, one had retired.
c Radiologists denominator reduced from 13 to 9 because R1 was not completed or participants were unable to score any
outcomes in R1.
d R2 non-response (known reasons) denominator reduced: one paediatric infectious disease specialist – telephone number
could not be found to chase (appeared to work abroad).
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FIGURE 5 Change in scores between rounds 1 and 2.
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TABLE 72 Results rating of CRP as outcome for a future study
Participants Delphi survey round 1 Delphi survey round 2 Consensus meeting
Number of participants 126 97 17
Number of respondents who gave a
rating for at least one CRP outcome
116 92 17
Number who scored at least one CRP
outcome ≥ 7 (A)
72 55 12
Percentage (A/n) 62.1 59.8 70.6
A, number of respondents who scored at least one CRP outcome ≥ 7; n, number of respondents who gave a rating for at
least one CRP outcome.
TABLE 73 Percentage of participants who scored 7, 8 or 9 for switch criteria round 2 by stakeholder group
Outcome: health
professionals
Outcome: parents and
young person
General
paediatrics
(%)
Orthopaedic
surgeons
(%)
Radiologists
(%)
Microbiologists
and paediatric
infectious disease
specialists (%)
CRP < 20mg/l Blood test showing level
of inflammation in body
39 38 0 38
CRP less than one-third
of the presenting value
10 19 67 28
CRP less than
two-thirds of the
presenting value
13 0 33 17
ESR < 20mm/hour Blood test showing level
of inflammation in the
body (not used as often
in children as it needs
more blood for
technical reasons)
3 10 0 0
Resolution of fever for
≥ 48 hours
Childs’ body
temperature has been
normal for past
48 hours
90a 95a 100a 86a
Weight bearing/return
of function to limb
Child able to put weight
on affected limb/use
affected body part
as normal
55 71a 67 65
Resolution of pain Child no longer feels
any pain
48 52 0 43
Tolerating oral input Child able to drink
and eat
83a 9 0 97a
Parental opinion
regarding improvement
or worsening of
condition
Parents opinion about
wellness of their child
16 5 75a 25
Pain improvement
(rather than resolution)
as oral switch criteria
Less pain felt by child 13 33 100a 33
a Consensus criteria were met: > 70% scored 7, 8 or 9 and < 15% scored 1, 2 or 3.
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TABLE 74 Percentage of participants who scored 7, 8 or 9 for infection-related outcomes
Outcome: health
professionals
Outcome: parents and
young person
General
paediatrics
(%)
Orthopaedic
surgeons
(%)
Radiologists
(%)
Microbiologists
and paediatric
infectious disease
specialists (%)
Need for non-diagnostic
surgical procedure
(e.g. decompression,
debridement)
Child has had to have
surgery in order to treat
the infection
48 38 60 61
Rehospitalisation or
recurrence of
symptoms while on
oral antibiotics
Child has returned to
the hospital or
symptoms have returned
while taking antibiotics
by mouth
97a 95a 100a 97a
Treatment failure:
recurrence of infection
(either at original site
or at new site)
Child has a new
infection in the same
area or a different area
100a 100a 100a 100a
Pain while on
antimicrobial treatment
Pain experienced by the
child while being treated
for the infection
0 10 0 0
Ongoing pain at
follow-up
Pain still experienced at
outpatient appointments
19 38 0 16
Disability at follow-up Child has continuing
movement problems at
outpatient appointments
81a 67 67 78a
Symptom free at 1 year Child has not
experienced any
symptoms after 1 year
61 90a 83a 68
Limb shortening
or deformity
Child’s limbs have
become shorter or
changed shape/
appearance
87a 80a 83a 76a
Duration to CRP
< 5mg/l
Time taken for
inflammation level to
return to normal in
the body
0 19 25 5
Duration to resolution
of fever
Time taken for child’s
temperature to return
to normal
16 19 0 43
Duration to resolution
of pain
Time taken for pain to
go away
16 5 60 8
Duration of hospital
stay
Time child has had to
stay in hospital
10 5 20 27
Fracture at or near site
of infection
Bone broken in the
same location as the
infection or near to
the infection
34 40 67 44
Prolonged antibiotic
therapy
Antibiotics needed for
longer than expected
27 24 50 56
Quality of life Child’s ability to enjoy
normal activities
71a 50 33 44
a Consensus criteria were met: > 70% scored 7, 8 or 9 and < 15% scored 1, 2 or 3. These should be considered for
primary and secondary outcomes in a future clinical trial.
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TABLE 75 Percentage of participants who scored 7, 8 or 9 for infection-related outcomes
Outcome: health
professionals
Outcome: parents and
young person
General
paediatrics
(%)
Orthopaedic
surgeons
(%)
Radiologists
(%)
Microbiologists
and paediatric
infectious disease
specialists (%)
Chronic OM Infection of the bone
that does not get better
with treatment
94a 100a 100a 95a
Chronic arthritis Joint inflammation that
does not get better
with treatment
84a 100a 83a 76a
Chronic myositis Muscle inflammation
that does not get better
with treatment
68 48 100a 39
Amputation
or fasciotomy
Removal of body part by
surgery or skin and
muscle have to be cut
by a surgeon to relieve
pressure between the
skin and bone
97a 86a 100a 94a
Death Death 97a 100a 100a 94a
PICU requirement
(e.g. PICU-free days at
day 30, if admitted)
Admission into a ward
(PICU) specialising in the
care of critically ill
children
77a 52 40 81a
PICU, paediatric intensive care unit.
a Consensus criteria were met: > 70% scored 7, 8 or 9 and < 15% scored 1, 2 or 3. These are rarer events to consider,
which need to be captured in a clinical trial
TABLE 76 Percentage of participants who scored 7, 8 or 9 for treatment-/line-related outcomes
Outcome: health
professionals
Outcome: parents and
young person
General
paediatrics
(%)
Orthopaedic
surgeons
(%)
Radiologists
(%)
Microbiologists
and paediatric
infectious disease
specialists (%)
Agranulocytosis/
neutropenia
Child more prone to
infection because of low
white cell count in body
as a result of infection
or treatments
32 43 75a 64
Deranged liver function Detection of
inflammation/damage to
the liver
3 14 0 47
C. difficile infection An infection affecting
the digestive system
caused by antibiotics
(very rare in children
under 2 years old)
10 33 33 28
Rash or allergic
reaction
Rash or allergic reaction 23 10 17 67
Suspected
drug-related fever
Child’s temperature
increases in line with
taking treatment
19 5 20 44
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TABLE 76 Percentage of participants who scored 7, 8 or 9 for treatment-/line-related outcomes (continued )
Outcome: health
professionals
Outcome: parents and
young person
General
paediatrics
(%)
Orthopaedic
surgeons
(%)
Radiologists
(%)
Microbiologists
and paediatric
infectious disease
specialists (%)
Line infection Infection of the drip that
is giving treatment to
the patient
45 33 33 83a
Line occlusion Blockage of the drip
that is giving treatment
to the patient
6 10 33 50
Vomiting/diarrhoea Sickness and diarrhoea 3 5 17 17
Insertion of PICC or
other central line
because of a need for
prolonged antibiotics at
home or in hospital
The need to provide the
child with a drip that
can be used for a
longer period
32 24 60 75a
Infiltration or
extravasation event
Medicine being given
into the veins is
accidently delivered to
the surrounding area as
a result of the drip
coming out of place
29 10 17 50
Any complication of
vascular access
Any complication of the
drip itself
23 24 60 58
a Consensus criteria were met: > 70% scored 7, 8 or 9 and < 15% scored 1, 2 or 3. These are rarer events to consider
whether or not there is a need to capture in a clinical trial.
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Chapter 7 Consensus meeting to assess the
feasibility of a future randomised clinical trial in
children with bone and joint infections
Aims and objectives
In the consensus meeting we aimed to:
l identify the oral switch criteria for use in a future RCT
l develop a core outcome set for use in clinical trials of children with bone and joint infections
l assess the overall feasibility of a future randomised clinical trial in children with bone and joint infections.
Methods
A consensus meeting was held on 27 April 2015 and an invitation to attend the meeting was sent to:
l health professionals who had completed both rounds of the online Delphi survey and expressed an
interest in attending future meetings
l principal investigators who had taken part in the service evaluation component of the study (although
individuals were advised that, if they had not completed both rounds of the Delphi survey, they would
be ineligible to formally vote but could be involved in discussions)
l members of the Comprehensive Research Network – Paediatrics London Young Persons Advisory Group
l all parents and children who had taken part in a qualitative interview (although none of the parents
participating in the qualitative study was able to attend, the meeting was attended by the study PPI
representative and a member of the Young Persons Advisory Group).
A separate session was scheduled immediately before the main consensus meeting for 30 minutes to allow
the qualitative investigators to meet with the parents and young people who attended the meeting. This
meeting allowed any questions to be answered about the structure of the day, expectations and for
additional information to be given with relation to the switch and core outcomes.
The meeting was chaired by Professor Adam Finn (University of Bristol), a co-investigator who had not
been part of the core study management group and who was a non-voting participant, to avoid the
possibility of Saul Faust introducing bias into the discussion when voting, and Carrol Gamble, who
monitored from a statistics perspective to ensure an unbiased session. The meeting was structured
according to the Dinosaur consensus meeting agenda (see Report supplementary material 6). Preliminary
results from the service evaluation (see Chapter 2) and qualitative study (see Chapter 4) were used to
inform the consensus meeting. The definition of consensus is shown in Tables 77 and 78.
Results
Participants
Meeting attendees and their representation are shown in Tables 79 and 80. In the items below, co-investigators
are referred to by initials (see Table 79) but other meeting participants by stakeholder group.
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TABLE 77 Definition of consensus for switch criteria
Consensus classification Description Definition
Consensus in Consensus that criterion is important when
deciding when or whether or not to switch from
i.v. to oral antibiotics
≥ 70% participants scoring as 7–9 AND
< 15% participants scoring as 1–3
Consensus out Consensus that criterion is not important when
deciding when or whether or not to switch from
i.v. to oral antibiotics
≥ 70% participants scoring as 1–3 AND
< 15% of participants scoring as 7–9
No consensus Uncertainty about importance of criterion Anything else
TABLE 78 Definition of consensus for outcomes
Consensus classification Description Definition
Consensus in Consensus that outcome should be included in
the core outcome set
≥ 70% participants scoring as 7–9 AND
< 15% participants scoring as 1–3
Consensus out Consensus that outcome should not be included
in the core outcome set
≥ 70% participants scoring as 1–3 AND
< 15% of participants scoring as 7–9
No consensus Uncertainty about importance of outcome Anything else
TABLE 79 Meeting attendees
Attendee Stakeholder group/role Initials
Professor Saul Fausta Chief investigator, paediatric infectious diseases SF
Professor Adam Finna Meeting facilitator, paediatric infectious diseases AF
Professor Nick Clarkea Orthopaedic surgeon NC
Priya Sukhtanker Clinical research fellow PS
Eileen Baildamb Paediatric rheumatology specialist EB
Deborah Eastwoodb Orthopaedic surgeon DE
Marieke Emontsb Paediatric infectious disease specialist ME
Katy Fidlerb Paediatric infectious disease specialist KF
Vana Gandhib General paediatrician VG
Adam Irwinb Paediatric infectious disease specialist AI
Dominic Kellyb Paediatric infectious disease specialist DK
Nick Makwanab General paediatrician NM
Nuria Martinez-Alierb Paediatric infectious disease specialist NMA
Piers Mitchellb Orthopaedic surgeon PM
Fergal Monsellb Orthopaedic surgeon FM
Karyn Moshalb Paediatric infectious disease specialist KM
Ann Pallettb Microbiologist with an interest in paediatrics AP
Colin Powella,b General paediatrician CP
Fiona Shackleyb Paediatric infectious disease specialist FS
Stefania Vergnanob Paediatric infectious disease specialist SV
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Formal voting was performed via Turning Point software (www.turningtechnologies.co.uk/). Only those
attendees who had previously completed rounds 1 and 2 of the Delphi survey were eligible to vote, but
involvement in discussion of the switch criteria and outcome set was encouraged from all attendees.
Two public contributors who were present voted separately using a paper-based voting system (as they
had not been involved in the qualitative interviews). One was the patient and public representative from
the study steering committee and had direct experience of a child suffering from the condition and the
other was a ‘trials-experienced’ member of the Medicines for Children Young Persons Advice Group.
Three clinicians attended the meeting who had not completed the online survey, votes again were
collected using a paper-based voting system (two complete voting sets and one partial were produced).
These votes have not been included in the results presented in this report.
TABLE 79 Meeting attendees (continued )
Attendee Stakeholder group/role Initials
Andy Wainwrightb Orthopaedic surgeon AW
Benjamin Jacobsc General paediatrician BJ
Kadri Ayoc General paediatrician KA
Kuldeep Stohrc General Paediatrician KS
Catherine Prichardc Parent representative CaP
Esme Lynchc Young persons advice group representative EL
Professor Carrol Gamblea Statistician CG
Claire Ballingera Qualitative researcher CB
Amanda Lees Qualitative researcher AL
Nicola Harman Meeting co-ordinator NH
Cath Spowart Meeting co-ordinator CS
Abigail Bennett Meeting co-ordinator AB
Chloe Middleton Meeting co-ordinator CM
a Co-investigator.
b Eligible to vote via Turning Point software (Turning Technologies, Belfast, UK).
c Paper-based voter.
TABLE 80 Stakeholder representation
Stakeholder group
Number of voting members attending the
consensus meeting
Percentage representation at
consensus meeting
General paediatrician 3 18
Microbiologist with an
interest in paediatrics
1 6
Orthopaedic surgeon 4 23
Paediatric infectious
disease specialist
9 53
Radiologist 0 0
Participants in
qualitative studya
0 0
a Although no qualitative study participants were able to attend, the consensus meeting was attended by the study PPI
representative and a member of the NIHR Comprehensive Research Network: London Young Persons Advisory Group.
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Presentation of the service evaluation data
l The definitions of complex and simple cases of SA or OM were discussed, as well as the numbers of
each case type. Forty-nine cases of misdiagnosis were recorded and the meeting queried if the patients
were treated appropriately in each of the cases. The data captured did not cover this information.
l A query was raised regarding whether or not some infection sites were more common than others.
Among the study population, the most commonly affected joints were hip, knee and ankle in simple
cases and femur and elbow in complex cases (and that this reflects the historical literature).
l The potential issue of missing data was raised, as 7% of children with simple disease and 3% with
complex disease did not appear to have received i.v. antibiotic treatment. Although concerning, there
are reports of oral therapy alone being used in recent European cohorts to treat bone and joint
infections (oral data from Spain presented at European Society for Paediatric Infectious Diseases,
Leipzig, May 2015; J Saavedra-Lozano, 2015, personal communication).
l There seems to be a lack of detailed information about the date that the child/parents first noticed
symptoms. The date of first presentation at the health-care service provider is recorded, but the
meeting participants agreed that this is often days, if not weeks, after first symptoms appear.
l The definition of diagnostic surgery was discussed as many of the surgeries listed as diagnostic would
normally be seen as therapeutic. For the service evaluation, diagnosis was defined as the start of
i.v. antibiotic therapy and therefore any surgery completed before this was included in the
diagnostic category.
l Surprise was expressed at the number of aspiration surgeries. Research nurses reported these based on
surgeons’ notes and/or cross-checking discussions with surgeons.
l The participants discussed and concluded that lavage should fall into arthrotomy and that they would
expect the numbers of arthrotomy procedures to be much higher as this is standard practice for simple
SA. The lower numbers of arthrotomy procedures is very likely a result of their inclusion in the ‘Incision
and drainage’ category.
l There were concerns over the low numbers of X-rays of abnormal bone, and it was hypothesised that
this can be attributed to failure to follow the norms of standard practice in a few centres lying, thus
skewing the results. This discrepancy could be caused by the department/specialist that the child is first
referred to, or junior doctors who lack experience.
l The number of blood cultures taken prior to initiation of antibiotic therapy is not available in the
existing data set.
l The preliminary results show that in only 42.3% of the 75.8% of children who underwent microbiology
tests was at least one micro-organism detected, a figure that may have been expected to be higher.
l Results of the service evaluation suggest that standard practice in the UK is short-course i.v. antibiotic
therapy (see Chapter 2). The data also imply that average timing of i.v./oral switch is between 1 and
2 weeks. The data set does not provide information about if location of infection impacted the timing
of switch or length of overall antibiotic treatment.
l Concerns were shared regarding discrepancies in dosing of i.v. ceftriaxone. There was general agreement
that in clinical practice a high (80 mg/kg) dose should be used for bone and joint infections (the
manufacturer, Roche, in the European summary of product characteristics states up to 1000 mg/kg/day),
but one participant noted that the BNFC allows a lower dose of 50 mg/kg.
l It was noted that only 40% of children underwent a blood test at the time of switching. It was queried
whether or not the blood tests could have been done a few days before, which would be standard
practice but not captured in the database. All agreed that this was an important question in relation to
future discussions for the trial.
l The results found for length of stay in hospital were discussed; hospital stay could be influenced (1) as
a result of patients being transferred to a district general hospital in the case of tertiary centres and
(2) by the age of the patient.
l The group noted that there were not as many complications as might be expected, but that this could
be due to the short length of follow-up.
l Discussed was whether or not pain at follow-up should be classified as a treatment failure.
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Presentation of the qualitative study
l Interviews provided a reminder that both i.v. and oral antibiotic therapy can be traumatic for children;
some may tolerate tablets/liquid well and find the i.v. insertion stressful, while others may not be
bothered by an i.v. line but find tablets/liquid hard to take/keep down. Parents need to feel that
therapy for their child is tailored to their individual case and this may make recruiting to a randomised
trial difficult as it removes the element of personalised care.
l Parents expressed their concern that complex conditions might not be suited to a randomised trial and
would remove any parental choice regarding the methods of treatment. The data indicated that the
period before diagnosis causes a high level of anxiety and a longer safer standard treatment arm would
be preferred.
l The qualitative researchers had thought carefully about how to explain a RCT to the children
interviewed. They concluded that it is important that all information (patient information leaflet/consent
and assent) is tailored to young persons’ needs and that PPI is important at this stage. Parents may be
more concerned with safety specifics, but a child/young person may be more focused on what is
required of them (e.g. blood test). It is sometimes important to discuss the trial with the child without
the parent/guardian present and it was pointed out that there appeared to be a lack of children’s
opinions in the qualitative research presentation.
l Timing of consent is important, as parents are unlikely to consent to a trial while waiting for their child
to go in for surgery or come round from anaesthetic, for example. It was suggested that discussion of
the trial should wait until treatment has started. Once the patient is settled, parents are more likely to
be receptive to a trial.
l It was also pointed out that bone and joint infection is perhaps not on a junior doctor’s ‘radar’.
Parents felt the that speed of diagnosis was often down to the treating medic, and therefore luck. It
was pointed out that a trial would increase awareness of bone and joint infection.
l The group should consider any subgroups of patients that clinicians would not be comfortable randomising.
Discussion and voting results
Oral to intravenous antibiotic switch criteria
Results from voting on oral to i.v. antibiotic switch criteria are presented in Table 81. Overall, resolution of
fever for ≥ 48 hours, tolerating oral input (medicines and food/drink) and pain improvement (rather than
resolution) were considered important criteria by consensus following the meeting voting.
Although there was no clear consensus regarding the absolute or relative (to presentation) of the CRP, there
was agreement in both rounds 1 and 2 of the Delphi survey that CRP is an important parameter in around
60% of respondents, and among approximately 70% of those at the consensus meeting. In addition, the
patient representative felt that a CRP < 20 mg/l was important but not critical.
Discussion about switching criteria:
l CRP levels are an important test for recognising improvement, but picking an arbitrary absolute CRP
level may not be appropriate.
l A two-thirds reduction in CRP might not be sufficient reduction if the baseline CRP was very high.
l A very high CRP level could also indicate a complex case as opposed to simple and should therefore
not be ignored.
l If CRP was used as a switch criterion, parents could find conflicting evidence online and not wish to
consent and/or withdraw their child from the study.
l The overall trend should be more important than any particular fixed value.
Conclusion
Monitoring CRP in terms of absolute value and trend would be important despite consensus not
being reached.
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Core outcomes voting
A summary of core outcome consensus is presented in Table 82. Overall, the outcomes assessed as
‘consensus in’ voting include rehospitalisation or recurrence of symptoms while on oral antibiotics,
treatment failure or recurrence of infection, disability at follow-up, being symptom free at 1 year, limb
shortening or deformity, chronic OM or chronic arthritis, amputation or fasciotomy, death, need for
paediatric intensive care and line infection.
Discussion about core trial outcomes
l All would be uncomfortable taking part in a study that included only outcomes that had been voted
as critical.
l Critical outcomes would form a core outcome set and other important outcomes would be included.
l Twelve out of 16 participants felt that an outcome should be included for both parental and child
stress/anxiety.
l It was agreed that a barrier to collecting quality-of-life data would be that often in these cases the
negative impacts may not be seen for several decades after recruitment.
Overall feasibility of future trial
It was noted that the number of cases reported in the service evaluation was very promising in terms of a
future trial.
Standard care
Concerns about standard care in a future RCT:
l The absence of any agreement on diagnosis, antibiotic dosing or defined standard care procedures as
identified in the service evaluation is a concern for a future RCT. A study aiming to standardise care is a
different research question for which it might be hard to attract funding as there is no specific clinically
related research question. Part of the rationale for this Dinosaur study was to review the current UK
practice and establish the parameters for current standard of care that can be tested against.
TABLE 81 Summary of switch criteria voting
Switch criterion
Percentage of meeting
participants scoring 7–9
Percentage of meeting
participants scoring 1–3 Consensus
CRP < 20mg/l 35.29 11.76 No consensusa
CRP less than one-third of the presenting value 23.53 17.65 No consensusa
CRP less than two-thirds of the presenting value 25.53 29.41 No consensusa
ESR < 20mm/hour 11.76 47.06 No consensus
Resolution of fever for ≥ 48 hours 100 0 Consensus in
Weight bearing/return of function to the limb 64.71 5.88 No consensus
Resolution of pain 29.41 11.76 No consensus
Tolerating oral input 100 0 Consensus in
Parental opinion regarding improvement or
worsening of condition
35.29 0 No consensus
Pain improvement (rather than resolution) 70.59 0 Consensus in
a Although there was no clear consensus regarding the absolute or relative (to presentation) of the CRP, 86.35% of
participants scored one of the three CRP criteria 7–9, showing consensus that the CRP is an important parameter but
not providing clear evidence regarding which should be used.
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TABLE 82 Summary of outcomes discussed
Outcome
Percentage of meeting
participants scoring 7–9
Percentage of meeting
participants scoring 1–3 Consensus
Need for non-diagnostic surgical procedure
(e.g. decompression, debridement)
25 25 No consensus
Rehospitalisation or recurrence of
symptoms while on oral antibiotics
100 0 Consensus in
Treatment failure or recurrence
of infection
100 0 Consensus in
Pain while on antimicrobial treatment 6.25 37.5 No consensus
Ongoing pain at follow-up 31.25 6.25 No consensus
Disability at follow-up 81.25 0 Consensus in
Symptom free at 1 year 100 0 Consensus in
Limb shortening or deformity 100 0 Consensus in
Duration to CRP of < 5mg/l 18.75 43.75 No consensus
Duration to resolution of fever 31.25 18.75 No consensus
Duration to resolution of pain 18.75 6.25 No consensus
Duration of hospital stay 18.75 18.75 No consensus
Fracture at or near site of infection 56.25 0 No consensus
Prolonged antibiotic therapy 50 0 No consensus
Quality of life 62.5 0 No consensus
Chronic OM 100 0 Consensus in
Chronic arthritis 100 0 Consensus in
Chronic myositis 50 6.25 No consensus
Amputation or fasciotomy 100 0 Consensus in
Death 100 0 Consensus in
PICU requirement (e.g. PICU-free days at
day 30, if admitted)
75 0 Consensus in
Agranulocytosis/neutropenia 56.25 0 No consensus
Deranged liver function 25 6.25 No consensus
C. difficile infection 18.75 12.5 No consensus
Rash or allergic reaction 37.5 0 No consensus
Suspected drug-related fever 6.25 25 No consensus
Line infection 81.25 0 Consensus in
Line occlusion 50 6.25 No consensus
Vomiting/diarrhoea 6.25 49.75 No consensus
Intravenous antibiotic necessitated insertion of
PICC or other central line
31.25 18.75 No consensus
Infiltration or extravasation event 31.25 6.25 No consensus
Any complication of vascular access 50 0 No consensus
PICU, paediatric intensive care unit.
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l Delay in diagnosing simple bone and joint infections overall in UK settings. The process of running a
study could itself help to define the approach to these cases and improve diagnosis and treatment by
raising awareness in participating centres. There is therefore a need to ensure that a study is accessible
to all and does not take place only in tertiary centres.
l Is the service evaluation coherent with personal experience of clinicians? This is the largest prospective
global study to date on childhood bone and joint infections, and part of the problem in this condition
is that treatment has been based on personal experience and mostly retrospective small cohort studies.
l Should primary care trusts be included in the future study to ensure that standard care is consistent
across the board? Running the future study would be the best way to increase awareness of these
conditions and improve normal care.
l Is 3 months’ follow-up, as that used in service evaluation, long enough to capture long-term
complications like growth problems? A relatively short follow-up is often standard practice (in routine
clinical care of the simple cases being considered for a RCT) but that perhaps conducting this study
could improve follow-up times for normal care.
l A future trial needs to consider the cost to the NHS within research costings.
Adherence to potential trial treatments
Adherence to oral antibiotics regimens potentially can influence/disrupt results for trial treatments involving
oral antibiotic therapy at home. The items discussed were:
l Parents are often better than doctors or nurses at complying with antibiotic regimens.
l Parents in the qualitative research had reported high levels of adherence to antibiotic therapy as
parents had a strong understanding of the consequences of not completing the course. This finding
could be influenced by a study effect and selection bias.
l Clinical experience shows concerns about adherence.
l Older children and young adults are often given responsibility for their own treatment by parents and
may report a higher level of compliance than is the case.
l Adult RCTs successfully used an oral treatment strategy.
Recruitment and inclusion criteria issues
l Parents often self-inform and have preferences for their child’s treatment (length of i.v. therapy, PICC
line, liquid/tablet form).
l Clinician preference for one type of therapy over another has made it harder than anticipated to recruit
to some paediatric clinical trials, for example the TORPEDO (Trial of Optimal Therapy for Pseudomonas
Eradication in Cystic Fibrosis) trial.92 Despite these issues the trial has proceeded and achieves a consent
rate of approximately 40%.
l Service evaluation data suggest that short-course i.v. therapy is now more common. Randomising
patients to longer than normal treatment may reduce participation.
l Parents are sometimes less willing to take part in randomised trials because of the perceived lack of
personalised care. The design and patient/parent information would have to clearly explain this issue,
as apparently shorter therapy duration may be off-putting to parents. Parents interviewed in the
qualitative research were generally happy with the timing of their child’s switch from i.v. to oral
antibiotics as they felt they were well enough to be switched.
l Children with bony (rather than soft tissue) abnormalities on X-ray imaging would need to be excluded
from participation in a clinical trial of simple OM or SA. The final feasibility assessment needs to take
into account cases from the service evaluation in which no bony abnormalities were found.
l The study population will remain heterogeneous despite aiming for clear definitions because patients
take different amounts of time to present at health-care service providers, doctors take differing
amounts of time to diagnose the infection and infections progress at differing rates.
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Developing the research question
A future study is thought to be important to reduce the use of antibiotics, reduce length of hospital stay
and to avoid complications of i.v. therapy.
Possible research questions:
1. For how long should bone and joint infections be treated with antibiotics in total?
2. When should the switch from i.v. to oral therapy occur?
3. Should the study compare early with late switch rather than type of antibiotic treatment?
4. Early switch point of 48 hours compared with longer, such as 9 days (as the latter appeared to be the
median time for switch in the data from the service evaluation).
Concerns noted:
l Assessing more than one research question in one study may impact on results, creating smaller groups
of patients with more compounding factors and reducing the power of the study.
l The umbrella title of bone and joint infections covers two very different conditions: acute OM is
perceived to have a lower risk of long-term problems due to treatment failure than SA, despite the fact
that, historically, duration of antibiotic therapy has been shorter in OM than in SA. Differences in
standard care procedures need to be examined from the service evaluation to decide if OM and SA
need to be evaluated in different study groups.
l Setting an arbitrary switch date would not take different infecting organisms into account. Any defined
switch timings should be within a range that is comfortable for clinicians and parents.
l Many clinicians would be uncomfortable switching as early as 48 hours. This would be possible only in
a subgroup with mild disease, affecting the recruitment and power of the study.
Conclusion
The meeting concluded that a future study looking at switch timing should be prioritised over one looking
at the effect of reducing the overall duration of antibiotic therapy.
DOI: 10.3310/hta21480 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 48
© Queen’s Printer and Controller of HMSO 2017. This work was produced by de Graaf et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
115

Chapter 8 Summary discussion and conclusions
for further research
Any future RCT will need to enrol children with simple disease in whom there is no underlying chronicdisease, no orthopaedic implants and no recent history (within 6 months) of orthopaedic surgery.
This study set out to establish the feasibility of a study in predefined simple or less complex bone and joint
infection in children, and the qualitative component of the study confirmed that parents would also be less
likely to consent to their children participating in such a trial if there was concern regarding the seriousness
of their child’s condition and/or previous trajectory leading to diagnosis.
Number of cases
A future RCT would need to recruit from all tertiary and most secondary hospitals in the UK NIHR
Comprehensive Research Network, where there are resources for recruiting children to clinical trials.
The number of cases seen in UK clinical practice is currently less than previously reported. There were
109 simple OM and 107 simple SA cases seen in 49 trusts over the 6-month study period. Given the
lower than expected monthly accrual (0–3 simple cases per month in tertiary centres, 0–0.7 per month in
secondary centres), in tertiary centres there would be approximately 24–36 cases of eligible simple disease
per year and in secondary care centres 8–12 potential eligible cases.
Logistics of a clinical trial including criteria for oral switch
From the service evaluation data, it appears that most children present to the emergency department and
not primary care. These data do not align directly with the findings of the qualitative study as regards
parents’ reported experience of the length of time before a formal diagnosis was made. From the
observations in the qualitative study, pre-trial information provided to and gathered from parents will need
to specifically address this issue by acknowledging that parents might have perceived a delay prior to
diagnosis, and researchers will need to give parents a chance to express their concerns. If parents have
experienced a delay in diagnosis, the service evaluation data can also be used to explain to parents of
potential participants that the clinical severity at presentation to hospital, rather than the length of
non-specific symptoms prior to presentation at hospital, is the key determinant of whether or not an
individual child should be considered for recruitment to a clinical trial.
Although in some centres home-based antibiotic delivery is possible (paediatric outpatient antimicrobial
therapy, paediatric OPAT), the overall length of hospital stay in our cohort of children with simple SA and
OM was very similar to the length of i.v. antibiotic course (median 6 days for simple SA, 9 days for
simple OM).
The service evaluation suggested that the at-home or in-hospital completion of an antibiotic course will not
be of any concern in a RCT. Parents of children with bone and joint infection understand the need to
complete antibiotic courses and report that they do so as per clinicians’ instructions. This is also reflected in
the experience of many past and current paediatric trials in which there are few reports of problems with
adherence to trial medications where adequate in-trial support is provided.
From a trial operation and logistical perspective, the qualitative study has shown the importance of
offering parents the opportunity to discuss their immediate experiences of the condition and its
presentation with the research team prior to being considered for a study. Embedding a future RCT in the
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routine NHS care of children with OM or SA would be a way of achieving this, and would also provide
reassurance that both potential arms of a study would not be expected in advance to negatively impact on
an individual child’s quality of care. Enrolment as part of routine care is also supported by a recent survey
showing that NHS patients are more likely to participate in research if the topic is introduced by the
potential research participant’s own doctor.93
The qualitative study also provided clear advice regarding the need to approach parents at times other
than ‘pinch points’ of anxiety/distress if at all possible, and regarding the need for a clear explanation of
potential risk and safety aspects.
Oral switch criteria for use in a clinical trial
In preparing the design and materials for a future trial, it will be important to clearly state that a research
protocol would not over-ride the individual need of the child in terms of when an oral switch was made.
This is feasible as a RCT would not be testing the oral switch criteria that will be according to an agreed
standard current practice. From the service evaluation, current clinical practice clearly is to switch with no
consistent evidence base used to make this decision. By ensuring that switch criteria were strict, clinicians
would be able to support following the trial protocol using predefined criteria such a modification of that
previously proposed.1 The Delphi survey and consensus meeting showed that resolution of fever for
≥ 48 hours, tolerating oral input (medicines and food/drink) and pain improvement (rather than resolution)
were considered important criteria. Although there was much variability in the Delphi survey and
consensus meeting regarding what the CRP criteria should be, around 60% of respondents in both
rounds 1 and 2 of the Delphi survey agreed that CRP is an important parameter, as did approximately
70% of those at the consensus meeting. These criteria resonate with the views parents expressed during
interviews. Parents were confident in the switch point when they had perceived an improvement in their
child’s condition and felt that doctors were basing decisions on clinical indicators. Where this was not
perceived to have been the case, parents expressed dissatisfaction and anxiety.
Recruitment following a child meeting specific clinical criteria in acute paediatric care has been used
successfully in the recently published NIHR HTA-funded clinical trial of the management of infants
admitted with bronchiolitis, who were randomised following admission requiring oxygen therapy to
maintain saturations.94 Other information that will be important to include in the pre-trial information
includes data to support the switch point in both standard care and the experimental intervention, details
of how a child would be monitored to ensure infection was being dealt with, trajectory of care in case of
failure to recover in the shorter treatment arm, and data to demonstrate safety of the shorter arm and
regarding the equivalence/equipoise about treatment in both arms.
Defining the core outcomes of a future randomised controlled trial in
bone and joint infections in children
The qualitative study demonstrated the importance to parents and children of consideration of short- and
long-term outcomes meaningful to the families themselves. Short-term examples that accord with
children’s and parents’ observations include appetite and weight, temperature, pain, weight bearing on
affected limb and functional movement in activities of daily living. Longer-term outcome examples
reflecting children’s and parents’ perspectives and priorities include functional activity and mobility levels,
pain, end of infection with no recurrence and the impact on bone/joint/growth.
Overall, the outcomes assessed as ‘consensus in’ from the Delphi and consensus meeting voting include
rehospitalisation or recurrence of symptoms while on oral antibiotics, treatment failure or recurrence of
infection, disability at follow-up, being symptom free at 1 year, limb shortening or deformity, chronic OM
or chronic arthritis, amputation or fasciotomy, death, need for paediatric intensive care and line infection.
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Consideration of possible trial designs in relation to the current standard
of care for length of intravenous and oral therapy courses, and in
relation to treatment failure reported in the service evaluation cohort
The most striking aspect of our data is that in the case of simple, non-complex disease, clinicians currently
initiate oral switch early, at a median of 7 days in children with simple SA and 9 days in those with simple
OM. What is very important for the design of a RCT of reduced duration of i.v. and/or total antibiotic
therapy is that these data also demonstrate less treatment failure in simple disease in which there was an
early oral switch, suggesting also that ‘more severe simple’ disease is more likely to fail initial therapy or
require additional interventions. Of the 73 children with simple disease in whom oral switch occurred very
early (< 1 week), 9.6% experienced a treatment failure, compared with 16.1% of those in whom switch
occurred early (between 1 and 2 weeks) and 18.2% of those in whom switch took place after 2 weeks of
i.v. antibiotic treatment.
Although there was no difference in the duration of i.v. antibiotic therapy between children with simple
SA and those with OM, total antibiotic treatment duration is around 10 days shorter simple SA than in
simple OM [median 30 (IQR 18–41) days compared with 40 (IQR 21–48) days]. These data suggest that,
although there has been a move to short-course i.v. antibiotic therapy for simple disease in current NHS
practice, overall course lengths have remained similar to ‘textbook’ longer overall courses of treatment.
As a result of differences in duration of treatment between SA and OM, children with diseases would need
to be enrolled in different groups in a future RCT.
To be able to conduct a RCT of even shorter courses of i.v. therapy (e.g. to randomise children with simple
OM or SA to very short-course i.v. therapy of 3–4 days compared with 7 days), clinicians, parents and
researchers would have to be convinced regarding the equipoise of potential treatment failure/safety, and
agree on clear oral switch criteria.
The service evaluation showed that, although 8.3% of children with simple disease experienced at least
one complication, only three such children (of 218) reported recurrence of infection requiring medical or
surgical intervention. However, in order to capture all possible cases in which the initial empirical antibiotic
and/or surgical therapy failed, necessitating further treatment, we instead used a broad definition of
treatment failure including fever, recurrence of infection including increase in CRP or development of
draining sinus, dislocation, subluxation, pathological fracture, pain, mobility problems, swelling, numbness,
hospital readmission, surgery and change of antibiotics. Using these criteria, 32 of 218 children with simple
disease (14.7%) experienced treatment failure and treatment failure was half as likely in SA (9.3%) as in
OM (19.3%). In summary, (1) treatment failure was less likely the earlier switch occurred (9.6% in switch
at < 1 week, 16.1% when between 1 and 2 weeks, 18.2% when after 2 weeks of i.v. therapy); (2) the
likelihood of treatment failure in children with simple SA and OM was not different in those who received
antibiotics for < 6 weeks as for who received antibiotics for > 6 weeks; and (3) differences in the rates of
treatment failure among children with simple SA and those with simple OM suggest that children with OM
and SA should be enrolled in separate groups in any future RCT.
Regarding the feasibility of a RCT to compare early with late oral switch, or of a trial to compare overall
short-course with longer-course therapy in simple OM or SA, a series of statements can be made on the
basis of the service evaluation data:
1. Clinicians and researchers would feel comfortable enrolling children to a trial of reduced total duration
of antibiotic treatment, and parents would consent to their children taking part, only if there is genuine
equipoise regarding whether or not reduced i.v. course length and/or reduced total length of therapy
would be likely to increase the risk of treatment failure.
2. Because of the current practice of early oral switch apparent in the service evaluation data, there
appears to be a group of children with simple disease who get better rapidly even though they receive
less i.v. antibiotic. It is a reasonable clinical assumption (although not proved by these data) that such
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children are less likely to experience treatment failure because they have less severe disease than
children in whom oral switch occurs later. Together with data from this study and from other countries
(data from Spain presented at ESPID 2015 Congress, Leipzig, Germany, May 2015), and with strict oral
switch criteria, a RCT in which those with very mild are treated with very short-course (1–3 days) i.v.
antibiotic therapy prior to oral switch could be considered. However, the Delphi survey and consensus
meeting showed that, although CRP is considered important in determining the timing of oral switch
(with no consensus regarding level), other criteria should include resolution of fever for ≥ 48 hours,
tolerating oral input (medicines and food/drink) and pain improvement (rather than resolution). This
finding, together with the fact that the number of children likely to meet oral switch criteria in the first
week of treatment is small, probably means such a study will not be feasible as a single-country
(UK) trial.
3. An alternative strategy would be to consider a trial to randomise children whom a clinician has decided
should be switched to oral antibiotics early to reduce overall length of antibiotic therapy compared with
the current standard of care. This trial design would avoid the potential problem of parental anxiety
about stopping i.v. therapy early, described in the qualitative study, as children currently treated with
i.v. antibiotics for < 1 week experience fewer complications than those in whom oral switch occurs
later. From the service evaluation data, it would be possible to plan that the duration of initial i.v.
therapy prior to oral switch would be the same for children with SA and OM, but to vary the duration
of oral antibiotic therapy in different study arms, for example in children with simple SA comparing
20 days’ treatment with 30 days’ treatment and in those with simple OM comparing 30 days’ treatment
with 40 days’ treatment. However, although this study design (a comparison of reduced duration of
oral antibiotic treatment with standard duration of treatment) appears to make sense based on current
practice data, the expressed preference of the consensus meeting was for prioritising investigation of
early oral switch rather than overall duration of therapy.
In addition, given the invasive nature of the initial diagnosis and the relatively low cost of home-based
antibiotic therapy given at times around school attendance, it is debatable if the cost benefit to the NHS
is great enough in such an uncommon disease to justify the large costs of a national multicentre clinical
trial of duration of oral antibiotic treatment after oral switch. Although a positive outcome of such a
trial would indeed reduce overall antibiotic use and consumption, as the condition affects so few
children the overall impact on antimicrobial resistance in the community or in individual children will be
very small. The cost saving of such a reduction in the duration of home-based oral therapy would also
be small in terms of the costs of antibiotics saved and clinician time, as well as economically as children
with disease mild enough to be randomised in this study would almost all be back at nursery or school
during their period of oral therapy (parents will be able to return to work).
4. A third study design would be a trial of reduced duration of antibiotics in children who have simple
disease but do not meet the criteria for oral switch in the first week of treatment, a group that appears
to represent most children with simple OM and SA. The clinical course of these patients is less
predictable, and it is not currently possible to predict clinically, or from biomarkers, which patients
would potentially do well with a shorter duration of i.v. or total antibiotic therapy. In a RCT, the oral
switch criteria defined in this study, together with a strict CRP cut-off level, could be key enrolment
criteria, with participants then randomised to immediate or delayed oral therapy once the oral switch
criteria were met after 7 days of i.v. therapy. Although there was no consensus on what the CRP
cut-off should be (reflecting wide variation in current clinical practice, not based on evidence), recent
experience in a commercial clinical trial suggests that a ‘cautious’ level of CRP change would be
accepted by investigators in the context of a RCT. In the recent commercial study that has completed
recruitment but not yet reported (clinicaltrials.gov NCT01922011), the CRP criterion was ‘CRP
decreased by at least 30% from baseline (if available)’, but we would anticipate that in a UK study this
would need to be ‘CRP reduced by at least 50% from baseline’ or perhaps ‘CRP reduced by at least
two-thirds from baseline’ to make sure that there was wide participation. Children would be excluded
from the trial if they met the criteria for oral switch in the first 7 days of i.v. therapy as the service
evaluation suggests that this group experiences less treatment failure than those in whom oral switch
occurs later. This study would compare shorter with longer i.v. therapy (e.g. 12–14 days’ total i.v.
therapy compared with 21–28 days’ i.v. therapy). It would therefore establish the safety and treatment
SUMMARY DISCUSSION AND CONCLUSIONS FOR FURTHER RESEARCH
NIHR Journals Library www.journalslibrary.nihr.ac.uk
120
failure equivalence of shorter or longer courses of i.v. antibiotic therapy, keeping the total duration of
antibiotic treatment (i.v. and oral combined) the same. In this design, which meets the preference of
clinicians at the consensus meeting, there would be clear differences in duration of i.v. therapy and a
potentially large impact on clinical and cost (length of stay) outcomes in the NHS.
5. Although this study has established three potentially feasible RCT designs (very short-course i.v.
antibiotics in children with simple SA or OM compared with current standard practice; reduced overall
duration of therapy compared with current standard practice following clinician-determined oral switch;
shorter or longer duration of i.v. therapy after defined oral switch are met, with no difference in total
i.v. or oral antibiotic combined total course), key questions remain. There are currently no biomarkers
(currently used or researched) that would provide certainty of potential study eligibility to a trial of very
early i.v. to oral switch, or aid decision-making in other trial designs. New biomarkers are required in
order to better stratify the severity of disease in children with simple OM or SA.
Do the microbiological conventional and molecular data provide information on which
empirical antimicrobial agent(s) could be used in a randomised clinical trial?
The available conventional tests and results of the targeted PCR substudy suggest that although S. aureus
remains the most common single identified pathogen in children of all ages, K. kingae occurs in a
significant proportion of younger children (aged 0.8–2.3 years in the molecular data from this study,
but more common in children aged < 6 years in other series) and GAS (Streptococcus pyogenes) is an
important pathogen in children of all ages. Other pathogens are much rarer, but using data from both
conventional and molecular tests include pneumococcus (Streptococcus pneumoniae), GBS, H. influenzae
(in one child) and Pseudomonas spp. (in one child). Importantly, where S. aureus was the identified
pathogen, only two cases (one simple, one complex) of resistant bacteria (MRSA) were identified.
The incidence of the more virulent PVL-positive S. aureus disease was also very low (two simple cases,
one complex case) in our data.
Regarding dose, although it is impossible from the service evaluation data to determine whether or not
any treatment failures are a result of non-maximum dose prescribing, in the case of the major in-hospital
i.v. antibiotics used to treat simple disease (flucloxacillin, clindamycin and cefuroxime) clinicians mostly
prescribed the maximum (high-dose) BNFC dose recommendations. When ceftriaxone was prescribed,
however, the lower dose band was prescribed more often than the higher, severe infection, dose. Dosing
strategies for orally prescribed antibiotics were more variable and often much lower than the formulary
maximum recommended for age or weight.
For a clinical trial, these data overall suggest that a broad-spectrum i.v. antibiotic (such as cefuroxime
50 mg/kg three times per day) should be used in younger children (possibly aged < 6 years) to cover less
common pathogens not completely sensitive to high-dose flucloxacillin. A narrower-spectrum antibiotic
such as high-dose flucloxacillin (50 mg/kg four times per day) could be used in older children and teenagers
in whom S. aureus and GAS predominate. To enable discharge from hospital while still on i.v. antibiotic
therapy, once-daily ceftriaxone at maximum dose (80 mg/kg once per day to a maximum of 4 g daily) would
provide empirical antibiotic cover for all common and less common organisms, as antimicrobial resistance is
still very uncommon. For children with definite penicillin allergy, clindamycin is an acceptable in-hospital
alternative (10 mg/kg four times per day), but there is no clear out-of-hospital once-daily alternative.
To complete the total course length after oral switch, in order to maximise the risk of treatment failure a
RCT would need to carefully define doses of antibiotics to use at the higher BNFC dose recommendations
that have both an acceptable palatability (taste) and achievable treatment regime. Although not shown in
our data, it is established paediatric practice that parents and children are more likely to adhere accurately
to three times per day dose regimens (such as midnight, 08.00 hours and 16.00 hours) than to four times
a day regimens (such as midnight, 06.00 hours, 12.00 hours and 18.00 hours), which means both two
night-time (usually when asleep) doses for children and a dose during school or nursery hours.
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Summary
A core outcome set for future clinical trials in paediatric bone and joint infections was established by a
Delphi survey and consensus meeting.
A service evaluation, qualitative study and consensus meeting discussion provided information to inform
the feasibility of a RCT, and of potential RCT designs.
1. A RCT of very early oral switch would be supported by the service evaluation data. However, the Delphi
survey and consensus meeting showed that, although CRP is considered important in determining the
timing of oral switch (with no consensus regarding level), other criteria should include resolution of
fever for ≥ 48 hours, tolerating oral input (medicines and food/drink) and pain improvement (rather
than resolution). Such strict criteria, together the fact that the number of children with simple OM and
SA likely to meet switch criteria in the first week of i.v. treatment is small, means that such a study will
likely not be feasible as a single-country (UK) trial.
2. A RCT of reduced duration of total antibiotic therapy after clinician-directed oral switch based on the
criteria determined in this study would be feasible, even though it was not the first choice study of the
consensus meeting participants. It would be possible to explain the study to parents and children, and
feasible to recruit in terms of numbers of cases and clinician willingness. It is unlikely that such a study
design will make an enormous impact on the overall cost to the NHS of treating bone and joint
infections in children or on the overall antibiotic burden of children in the community.
3. A RCT in children with simple OM and SA comparing shorter or longer i.v. therapy with no reduction in
the duration of total (i.v. and oral combined) antibiotic therapy would be feasible with children
randomised after the strict oral switch criteria had been met after 7 days of i.v. therapy. Children would
be excluded from the trial if they met the criteria for oral switch in the first week of i.v. therapy as the
service evaluation suggests that this group experiences less treatment failure than those in whom oral
switch occurs later. This study design meets clinician preference and addresses parental concerns not to
randomise prior to currently used oral switch criteria. It would also provide important information on
whether or not i.v. therapy can be reduced without increasing treatment failure compared with longer-
course i.v. therapy, or whether or not outcomes are worse in those treated with more i.v. antibiotics as
a result of treatment failures being caused by the treatment modality itself.
Regardless of RCT design, the qualitative study has demonstrated gaps remaining in the understanding of
parental and family decisions to participate in clinical trials. In order to explore prospectively the issues
identified in the qualitative study (e.g. an understanding of the condition, actual circumstances around
making a choice to join a study etc.), a longitudinal qualitative study could take place alongside any trial,
including semistructured interviews with parents and children, focus groups with staff and ethnographic
observation.
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Appendix 1 Core outcome literature review
Search strategy used to identify trials investigating duration of
antibiotics in paediatric bone and joint infection
The search was executed using MEDLINE and EMBASE databases. All publications from 1946 to the
present were included in the search. The search was carried out in May 2012 and updated in July 2014.
# Search term Number of hits
1 osteomyelitis.mp. 39,394
2 bone infection.mp. 3979
3 osteitis.mp. 9113
4 septic arthritis.mp. 7340
5 bacterial arthritis.mp 6369
6 joint infection.mp 2450
7 Staphylococc*.mp. 322,123
8 Streptococc*.mp. 230,550
9 Skeletal infection.mp 109
10 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 565,232
11 child$.mp 2,991,039
12 paediatric or pediatric.mp. 432,403
13 neonat$.mp 367,776
14 infan$.mp. 1,244,482
15 (baby or babies).mp. 119,622
16 11 or 12 or 13 or 14 or 15 4,882,434
17 10 and 16 98,071
18 antibiotic.mp. 549,340
19 treatment.mp. 6,513,851
20 18 or 19 6,866,563
21 duration.mp. 914,091
22 course.mp. 1,010,339
23 length.mp 831,145
24 shortened.mp. 56,581
25 21 or 22 or 23 or 24 2,641,076
26 17 and 25 7342
27 remove duplicates from 26 1321
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Appendix 2 Tables of the consensus meeting
Criteria for switching
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FIGURE 6 Results of scoring: CRP of < 20mg/l.
TABLE 84 C-reactive protein of < 20mg/l
Switch criterion
CRP (non-specific blood test done at diagnosis and for monitoring)
of ≤ 20mg/l
Number of participants scoring 1–9 13
Number of participants unable to score 4
Notes
Discussed and voted.
The room felt that this is difficult to assess as CRP results would be more important in a patient with a very high baseline
score than patients with a lower baseline score. However, it was pointed out that it would be very unusual not to
include CRP.
Unanimous decision that CRP should be included but that the criteria needed clarification and rewording. Agreement to
reword and recirculate.
TABLE 83 Breakdown of individual switch criteria discussions and scores
Switch criteria Discussion Number voting
What criteria are important to you when deciding when or whether or not to switch from i.v. to oral
antibiotic therapy?
17
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FIGURE 7 Results of scoring: CRP less than one-third of the presenting value.
TABLE 85 C-reactive protein less than one-third of the presenting value
Switch criterion CRP less than one-third of the presenting value
Number of participants scoring 1–9 13
Number of participants unable to score 4
Note
No discussion, voting only.
TABLE 86 C-reactive protein less than two-thirds of the presenting value
Switch criterion CRP less than two-thirds of the presenting value
Number of participants scoring 1–9 17
Number of participants unable to score 0
Note
No discussion, voting only.
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FIGURE 8 Results of scoring: CRP less than two-thirds of the presenting value.
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FIGURE 9 Results of scoring: ESR of < 20mm/hour.
TABLE 87 Erythrocyte sedimentation rate of < 20mm/hour
Switch criterion ESR of ≤ 20mm/hour
Number of participants scoring 1–9 17
Number of participants unable to score 0
Notes
Discussed and voted.
There was a brief discussion regarding the relative merits of ESR over other tests.
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FIGURE 10 Results of scoring: resolution of fever for ≥ 48 hours.
TABLE 88 Resolution of fever for ≥ 48 hours
Switch criterion Resolution of fever for ≥ 48 hours (body temperature normal)
Number of participants scoring 1–9 17
Number of participants unable to score 0
Note
No discussion, voting only.
TABLE 89 Weight bearing/return of function to limb
Switch criterion Weight bearing/return of function to limb
Number of participants scoring 1–9 17
Number of participants unable to score 0
Notes
Discussed and voted.
There was some participant confusion over whether this referred to weight bearing before or after surgery. SF confirmed
that this should be interpreted as being non-surgical cases. All were asked to score based on a child who has not had
surgery and should not be interpreted as lack of weight bearing imposed by the clinician.
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
138
05
10
15
20
25
45
40
35
30
Pe
rc
en
ta
g
e 
sc
o
ri
n
g
 (
%
)
Score
1. 
No
t i
m
po
rta
nt 2 3 4 5 6 7 8
9. 
Ve
ry
 im
po
rta
nt
Un
ab
le 
to
 sc
or
e
FIGURE 11 Results of scoring: weight bearing/return of function to limb.
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FIGURE 12 Results of scoring: resolution of pain.
TABLE 90 Resolution of pain
Switch criterion Resolution of pain (pain completely better)
Number of participants scoring 1–9 17
Number of participants unable to score 0
Notes
Discussed and voted.
As above, SF confirmed that when scoring participant should exclude pain following surgery.
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FIGURE 13 Results of scoring: tolerating oral input.
TABLE 91 Tolerating oral input
Switch criterion Tolerating oral input (can eat and drink)
Number of participants scoring 1–9 17
Number of participants unable to score 0
Notes
There was some misunderstanding of tolerating oral input. A participant was anxious responses could have been made on
the basis of children being able to take oral antibiotics only rather than the ability to eat and drink. It was also suggested
that if the patient had a feeding tube they could then also tolerate oral input.
TABLE 92 Parental opinion regarding improvement or worsening of condition
Switch criterion Parental opinion regarding improvement or worsening of condition
Number of participants scoring 1–9 17
Number of participants unable to score 0
Notes
Discussed and voted.
At this stage queries were raised about the scoring categories and definition of consensus. These were reiterated to
the group.
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FIGURE 14 Results of scoring: parental opinion regarding improvement or worsening of condition.
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FIGURE 15 Results of scoring: pain improvement.
TABLE 93 Pain improvement
Switch criterion Pain improvement (rather than resolution)
Number of participants scoring 1–9 17
Number of participants unable to score 0
Note
No discussion, voting only.
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FIGURE 16 Results of scoring: need for non-diagnostic surgical procedure.
TABLE 94 Breakdown of individual outcome discussions and scores
Outcomes Discussion Number voting
What outcomes should be measured to assess whether or not treatment has been effective? 16
TABLE 95 Need for non-diagnostic surgical procedure
Outcome name
Need for non-diagnostic surgical procedure (surgery for treatment of
the infection itself, e.g. decompression, debridement)
Number of participants scoring 1–9 15
Number of participants unable to score 1
Notes
Discussed and voted.
Discussion whether or not this would differ between cases of OM and SA.
TABLE 96 Rehospitalisation or recurrence of symptoms while on oral antibiotics
Outcome name
Rehospitalisation or recurrence of symptoms while on oral
(by mouth) antibiotics
Number of participants scoring 1–9 16
Number of participants unable to score 0
Notes
No discussion, voting only.
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FIGURE 17 Results of scoring: rehospitalisation or recurrence of symptoms while on oral antibiotics.
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FIGURE 18 Results of scoring: treatment failure – recurrence of infection.
TABLE 97 Treatment failure: recurrence of infection
Outcome name
Treatment failure: recurrence of infection
(either at original site or at new site)
Number of participants scoring 1–9 16
Number of participants unable to score 0
Notes
Discussed and voted.
Discussion included presentation of possible treatment failures and the results of the service evaluation.
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FIGURE 19 Results of scoring: pain while on antimicrobial treatment.
TABLE 98 Pain while on antimicrobial treatment
Outcome name Pain while on antimicrobial treatment
Number of participants scoring 1–9 16
Number of participants unable to score 0
Notes
Discussed and voted.
Discussion noted pain differs depending on whether or not the child is in a cast.
TABLE 99 Ongoing pain at follow-up
Outcome name Ongoing pain at follow-up
Number of participants scoring 1–9 16
Number of participants unable to score 0
Notes
Discussed and voted.
Follow up clarified as orthopaedic follow-up at outpatient appointments.
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FIGURE 20 Results of scoring: ongoing pain at follow-up.
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FIGURE 21 Results of scoring: disability at follow-up.
TABLE 100 Disability at follow-up
Outcome name
Disability at follow-up (any functional movement problems
due to the original infection)
Number of participants scoring 1–9 16
Number of participants unable to score 0
Notes
Discussed and voted.
Discussion on question of whether or not ‘disability’ should be separate from ‘functionality’. SF confirmed that for purposes
of scoring, disability should be read as impairment of function at orthopaedic follow-up appointment, not long-term
disability. Cross-reference was made to the qualitative research presentation.
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FIGURE 22 Results of scoring: symptom free at 1 year.
TABLE 101 Symptom free at 1 year
Outcome name Symptom free at 1 year
Number of participants scoring 1–9 16
Number of participants unable to score 0
Notes
Discussed and voted.
CG noted that one group was close to achieving consensus and two groups were in consensus in following round 1 of the
Delphi survey.
SF reminded the group that they should not be thinking about how these would be recorded at this point, but the
importance of the outcome.
TABLE 102 Limb shortening or deformity
Outcome name Limb shortening or deformity
Number of participants scoring 1–9 16
Number of participants unable to score 0
Notes
No discussion, voting only.
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FIGURE 23 Results of scoring: limb shortening or deformity.
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FIGURE 24 Results of scoring: duration to CRP of < 5mg/l.
TABLE 103 Duration to CRP of < 5mg/l
Outcome name Duration to CRP of ≤ 5mg/l
Number of participants scoring 1–9 16
Number of participants unable to score 0
Notes
Discussed and voted.
Clarification given that < 5mg/l referred to the value of CRP and not days.
DOI: 10.3310/hta21480 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 48
© Queen’s Printer and Controller of HMSO 2017. This work was produced by de Graaf et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
147
05
10
15
20
35
30
25
Pe
rc
en
ta
g
e 
sc
o
ri
n
g
 (
%
)
Score
1. 
No
t i
m
po
rta
nt 2 3 4 5 6 7 8
9. 
Ve
ry
 im
po
rta
nt
Un
ab
le 
to
 sc
or
e
FIGURE 25 Results of scoring: duration to resolution of fever.
TABLE 104 Duration to resolution of fever
Outcome name Duration to resolution of fever (number of days for fever to get better)
Number of participants scoring 1–9 16
Number of participants unable to score 0
Notes
No discussion, voting only.
TABLE 105 Duration to resolution of pain
Outcome name Duration to resolution of pain (number of days for pain to get better)
Number of participants scoring 1–9 16
Number of participants unable to score 0
Notes
No discussion, voting only.
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FIGURE 26 Results of scoring: duration to resolution of pain.
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FIGURE 27 Results of scoring: duration of hospital stay.
TABLE 106 Duration of hospital stay
Outcome name Duration of hospital stay
Number of participants scoring 1–9 16
Number of participants unable to score 0
Notes
No discussion, voting only.
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FIGURE 28 Results of scoring: fracture at or near site of infection.
TABLE 107 Fracture at or near site of infection
Outcome name Fracture at or near site of infection
Number of participants scoring 1–9 16
Number of participants unable to score 0
Notes
Discussed and voted.
Fracture definition clarified as direct consequence of infection rather than unrelated injury. One participant reflected that
this might have been misinterpreted in the Delphi survey.
TABLE 108 Prolonged antibiotic therapy
Outcome name Prolonged antibiotic therapy
Number of participants scoring 1–9 16
Number of participants unable to score 0
Notes
No discussion, voting only.
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FIGURE 29 Results of scoring: prolonged antibiotic therapy.
0
5
10
15
20
35
30
25
Pe
rc
en
ta
g
e 
sc
o
ri
n
g
 (
%
)
Score
1. 
No
t i
m
po
rta
nt 2 3 4 5 6 7 8
9. 
Ve
ry
 im
po
rta
nt
Un
ab
le 
to
 sc
or
e
FIGURE 30 Results of scoring: quality of life.
TABLE 109 Quality of life
Outcome name Quality of life
Number of participants scoring 1–9 16
Number of participants unable to score 0
Notes
Discussion regarding how to define quality of life as may mean different things to clinicians as it does to patients/parents.
Participants became concerned with when and how quality of life should be measured, and so it was clarified that the
purpose of this meeting was to agree ‘what’ was important and that the how and the when would need to be
considered later.
Needs further discussion with parents/PPI engagement for future trial.
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FIGURE 31 Results of scoring: chronic OM.
TABLE 110 Chronic OM
Outcome name Chronic OM (infection that does not get better with treatment)
Number of participants scoring 1–9 16
Number of participants unable to score 0
Notes
No discussion, voting only.
TABLE 111 Chronic arthritis
Outcome name
Chronic arthritis (joint inflammation that does not get better
with treatment)
Number of participants scoring 1–9 16
Number of participants unable to score 0
Notes
Discussed and voted.
Discussion indicated that the outcome wording may have been better clarified. It was not clear to some if this outcome
related to diagnosing chronic arthritis specifically as a result of the acute infection.
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FIGURE 32 Results of scoring: chronic arthritis.
0
5
10
15
20
25
Pe
rc
en
ta
g
e 
sc
o
ri
n
g
 (
%
)
Score
1. 
No
t i
m
po
rta
nt 2 3 4 5 6 7 8
9. 
Ve
ry
 im
po
rta
nt
Un
ab
le 
to
 sc
or
e
FIGURE 33 Results of scoring: chronic myositis.
TABLE 112 Chronic myositis
Outcome name
Chronic myositis (muscle inflammation that does not get better
with treatment)
Number of participants scoring 1–9 16
Number of participants unable to score 0
Notes
Discussed and voted.
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FIGURE 34 Results of scoring: amputation or fasciotomy.
TABLE 113 Amputation or fasciotomy
Outcome name
Amputation or fasciotomy (when the skin and muscle have to be
cut by a surgeon to relieve pressure between the skin and bone)
Number of participants scoring 1–9 16
Number of participants unable to score 0
Notes
No discussion, voting only.
TABLE 114 Death
Outcome name Death
Number of participants scoring 1–9 16
Number of participants unable to score 0
Notes
No discussion, voting only.
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FIGURE 35 Results of scoring: death.
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FIGURE 36 Results of scoring: paediatric intensive care unit requirement.
TABLE 115 Paediatric intensive care unit requirement
Outcome name PICU requirement (e.g. PICU-free days at day 30, if admitted)
Number of participants scoring 1–9 16
Number of participants unable to score 0
PICU, paediatric intensive care unit.
Notes
No discussion, voting only.
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FIGURE 37 Results of scoring: agranulocytosis/neutropaenia.
TABLE 116 Agranulocytosis/neutropaenia
Outcome name Agranulocytosis/neutropaenia (abnormal white cell count)
Number of participants scoring 1–9 16
Number of participants unable to score 0
Notes
No discussion, voting only.
TABLE 117 Deranged liver function tests
Outcome name Deranged (abnormal) liver function tests
Number of participants scoring 1–9 16
Number of participants unable to score 0
Notes
Discussed and voted.
Discussion comments included that deranged liver function would not be informative for the effectiveness of the treatment
and therefore should not be in the core outcome set.
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FIGURE 38 Results of scoring: deranged liver function tests.
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FIGURE 39 Results of scoring: C. difficile infection.
TABLE 118 Clostridium difficile infection
Outcome name
C. difficile infection (infectious complication of prolonged antibiotic
treatment, unusual in children and not able to be diagnosed in children
aged < 2 years as the infection is carried by young children as a normal
finding without causing problems)
Number of participants scoring 1–9 16
Number of participants unable to score 0
Notes
No discussion, voting only.
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FIGURE 40 Results of scoring: rash or allergic reaction.
TABLE 119 Rash or allergic reaction
Outcome name Rash or allergic reaction
Number of participants scoring 1–9 16
Number of participants unable to score 0
Notes
Discussed and voted.
Comment raised that this could be a non-specific rash. Also, that this should be scored as separate outcomes ‘rash’ and
‘allergic reaction’.
TABLE 120 Suspected drug-related fever
Outcome name Suspected drug-related fever
Number of participants scoring 1–9 16
Number of participants unable to score 0
Notes
Discussed and voted.
Discussion that this was an uncommon side effect and that this might be captured as a drug reaction. CaP put forward her
and her child’s experience of drug-related fever.
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FIGURE 41 Results of scoring: suspected drug-related fever.
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FIGURE 42 Results of scoring: line infection.
TABLE 121 Line infection
Outcome name Line infection (infection of the drip-line itself)
Number of participants scoring 1–9 16
Number of participants unable to score 0
Notes
Discussed and voted.
SF referred to a more recent paediatric paper here that described complications of PICC lines in and out of hospital.
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FIGURE 43 Results of scoring: line occlusion.
TABLE 122 Line occlusion
Outcome name Line occlusion (block of the drip line)
Number of participants scoring 1–9 16
Number of participants unable to score 0
Notes
No discussion, voting only.
TABLE 123 Vomiting/diarrhoea
Outcome name Vomiting/diarrhoea
Number of participants scoring 1–9 16
Number of participants unable to score 0
Notes
No discussion, voting only.
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FIGURE 44 Results of scoring: vomiting/diarrhoea.
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FIGURE 45 Results of scoring: antibiotic necessitated insertion of PICC or other central line.
TABLE 124 Intravenous antibiotic necessitated insertion of PICC or other central line
Outcome name
i.v. antibiotic necessitated insertion of PICC or other central line
(need to insert another longer-term i.v. drip)
Number of participants scoring 1–9 16
Number of participants unable to score 0
Notes
Discussion over whether or not this should be classified as an outcome.
Some confusion about what the outcome meant. Was a PICC needed because of the need for long-term antibiotics
(i.e. part of the treatment plan, becoming more common in routine NHS care of bone and joint infections in children) or
because of difficulty with access in the initial period of illness? There is a possibility that the time to PICC insertion at an
institution could affect the response. One person suggested rewording the outcome.
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FIGURE 46 Results of scoring: infiltration or extravasation event.
TABLE 125 Infiltration or extravasation event
Outcome name
Infiltration or extravasation event (medicine being given into the
veins accidently is delivered to the tissues due to the drip coming out
of the blood vessel)
Number of participants scoring 1–9 16
Number of participants unable to score 0
Notes
Lay summary was verbally read for clarity.
No discussion, voting only.
TABLE 126 Any complication of vascular access
Outcome name Any complication of vascular access (any complication of the drip itself)
Number of participants scoring 1–9 16
Number of participants unable to score 0
Notes
Discussed and voted.
Explanation given that it’s important to look at complications across arms of the trial.
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FIGURE 47 Results of scoring: any complication of vascular access.
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